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Abstract 
In this thesis we will disclose the results obtained from the diastereoisomeric salt 
formation (n salt, p salt and p1,n1 salt) between non-racemic trans-chrysanthemic acid 
(trans-ChA) and pure enantiomers of threo-2-dimethylamino-1-phenyl-1,3-propanediol 
(DMPP). The occurrence of p1,n1 salt formation can have profound effects on 
enantiomer separation of scalemic (non-racemic) mixtures. This phenomenon when 
accompanied by substrate self-association impedes the complete recovery of the major 
enantiomer through formation of an inescapable racemate cage.  
A synthetic sequence for the asymmetric synthesis of bicyclo[3.2.0]heptanones and 
bicyclo[3.2.0]hept-3-en-6-ones through a cycloaddition strategy is reported. The 
fundamental step is a [2+2]-cycloaddition of an enantiopure amide derived from the 
reaction between a set of acids and an oxazolidinone as the chiral auxiliary. The inter- 
and intramolecular cycloaddition of in situ-generated keteniminium salts gives bicycles 
with a good enantioselection.  
A key intermediate of Iloprost, a chemically stable and biologically active mimic of 
prostacyclin PGI2 is synthesized following a ‘green approach’. An example of simple 
optical resolution of this racemic intermediate involving the diastereoisomeric salt 
formation is described. 
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Chapter 1 
 
Introduction 
 
1.1 The importance of enantiopure compounds            
One aim of synthetic organic chemistry is to provide discoveries and inventions that 
have a great impact in many areas like biology, medicine and agriculture. Many 
efficient procedures have been devised which allow the preparation of complex 
compounds with chemo- regio- stereo- and especially enantioselection. Asymmetric 
control of reaction is therefore essential every time biologically active molecules are 
involved. In the early 1960s the Thalidomide tragedy had brought to the public’s 
attention the importance of producing drugs in enantiomeric pure form. In England, 
Thalidomide was marketed in racemic mixture and widely used to alleviate the 
undesired symptoms of pregnancy. Unfortunately too late, it was found that while the 
(R) enantiomer is the active analgesic principle, the opposite (S) enantiomer is teratogen 
and so responsible of birth deformities of numerous babies. The importance of 
enantiopure compounds results from the close relationship between the absolute 
configuration of a molecule and its biological properties and effects. Since then most 
drugs are now marketed as single enantiomers,1 even if they are synthesized as racemic 
mixture. The required enantiomer has been achieved by optical resolution and 
purification of racemic mixture or by asymmetric reaction. 
 
1.2 An industrial and green point of view               
In the attempt to meet the evermore stringent social demands of new products with 
improved performance, lower financial price and lower environmental impact, the 
chemists have been focused on the development of new processes and products based 
                                                 
1
 In 1992, the US Food & Drug Administration (FDA) issued a policy on stereoisomeric drugs: 57 Fed. 
Reg. 22 249 (1992). According to this regulation, racemates can be sold, but both enantiomers must be 
characterized pharmacologically and toxicologically. This characterization is usually so long and 
expensive that the single enantiomer synthesis is often preferred. 
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on the so called ‘green chemistry’. In 1998, Anastas and Warner2 exposed the twelve 
principles of green chemistry: 1) prevention, 2) atom economy, 3) less hazardous 
chemical synthesis, 4) designing safer chemicals, 5) safer solvent, 6) design for energy 
efficiency, 7) use of renewable feedstock, 8) reduce derivates, 9) catalysis, 10) design 
for degradation, 11) real-time analysis for pollution prevention, 12) inherently safer 
chemistry for accidental prevention. The goal of this chemistry is the optimization of 
production processes and of the resources exploitation. To be successful this technology 
should be applied in an economically viable manner, without side effects for 
environment following the concepts of ‘intensification’ and ‘minimization’ of the 
industrial process. 
 
1.3 Chrysanthemic acid                
Nature is the uncontested master in the design of biologically active compounds. From 
Nature we have discovered many compounds that have strongly enhanced life in the 
developed societies. For example, a famous and potent class of insecticides, the natural 
esters Pyrethrins, contains Chrysanthemic acid as the fundamental active constituent 
(Figure 1).  
 
 
Figure 1 
To improve the repellent activity and delete the photo instability of these esters a new 
generation of pyrethroids was developed. The biological properties of this repellents 
used in crop protection are related to the relative and absolute configuration of the 
                                                 
2
 Anastas, P. T., Warner, J. C. Green Chemistry: theory and practice, 1998, Oxford University Press, p 
30. 
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Chrysanthemic acid. Hence, again the necessity to develop efficient asymmetric 
resolution methods results evident. 
 
1.4 Prostaglandin precursors and analogues          
Prostaglandins have an immense biochemical importance because of their fascinating 
pharmacological properties. Several useful intermediates were synthesized in these 
years, and the bicycle-ketene here represented is just an example of these classes of 
attractive precursors (Scheme 1).  
 
bicycloketone prostacyclin Iloprost 
 
PRECURSOR  STABLE ANALOGUE 
Scheme 1 
Compounds belonging to this class have a versatile structure, a rigid skeleton and two 
fused rings with different functionalizable groups, therefore they are attractive 
precursors for the asymmetric synthesis of prostaglandin and their biosynthesized 
analogues, prostacyclins. Since the discovery of prostacyclins the search for more 
chemically and biologically stable mimics has been ongoing. The carbocyclic analogue 
Iloprost is a valuable drug for the treatment of pulmonary hypertension and it is a potent 
inhibitor of blood platelet aggregation.  
 
1.5 Outline of the thesis                
These reflections are at the basis of the work discussed in this thesis and of many efforts 
made in my group. In particular, the first topic deals with an optical resolution of a 
chrysanthemic acid scalemic mixture by formation of diastereomeric salts. In this case, 
the influence of the p1,n1 salt formation in the separation process is highlighted and 
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explained (Chapter 2). Then a method of synthesis of enantiopure bicycloketones based 
on [2+2]-cycloaddition of chiral amides will be discussed. First, synthetic route to these 
chiral intermediates will be described (Chapter 3). Finally the attention is focused on the 
total synthesis of Iloprost. The intensification of the synthetic process of a key racemic 
precursor is presented. The description of a new methodology for its enantiomeric 
resolution is explained (Chapter 4).  
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Chapter 2 
 
Influence of p1,n1 salt in the enantiomeric separation of  
trans-Chrysanthemic acid 
 
2.1 History 
In 1924 Staudinger and Ruzicka3 discovered that the pyrethrin natural active 
compounds are esters of chrysanthemic acid and pyrethric acid (Figure 2). Pyrethrins 
are natural insecticides obtained by dried flowers of pyrethrum (Chrysanthemum 
cinerariaefolium and C. coccineum). Those natural repellents and related synthetic 
analogues (first synthesized by Staudinger4) are instable in air and light, so this limit 
restricts and penalizes their use in agriculture crop protection against pests. Extensive 
research has product important industrial works and academic papers of a new and 
powerful class of esters.5 Those pyrethroids are photostable, biodegradable and couple a 
high insecticidal activity with a low mammalian toxicity.6 
 
 
R R’ 
                
 
Pyrethrin I 
Pyrethrin II 
Cinerin I 
Cinerin II 
Jasmolon I 
Jasmolon II 
Me 
CO2Me 
Me 
CO2Me 
Me 
CO2Me 
CH=CH2 
CH=CH2 
CH2Me 
CH2Me 
Me 
Me 
Figure 2 
                                                 
3
 H. Staudinger, L. Ruzicka, Helv. Chim. Acta 1924, 7, 177, 201, 212, 236, 245, 377.  
In 1939 L. Ruzicka was Nobel laureate in Chemistry and in 1953 H. Staudinger  too. 
4
 H. Staudinger, L. Ruzicka, Helv. Chim. Acta 1924, 7, 448. 
5
 a) S. Jeanmart, Aust. J. Chem., 2003, 56, 559 and references cited therein; b) A. Fishman, D. Kellner, D. 
Ioffe and E. Shapiro, Org. Process Res. Dev. 2000, 4, 77 and references cited therein; c) J. Crosby, Pestic. 
Sci., 1996, 46, 11; d) J. Martel, in Chirality in Industry, ed. A. N. Collins, G. N. Sheldrake and J. Crosby, 
John Wiley & Sons, Chichester, UK, 1992, ch. 4 pp. 87–109; e) K. Naumann, in Chemistry of Plant 
Protection, ed. W. S. Bowers, W. Ebing, D. Martin and R. Wegler, Springer Verlag, Berlin, Germany, 
1990, vol. 5, ch.1, pp. 3–100; f) J. Tessier, Chem. Ind., 1984, 199; g) Pyrethrum–The Natural Insecticide, 
ed. J. E. Casida, Academic Press, New York, USA, 1973; h) D. Arlt, M. Jautelat and R. Lantzsch, Angew. 
Chem., Int. Ed. Engl., 1981, 20, 703; i) M. Elliott and N. F. Janes, Chem. Soc. Rev. 1978, 7, 473. 
6
 M. Elliott, ACS Symp. Ser. 1977, 42,1 and references cited therein. 
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trans- and cis-2,2-Dimethyl-3-(2-methylprop-2-enyl)cyclopropane carboxylic acids 
(Chrysanthemic acid, ChA) so are important starting material for the preparation of 
several natural and synthetic insecticides for the control of many kinds of undesired 
mites, insects, and spiders in agriculture crop and in the public health sector. The 
biologic activity is correlated to the chirality of the optical isomers: the more effective 
one is shown to be (+)-trans isomer, followed by (+)-cis, instead the (–)-cis and (–)-
trans are almost ineffective7 (Figure 3). 
 
 
(1R,3R)-(+)-trans 1a  (1R,3S)-(+)-cis 1b (1S,3R)-(–)-cis 1c (1S,3S)-(–)-trans 1d 
         
Insecticidal activity among the four isomers of chrysanthemate moiety 
Figure 3 
The first asymmetric synthesis was made by Aratani and co-workers8 exploiting the 
reaction of alkyl diazoacetate with an olefin catalyzed by a chiral copper complex to 
obtain an optically active alkyl cyclopropanecarboxylate (Figure 4).  
 
 
 
                       Copper catalyst 
R trans-cis % ee (trans) 
% ee 
(cis) 
Et 51/49 68 62 
t-Bu 75/25 75 46 
l-adamantyl 84/16 85 46 
 
l-menthyl (de) 93/7 94 46 
Figure 4 
The asymmetric cyclopropanation  is one of the most efficient methods to synthesize 
optically active chrysathemic acid esters.9 To be employed in an industrially applicable 
                                                 
7
 For the racemization and epimerization of chrysanthemic acid isomers, see G. Suzukamo, M. Fukao and 
T. Nagase, Chem. Letters 1984, 1799; G. Suzukamo, M. Fukao and M. Tamura, Tetrahedron Letters 25, 
1984, 1595. 
8
 Aratani, T.; Yoneyoshi, Y.; Nagase, T. Tetrahedron Letters 1975, 1707; 1977, 2599; 1982, 685. Aratani, 
T. 1985, 1839. 
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process this reaction needs to proceed with good stereo- and enantioselectivity, and to 
use a simple alkyl diazoacetate and high catalyst efficiency: a panoramic summary of 
reactions and catalysts has been made by Itagaky and co-workers.10 The use of ethyl 
diazoacetate (although a toxic and hazardous chemical product) allows a great atom 
economy, and still now many industries prepare tonnes of racemic chrysathemic acid in 
mixtures of trans- and cis-isomers in ratios ranging from 65:35 to 9:1 exploiting a metal 
catalyzed carbene insertion reaction of this starting material on 2,5-dimethyl-2,4-
hexadiene.11 Mixtures with a poor content of trans-ChA can be enriched by 
epimerization because of this isomer is the thermodynamically more stable and the 
equilibrium ratio (depending on the operative conditions) is on the order of 9:1. 
 
2.2 Optical resolution 
Enantiopure trans- and cis-ChA 1 are fundamental for the syntheses of pyrethroids with 
greater insecticidal and repellent activity like cypermethrin 2a, deltamethrin 2b and (S)-
bioallethrin 2c (Figure 5).  
 
 
 X= Cl, cypermethrin 2a 
X= Br, deltamethrin 2b 
(S)-bioallethrin 2c 
Figure 5 
Asymmetric catalysis is an elegant and fascinating route to the “chirality” but, many 
limits hamper the industrial use of catalysis in product, for example: a) the catalyst cost, 
stability, availability and efficiency; b) the costs resulting from licensing patents; c) the 
need of specialized equipment d) (frequently) the use of low temperatures, high 
                                                                                                                                               
9
 Doyle, M. P.; McKervey, M. A.; Ye, T. Modern Catalytic Methods for Organic Synthesis with Diazo 
Compounds; John Wiley & Sons: New York, 1998; Lebel, H.; Marcoux, J.-F.; Molinaro, C.; Charette, B. 
A. Chem. Rev. 2003, 103, 977. 
10
 Itagaki, M.; Masumoto, K.; Suenobu, K.; Yamamoto, Y. Org. Process & Rev. 2006, 10, 245. 
11
 Campbell, I. G. M.; Harper, S. H. J. Chem. Soc. 1945, 283; Sanders, H. J.; Taff, A. W. Ind. Eng. Chem. 
1954, 46, 414. 
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dilutions and purities of reagents and solvents.12 Though progresses in this field during 
the last two decades are indubitable and impressive, the optical resolution of racemic 
acids and bases via formation of diastereomeric p and n salt13 (Scheme 2), and their 
separation by crystallization, is still the preferred method to obtain a vast majority of 
enantiopure molecules that are pharmaceutical and agrochemical targets.  
 
(±)-A + (+)-B 
 
(+)-A . (+)-B       + (–)-A . (+)-B 
  p salt n salt 
  
  
Resolution of a racemic acid (±)-A with an enantiopure base (+)-B 
The letter p is used to designate the 
diasteroisomers resulting from 
reaction of two constituents having 
like sign of rotation, the letter n to 
unlike sign. 
Scheme 2 
The essence of this type of resolution (a substrate selective process) is the differential 
interaction of the enantiomers of a racemic mixture with the resolving agent to form a 
pair of diastereomers, which exhibit different physicochemical properties and can be 
separated by an achiral method. Finally the single diastereoisomers have to be 
decomposed to obtain the unchanged agent and the pure enantiomers.14 Resolution can 
be yielded by formation of covalent or non-covalent diastereomers (Scheme 3); in the 
second case, for example, by salt formation (with acidic or basic substrate) or complex 
formation (with neutral racemate).  
 
Optical Resolution 
• Spontaneous resolution, induced 
crystallization 
 
• By Formation of Diasteromers # covalent # non -covalent 
• By substrate selective reactions 
 
 
• Combined with 2nd order asym. 
transformation: racemization and 
deracemization 
 
Salt Formation 
Complex Formation 
“Half equivalent” method 
With mixture or resolving agent 
With a derivate of the target 
compound 
Enantioselective chromatography 
Enantioselective phase-transfer 
 
 
Scheme 3 
Formation of p and n salt is the preferred methodology particularly when the undesired 
enantiomer can be recycled, as in the case, and when the goal is an industrial application 
                                                 
12
 Blaser, H. U. Chem. Comm. 2003, 293. 
13
 David Kozma CRC Handbook of Optical Resolutions via Diastereoisomeric Salt formation, CRC Press, 
London, 2001; Jacques, J.; Collet, A.; Wilen, S. H. Enantiomers, Racemates, and Resolutions, Wiley and 
Sons, New York, 1981. 
14
 Fogassy, E.; Nogradi, M.; Kozma, D.; Egri, G.; Palovics, E.; Kiss, V. Org. Biomol. Chem. 2006, 3011. 
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(crystallization techniques is economical, scalable and in general no complex or 
expensive equipment is necessary). 
 
2.3 The small molecule: DMPP 
In the resolution of the trans-ChA 1a Roussel-Uclaf has developed the most efficient 
process,15 that uses as the resolving agent the enantiopure (1R,2R)-(–)-(threo-2-
dimethylamino-1-(4-nitrophenyl)-1,3-propanediol) 3 (DMAD). The precipitation of the 
n salt occurs when this base is used with a crystallization co-solvent (i-Pr2O/MeOH). 
Methanol is incorporated into the crystals of the less soluble salt, and promotes the 
nucleation and the crystal growth (Scheme 4).16  
 
DMAD  
solvent Yield  Optical purity   S 
    
i-Pr2O/MeOH 84.4 % 96.7 % 0.82 
di-n-butyl ether/MeOH 99.2 % 83.9 % 0.83 
diethyl ether/MeOH 86.5 % 99.3 % 0.86 
    
 
 
E. Fogassy, et al. J. Chem. Soc., Perkin Trans. 2, 2000, 149. 
Scheme 4 
In the scheme a new parameter is highlighted: the Resolving Efficiency (S), also called 
Fogassy’s parameter. This is used for a numerical characterization of the resolution and 
so, it allows comparing the efficiency of different processes. Resolving Efficiency is the 
product of yield (y) times the enantiomeric purity (e.e.) (Equation 1). 
 
 
 
                                                 
15
 Inter alia: a) quinine: (i) I. C. M. Campbell and S. H. Harper, J. Sci. Food Agric. 1952, 3, 189, (ii) L. 
Crombie, J. Crossley and D. A. Mitchard, J. Chem. Soc. 1963, 4957; b) L-lysine: M. Matsui and F. 
Horiuchi, Agric. Biol. Chem. 1971, 35, 1984; c) L-2-benzylaminopropanol: F. Horiuchi and M. Matsui, 
Agric. Biol. Chem. 1973, 37, 1713; d) (–)-α-(1-naphthyl)ethylamine: (i) F. Horiuchi, A. Higo and H. 
Yoshioka, Sumitomo Chemical Co. Ltd., German Pat. 2 300 325, 1975, (ii) K. Sasaki, Sumitomo Chem. 
Co. Ltd, Japanese Pat. 98–16789, 1999; e) (S)-1-phenyl-2-(p-tolyl)ethylamine: (i) M. Itagaki, G. 
Suzukamo, K. Sasaki and K. Fujita, Sumitomo Chem. Co. Ltd, Eur. Pat. 933349 A1, 1999, (ii) G. 
Suzukamo and K. Sasaki, Sumitomo Chemical Co.Ltd., Eur. Pat. 1236708 A1, 2002; f) (S)-1-phenyl-2-
methylpropylamine: H. Hagiya, Sumitomo Chemical Co. Ltd., Japanese Pat. 2001114728 A2, 2001; g) 
L- or D-N-methyl-ephedrine: C. Pavan, J. Bulidon, Roussel Uclaf, US Pat 4 257 976, 1981; h) 
phenylglycinamide or 2-phenylglycinonitrile: F. Faigl, E. Fogassy, L. Nagy, L. Csiz, I. Czudor and E. 
Kovacsne Kozsda, CHINOIN-Budapest, PCT WO 90/08126, 1990. 
16
 Kozsda-Kovács, E´., Keserü, G. M., Böcksei, Z., Szilágyi, I., Simon, K., Bertók, B., Fogassy, E. J. 
Chem. Soc., Perkin Trans. 2 2000, 149. 
Chapter 2 
 10 
Resolving Efficiency  
y = (PD + PL)/0.5C0 
# PD and PL are the quantities (mol/l) of diastereomeric 
salts precipitated 
# C0 in the initial concentration of the racemate 
S = ( y × e.e. ) 
 
 
Equation 1 
The use of a threo-2-dimethylamino-1-aryl-1,3-propanediol, like in our case the DMPP 
4, as resolving agent gives to the process a possible industrial and green application (in 
accordance to the principles of green chemistry17). The synthesis of those compounds 
exploits the synthesis process technologies of the base of chloramphenicol 518, a potent 
bacteriostatic antimicrobial, isolated from bacterium Streptomices venezuelae. In the 
past, this antibiotic was produced and used in large scale until the discovery of its 
human toxicity. Due to this rare but serious side effect (aplastic anemia), it was bandit 
and a new similar drug was introduced in commerce: thiamphenicol 6. It is the methyl-
sulfonyl analogue of  chloramphenicol 5, but more potent and without the dangerous 
side effects. The limit of this compound is that only the levorotating (–)-enantiomer (–)-
6 is active. The industrial synthesis provides in large scale both the (+)- and the (–)-
enantiomer of a racemic precursor of 6. We could “recover” and exploit these optimized 
synthetic industrial technologies to obtained a wide set of chiral target compounds in 
both enantiomeric forms, that can be employed for example to obtain versatile and good 
resolving agents (Scheme 5). 
 
Chloramphenicol      5 Thiamphenicol      6 Resolving agent 
 
 
 
bandit drug 6 (1R,2R)-(–) antibiotic 6 (1S,2S)-(+) inactive (DMPP) 
Scheme 5 
                                                 
17
 Poliakoff, M.; Fittzpatrick, J. M.; Farren, T. R.; Anastas P. T. Science 2002, 297, 807. 
18
 “Chloramphenicol” is the assigned generic name to the compound D-(–)-threo-N-(1,10-dihydroxy-1-
pnitrophenylisopropyl)- dichloroacetamide for which Parke, Davis and Co. has adopted ‘Chloromycetin’ 
as its trademark; Bartz, Q. R. J. Biol. Chem. 1948, 172, 445. 
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2.4 The p1,n1 salt19 
Due to this background, the aim of this work is to develop a practical process to resolve 
racemic ChA mixtures 1 of industrial origin by formation and separation of crystalline 
diastereomeric salts exploiting, like optically pure resolving agent, the threo-2-
dimethylamino-1-phenyl-1,3-propanediol 4 (DMPP). Despite the innumerable qualities 
of the above described resolution method, some times unpredictable and exceptional 
results occur: a well-crystallized and poorly soluble mixture brings to a racemic acid, 
even after several recrystallizations. This phenomenon can be ascribed to the formation 
of a 1/1 double salt, a third salt (called p1,n1 salt) originating from a stable combination 
of the p and n salts. Ladenburg20 has postulated the existence of those salts at the 
beginning of the last century, while the first structural evidence came later.21 In our case 
racemic trans-ChA 1a forms p1,n1 salts when treated with the pure enantiomers of 
DMPP 4, where those new salts have the same rotation of the DMPP 4 enantiomer used 
(Scheme 6).  
 
 
Trans-ChA 1a (+)-DMPP 4 
 
(a)   (±)-ChA + 2 (+)-B 
 
(+)-ChA . (+)-B     + (–)-ChA . (+)-B 
  p salt n salt 
(b)   (±)-ChA + 2 (+)-B 
 
[(±)-ChA . (+)-B2]      
  p1,n1 salt  
 
Scheme 6 
The single-crystal X-ray diffraction analysis (Figure 6) has proved the uniqueness of 
this salt, its supramolecular architecture and that it isn’t a simple mechanical mixture of 
the p and n salts.22  
                                                 
19
 Rosini, G.; Borzatta, V.; Boschi, F.; Candido, G.; Marotta E.; Righi, P. Chem. Commun. 2007, 2717. 
20
 Ladenburg, A. Justus Liebigs Ann. Chem. 1908, 340, 227. 
21
 Turkington, D. E.; MacLean, E. J.; Lough, A. J.; Ferguson G.; Glidewell, C. Acta Crystallogr., Sect. B: 
Struct. Sci. 2005, 61, 103. 
22
 Rosini, G.; Ayoub, C.; Borzatta, V.; Mazzanti, A.; Marotta E.; Righi, P. Chem. Commun. 2006, 4294. 
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Figure 6 
The presence of this salt can be exploited to recover the exceeding fraction of the major 
enantiomer from non-racemic mixture.23 When a (+)-trans-ChA (+)-1a enriched 
mixture (50% ee) was treated with (+)-DMPP (+)-4, the first 0.5 equivalents of added 
base caused the precipitation of the p1,n1 salt (Figure 7).  
 
 
Figure 7 
                                                 
23
 For a very efficient resolution see: Rosini, G.; Ayoub, C.; Borzatta, V.; Marotta E.; Mazzanti, A.; 
Righi, P. Green Chem. 2007, 441. 
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The same experiment was performed using the same 50% ee (+)-trans-ChA (+)-1a 
enriched mixture, but changing the base enantiomer. A completely different behavior 
was found: the addition of 0.5 equivalents of the (–)-DMPP (–)-4 (that is stoichiometric 
to the excess of acid ee) caused the precipitation of  n salt (Figure 8). 
 
 
Figure 8 
In summary, when a non-racemic mixture of trans-ChA 1a is treated with the pure 
enantiomer of DMPP 4 with the same sign of rotation the p1,n1 salt is formed leaving 
the exceeding enantiomer in solution. On the other hand, when an enriched mixture of 
acid is treated with the pure enantiomer of base with opposite sign and stoichiometric to 
the exceeding fraction of the trans-ChA 1a enantiomer, n salt always forms first, 
leaving the acid racemate in solution. Characterization and solubility data of the salts 
(Table 1,Table 2) did not fully explain this absolute specificity for n salt formation.  
 
DSC 
 Mp/°C Peak/°C ∆Hf/J g-1 [α]D
 
 (c/g (100mL)-1) 
 in CHCl3 solution at 23°C 
 
    
(+)-p salt 90.0-92.0 88.81 -111.2 +39.7                  (0.97) 
(+)-n salt 132.6-134.0 131.27 -126.7 +12.3                 (0.93) 
(+)-p1,n1 salt 110.0-111.5 110.97 -146.4 +26.8                 (1.04) 
     
Table 1 
 
 
 
 
 
 
 
 
Chapter 2 
 14 
Solubilities in i-Pr2O/mg ml-1 
(performed by equilibrating the solid/liquid mixture of the salt for 24h at the given temperature) 
T/°C n salt p1,n1 salt p salt  
 
    
15 4.21 4.84 N.d. 
31 7.78 8.72 N.d. 
68 33.0 46.6 soluble 
p salt is soluble in refluxing i-Pr2O. Once 
dissolved, it forms metastable solutions from 
which precipitation is achieved only by 
scratching the container’s walls. 
     
Table 2 
In the case depicted in Figure 7, the system has the opportunity to choose between the 
precipitation of the racemate as the p1,n1 salt and that of the exceeding enantiomer as the 
n salt. In such cases a specific and quantitative precipitation of the n salt has always 
been observed. Unfortunately, this great selectivity no allows a quantitative recovery of 
the major trans-ChA 1a: the addition of 0.75 eq. (–)-DMPP (–)-4 causes the 
precipitation of a salt with only 66% ee. This % ee value can be ascribed to 2 : 1 
mixture of n and p1,n1 salts respectively.  
To better understand this result we performed a set of ten crystallization experiments in 
a parallel reactor (Table 3). The ten vessels were charged with increasing amounts of (–
)-DMPP (–)-4 (from 0.1 equiv. in vessel #1 up to 1 equiv. in vessel #10, in linear steps 
of 0.1 equiv.). Then all the ten vessels were added with 1 equiv. of the scalemic mixture 
of (+)-trans-ChA (+)-1a with 50% ee in i-Pr2O. The parallel reactor was heated at reflux 
for 30 min and then the ten mixtures were let to crystallize. Chrysanthemic acid 
obtained from solids and mother-liquors of each vessel was collected and separately 
analyzed. The analyses showed that n salt precipitation occurs first (vessels 1–5) up to 
the point were all the exceeding (+)-trans-ChA (+)-1a enantiomer is consumed (0.5 
equiv. of base for a 50% ee of ChA) leaving in solution the trans-ChA 1a racemate. 
Larger additions of the same DMPP 4 base enantiomer (vessels 6–10) cause the 
precipitation of the trans-ChA 1a racemate as the p1,n1 salt.  
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vessel (–)-DMPP (–)-4 (equivalent) Operation Precipitate 
1 0.1  
2 0.2  
3 0.3  
4 0.4  
5 0.5  
n salt 
6 0.6  
7 0.7  
8 0.8  
9 0.9  
10 1.0  
 
# addiction of (+)-trans-ChA 
(+)-1a (50% ee) in i-Pr2O 
# reflux for 30 min 
# crystallization 
# precipitate and mother liquor 
separation 
# analysis  p1,n1 salt 
Table 3 
This behavior may be explained by considering trans-ChA 1a enantiomers self-
association in solution. 
 
2.5 The diastereomeric dimer 
In solution, the enantiomers can give rise to the formation of three distinct dimers 
(Scheme 7), namely the diastereomeric heterodimer and the two enantiomeric 
homodimers.24  
 
Trans-ChA self-association in solution 
 
n  [(+)-ChA. (–)-ChA]      + 
 
m – n  [(–)-ChA]    
Heterodimer 
 
 
m/2  [(+)-ChA]2                +    n/2  [(–)-ChA]2                      
 
m [(–)-ChA] + n  [(+)-ChA] 
 
m ≥ n         
 
Homodimer 1 
 
Homodimer 2 
Scheme 7 
Three different situations can be considered. (a) Initial racemic composition (m = n): 
independently of the system preference, equal amounts of the two enantiomeric 
homodimers are always formed (m = n) and no free unmatched enantiomer is left after 
the formation of heterodimer (m - n = 0). (b) Initial non-racemic composition (m ≠ n) 
with a preference for homodimers: the enantiomeric homodimers are formed in the 
same initial m/n ratio. (c) Initial non-racemic composition (m ≠ n) with a preference for 
the heterodimer: after the formation of heterodimer, the exceeding fraction of the major 
enantiomer remains free in solution; this is the only case where the initial m/n ratio 
                                                 
24
 Gavezzotti, A.; Filippini, G. Chem. Comm. 1998, 287. 
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between enantiomeric species is broken. This latter phenomenon has been exploited in a 
few cases for the achiral separation of the exceeding enantiomer from the racemate of a 
non-racemic mixture of a chiral substance.25 
The assumption that, in solution, trans-ChA 1a strongly prefers to form heterodimers, 
can explain the different results obtained with two enantiomers of DMPP 4. This can 
also be implied by the fact that at room temperature racemic trans-ChA 1a is solid (mp 
54°C), while in enantiopure form is liquid (mp 17-21°C). 
Thus, in a solution of enantioenriched trans-ChA 1a, the heterodimer actually acts as a 
sequestrant of the minor enantiomer. Any base added to the system would preferentially 
react with the free fraction of the major enantiomer, without disrupting the stable 
heterodimer. Given this picture, the addition of either of the DMPP 4 enantiomers 
makes a big difference. If the DMPP 4 base added has the same rotation sign as the 
exceeding trans-ChA 1a enantiomer [(–)-DMPP (–)-4, in Figure 7], reaction with the 
free (–)-ChA (–)-1a would form the p salt, which is soluble (Table 2) and does not 
precipitate. The only alternative for this base is to disrupt heterodimeric aggregate and 
form the p1,n1 salt. If the added enantiopure DMPP 4 has the opposite rotation sign with 
respect to the exceeding trans-ChA 1a enantiomer [(+)-DMPP (+)-4, in Figure 8], 
reaction with the free (–)-ChA (–)-1a precipitates the less soluble n salt (Table 2). When 
the free fraction of (–)-ChA (–)-1a is consumed up to the n salt solubility level, further 
additions of the base would precipitate the heterodimer as the p1,n1 salt. 
In an attempt to study the relative stability of the n,  p1,n1 and p salts we performed the 
set of experiments depicted in Figure 9. In any case a salt was suspended in hot i-Pr2O, 
then 0.5 eq. of a pure enantiomer of trans-ChA 1a were added. The mixture was kept at 
reflux for 30 min and then filtered. Enantiomer composition of trans-ChA 1a obtained 
from the salts and the mother-liquors was determined.  
 
                                                 
25
 a) Tsai, W.-L.; Hermann, K.; Hug, E.; Rohde, B.; Dreiding, A. S. Helv. Chim. Acta 1985, 68, 2238; b) 
Fogassy, E.; Faigl, F.;A´cs, M. Tetrahedron 1985, 41, 2841; c) Nicoud, R.-M.; Jaubert, J.-N.; Rupprecht, 
I.; Kinkel, J. Chirality 1996, 8, 234. 
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Figure 9 
The results were the following: (a) addition of 0.5 eq. of (–)-ChA (–)-1a to (+)-p salt 
displaces 0.5 eq. of (+)-ChA (+)-1a from the salt to form the more stable and insoluble 
(+)-p1,n1 salt; (b) addition of 0.5 eq. of (–)-ChA (–)-1a to (+)-p1,n1 salt, does not 
displace the remaining 0.5 eq. of (+)-ChA (+)-1a from the salt to form the n salt: it only 
displaces half of the remaining (+)-ChA (+)-1a to form a 1 : 1 mixture of n and p1,n1 
salts, so that a racemic composition is attained in solution; (c) n salt formation is 
completed by a addition of further 0.5 equiv. of (–)-ChA (–)-1a and again attaining a 
racemic composition in solution. Experiments (d)–(f) show that it is possible to convert 
the more stable and less soluble n salt into the p1,n1 salt, provided that a racemic 
composition of 1 is attained in solution: (d) addition of 0.5 eq. of (+)-ChA (+)-1a to n 
salt leads to the formation of the 1 : 1 mixture of n and p1,n1salts and a racemic solution 
of ChA 1a; (e) addition of further 0.5 eq. of (+)-ChA (+)-1a to this mixture of salts 
leads to the p1,n1 salt and a racemic solution of ChA 1a; and (f) addition of 0.5 eq. of 
(+)-ChA (+)-1a to p1,n1 salt causes no change since this would form the less stable and 
more soluble p salt without the possibility to achieve a racemic solution of 1. 
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2.5 Conclusion 
Considering its behavior with respect to the base DMPP 4, the major enantiomer in a 
trans-ChA 1a non-racemic mixture it is not all the same. The part of the major 
enantiomer that exceeds the racemate forms the n salt, while the fraction of the major 
enantiomer that is part of the racemate behaves in a totally different way, forming the 
p1,n1 salt. 
This salt formation influence the enantiomer separation process: when this phenomenon 
is accompanied by the substrate self-aggregation, an inescapable racemate ‘‘cage’’ may 
form both in the solid phase (the p1,n1 salt) on one side and in the solution phase self-
aggregation of the substrate with preference for the heterodimer aggregate (Figure 10). 
This cage impedes the complete recovery of the major enantiomer of the substrate in an 
enantioenriched mixture, allowing to recover only the exceeding part of it. 
 
 
Figure 10 
 
 
2.7 Experimental section 
Enantiomeric composition of chrysathemic acid samples was determined by CSP GC 
(capillary column Rt-βDEXsm™-RESTEK Corp.; 30 m; 0.32 mmID; 0.25µm; injector 
275 °C; FID detector 300 °C; 80 °C (2 min) then to 125 °C (1.5 °C/min): tr[(+)trans-
ChA] = 29.4min, tr[(–)trans-ChA] = 30.3min. Differential scanning calorimetric 
measurements were performed with a TA-Instruments DSC-2920 apparatus adopting a 
temp. program consisting of one heating ramp starting from room temperature at a 
heating rate of 4°C/min under N2. 
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Preparation of  (+)-n,  (+)-p and  (+)-p1,n1 salts: General procedure 
A 250 mL round-bottomed flask was fitted with a magnetic stirbar and a reflux 
condenser. The flask was charged with (1S,2S)-(+)-DMPP (+)-4 (5.85 g, 30 mmol) and 
100 mL of iPr2O. The suspension was heated to reflux until the base was completely 
dissolved, then the heating was stopped to add 30 mmol  (5.04 g dissolved in 20 mL of 
iPr2O) of (–)-trans-ChA (–)-1a, (+)-trans-ChA (+)-1a, or (±)-trans-ChA 1a in one 
portion to obtain, respectively, the (+)-n salt, the (+)-p salt and the (+)-p1,n1 salt. The 
addition of (–)-trans-ChA (–)-1a and (±)-trans-ChA 1a produced the quick precipitation 
of, respectively the (+)-n salt and the (+)-p1,n1 salt. The mixtures were heated for one 
more hour, cooled to room temperature and the resulting microcrystalline solids were 
isolated by filtration, washed with n-hexane and dried in vacuo to give the (+)-n salt 
(95% yield ) or the (+)-p1,n1 salt (94% yield).  After the addition of (+)-trans-ChA (+)-
1a no precipitation of (+)-p salt occurred, the solution was refluxed for one additional 
hour and then cooled at room temperature. It was necessary to scratch the walls of the 
flask to start the precipitation of the p salt as a white solid (80% yield). 
 
(±)-trans-ChA•(1S,2S)-(+)-DMPP 
[(+)-p1,n1 salt] 
1H NMR (300 MHz, CDCl3): δ 1.08 (s, 3H); 1.22 (s, 3H); 1.30 (dd, 1H, J1 = 5.4 Hz, 
J2 =1.8 Hz); 1.68 (s, 6H); 1.94 (dd, 1H, J1 = 8.0 Hz, J2 =5.4 Hz); 2.71 (s, 6H); 2.94 (m, 
1H);  3.33 (dd, 1Ha, J1 = 12.9 Hz, J2 =6.2 Hz); 3.52 (dd, 1Hb, J1 = 12.9 Hz, J2 = 2.8 Hz); 
4.67 (d, 1H, J1 = 9.5 Hz); 4.85 (d, 1H, J1 = 5.2 Hz); 7.34 (m, 5H); 7,41 (bs, 3H). 13C-
NMR (75 MHz, CDCl3): δ 19.10; 21.35; 23.06; 26.16; 27.94; 32.31; 32.42; 37.49; 
37.63; 42.06; 58.41; 71.51; 71.69; 122.80; 122.85; 127.68; 128.91; 129.27; 134.85; 
141.86; 179.60; IR (KBr) υ: 3,151; 2,922; 1,568; 1,421 cm-1. MS (ES+, m/z): 196 
(M++1); 197 (M++2); (ES-, m/z):167 (M--1); 168 (M-). [α]D20 + 26.8 (c 1.036, CHCl3); 
m.p.: 109.7-111.5 °C; DSC: peak: 110.97 °C; ∆Hf -146.4 Jg-1. 
 
X-Ray crystal structure: orthorhombic, space group P212121, a = 11.1297(6), b = 
13.4914(7), c = 28.0333(14) Å, V = 4209.3(4) Å3, T = 293(2) K, Z = 8, ρc = 1.147 g cm–
3
, F(000) = 1584.0, graphite-monochromated MoKα radiation (λ = 0.71073 Å), µ(MoKα) 
= 0.078 mm–1, colorless block (0.4 × 0.3 × 0.1 mm3), empirical absorption correction 
with SADABS (transmission factors: 0.9694 – 0.9922), 2400 frames, exposure time 10 
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s, θmax = 27.50, hmax = 14, kmax = 17, lmax = 36, 45793 reflections collected, 9681 
independent reflections (Rint = 0.045), solution by direct methods (SHELXS9726) and 
subsequent Fourier syntheses, full-matrix least-squares on Fo2 (SHELX9726), hydrogen 
atoms refined with a riding model, data / parameters = 9681 / 495, S(F2) = 1.030, R(F) = 
0.0605 and wR(F2) = 0.1136 on all data, R(F) = 0.0387 and wR(F2) = 0.1187 for 1652 
reflections with I > 2σ(I), weighting scheme w = 1/[σ2(Fo2) + (0.0567P)2 + 0.2527P] 
where P = (Fo2 + 2Fc2)/3, largest difference peak and hole 0.144 and –0.177 e Å–3. 
 
(–)-trans-ChA•1S,2S-(+)-DMPP 
[(+)-n salt] 
1H-NMR (300 MHz, CDCl3): δ 1.08 (s, 3H); 1.22 (s, 3H); 1.30 (dd, 1H, J1 = 5.4 Hz, J2 = 
1.8 Hz); 1.69 (s, 6H); 1.94 (dd, 1H, J1 = 7,9 Hz, J2 =5.4 Hz); 2.71 (s, 6H); 2.94 (m, 1H);  
3.31 (dd, 1Ha, J1 = 12.9 Hz, J2 = 6.2 Hz); 3.4 (dd, 1Hb, J1 = 12.9 Hz, J2 = 2.8 Hz); 4.68 
(d, 1H, J1 = 9.5 Hz); 4.85 (d, 1H, J1 = 5.2 Hz); 7.32 (m, 5H); 7.67 (bs, 3H). 13C-NMR 
(75  MHz, CDCl3 ): δ 18.60; 20.83; 22.57; 25.67; 27.33; 31.77; 37.56; 41.53; 57.83; 
71.00; 122.37; 127.20, 128.42, 128.77; 134.32; 141.39; 179.20. IR (KBr) υ: 3,151; 
2,922; 1,568; 1,421 cm-1. MS: (ES+, m/z): 196 (M++1); 197 (M++2); (ES-, m/z): 167 
(M--1); 168 (M-). [α]D20 + 12.3 (c 0.9720, CHCl3); m.p.: 132.6-134.0 °C. DSC: peak: 
131.27 °C; ∆Hf -126.7 Jg-1. 
 
X-Ray crystal structure: orthorhombic, space group P212121, a = 7.3883(8), b = 
10.1582(11), c = 28.935(3) Å, V = 2171.6(4) Å3, T = 293(2) K, Z = 4, ρc = 1.112 g cm–3, 
F(000) = 792.0, graphite-monochromated MoKα radiation (λ = 0.71073 Å), µ(MoKα) = 
0.076 mm–1, empirical absorption correction with SADABS (transmission factors: 
0.9694 – 0.9922), 2400 frames, exposure time 10 s, θmax = 29.98, hmax = 10, kmax = 14, 
lmax = 40, 6299 reflections collected, 3606 independent reflections, solution by direct 
methods (SHELXS9726) and subsequent Fourier syntheses, full-matrix least-squares on 
Fo2 (SHELX9726), hydrogen atoms refined with a riding model, data / parameters = 
3606 / 495, S(F2) = 1.045, R(F) = 0.0560 and wR(F2) = 0.1441 on all data, R(F) = 
0.0387 and wR(F2) = 0.1187 for 1652 reflections with I > 2σ(I), weighting scheme w = 
1/[σ2(Fo2) + (0.0567P)2 + 0.2527P] where P = (Fo2 + 2Fc2)/3, largest difference peak 
and hole 0.144 and –0.177 e Å–3. 
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 Sheldrick, G. M. SHELX97; Universität Göttingen, Germany, 1997. 
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X-ray crystal structure of the n salt 
CCDC 287292 contains the supplementary crystallographic data for the n salt. These 
data can be obtained free of charge from The Cambridge Crystallographic Data Centre 
via www.ccdc.cam.ac.uk/data_request/cif. 
 
A. L. Spek (2005) PLATON, A Multipurpose Crystallographic Tool, Utrecht University, Utrecht, The 
Netherlands. 
 
(+)-trans-ChA•1S,2S-(+)-DMPP 
[(+)-p salt] 
1H-NMR (300 MHz, CDCl3): δ 1.08 (s, 3H); 1.23 (s, 3H); 1.32 (dd, 1H, J1 = 5.4 Hz, J2 = 
1.78 Hz); 1.69 (s, 6H); 1.94 (dd, 1H, J1 = 8,0 Hz, J2 =5.4 Hz); 2.70 (s, 6H); 2.94 (m, 
1H);  3.33 (dd, 1Ha, J1 = 12.9 Hz, J2 = 6.2 Hz); 3.51 (dd, 1Hb, J1 = 12.9 Hz, J2 = 2.9 Hz); 
4.65 (d, 1H, J1 = 9.6 Hz); 4.87 (d, 1H, J1 = 5.3 Hz); 7.32 (m, 5H); 7.50 (bs, 3H). 13C-
NMR (75  MHz, CDCl3 ): δ 18.41; 20.66; 22.37; 25.48; 27.32; 31.78; 36.76; 41.40; 
57.82; 70.86; 71.13; 122.10; 126.98, 128.21, 128.59; 134.25; 141.19; 178.73. IR (KBr) 
υ: 3,151; 2,922; 1,568; 1,421 cm-1. MS: (ES+, m/z): 196 (M++1); 197 (M++2); (ES-, 
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m/z): 167 (M--1); 168 (M-). [α]D20 + 39.7 (c 0.9320, CHCl3); m.p.: 93.7-96.6 °C. DSC: 
peak: 88.81 °C; ∆Hf -111.2 Jg-1. 
 
The levorotating enantiomers of n-, p- and p1,n1 salts were prepared by reacting 
(1R,2R)-(–)-DMPP and, respectively, (+)-trans-ChA and (–)-trans-ChA and (±)-trans-
ChA. 
 
 
 
General procedure for the recovery of the enantiomeric excess of (+)-trans-ChA 
(+)-1a from a scalemic mixture through formation of (+)-p1,n1 salt. 
(1S,2S)-(+)-DMPP (+)-4 (2.34 g, 12 mmol) was dissolved in 40 mL of hot iPr2O and to 
this solution was added a solution of 5.04 g (30 mmol) of a scalemic (+)-trans-ChA (+)-
1a (ee = 60%) in 20 mL of iPr2O. The mixture was heated at 65 °C under stirring, then 
cooled to ambient temperature. When a solid started to precipitate heating was 
protracted for half an hour and then cooled to 0°C under stirring for 15 min. The solid is 
filtered and washed twice with iPr2O  (10 mL). 
The salt was dried and afforded 4.05 g (93 % yield) of (+)-p1,n1 salt with mp 110.0-
111,5°C and [α]D +26.3 (c 1.026, CHCl3). From this salt, after the acidic/basic 
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treatment described previously, both racemic (±)-trans-ChA 1a and the free base were 
recovered. 
Washing of the mother liquors with an aqueous HCl solution until pH 3.5, drying and 
evaporation under vacuum (30 °C/24 mbar) afforded 2.66 g of (+)-trans-ChA (ee > 
95%, 88% yield based on excess of (+)-trans-ChA (+)-1a  of the starting mixture). 
 
Recovery of the excess of (+)-trans-ChA, with (1S,2S)-(+)-DMPP through 
precipitation of (+)-p1,n1 salt. 
 
(+)-trans-ChA 
(+)-1a 
(+)-DMPP 
(+)-4 
p1,n1 salt (+)-trans-ChA(+)-1a from ML 
(+):(–),   ee (%)(a) (eq) yield(b) (%) ee (%)(a) yield(c) (%) 
75:25,   50 0.5 92 94 92 
80:20,   60 0.4 93 96 94 
85:15,   70 0.3 92 96 93 
90:10,   80 0.2 88 94 90 
a) Determined by CSP GC; b) Referred to (±)-trans-ChA 1a present in the starting mixture; c) Referred 
to the excess of (+)-trans-ChA (+)-1a present in the starting mixture.  
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Chapter 3 
 
[2+2]-Cycloaddition reactions with chiral keteniminium salt 
 
3.1 Background 
3.1.1 First part 
Prostaglandins (PGs), which are one of the classic example of lipid mediators acting as 
local hormones, were discovered27 by Von Euler in the 1930s and their structures were 
elucidated in the mid-1960s by the pioneering study of Bergström28 and his group. An 
extraordinary chemical and biological research29 has been induced by the possible 
pharmacological utility of this type of lipids. They show a remarkable activity in a wide 
variety of mammalian tissues. Therefore they play a key role in immune response, 
inflammation and in tissue repair. These lipid mediators belong to the natural family of 
ecosanoids (derived from essential fatty acids oxidation). They are potent but very labile 
molecules, so they are not stored but biosynthesized. In the Scheme 8 the oxygenated 
metabolism of arachidonic acid is shown, where the biotransformation affords the key 
intermediate PGH2 by exploiting a prostaglandine H2 synthase and two oxygen 
molecules. In turn, this is transformed into prostacyclin PGI2 (see chapter 4, paragraph 
4.1), molecule with vasodilating and platelet antiaggregatory properties, and 
transformed into thromboxane TXA2 (vasoconstriction mediator) and different 
prostaglandins PGS as well. 
 
 
                                                 
27
 Von Euler, U. S. Arch. Exp. Pathol. Pharmakol. 1934, 175, 78.  
28
 a) Bergström, S.; Sjövall, J. Acta Chem. Scand. 1957, 11, 1086; b) Bergström, S.; Sjövall, J. Acta 
Chem. Scand. 1960, 14, 1693 ; c) Bergström, S.; Sjövall, J. Acta Chem. Scand. 1960, 14, 1701; d) 
Bergström, S.; Ryhase, R.; Samuelsson, B.; Sjövall, J. Acta Chem. Scand. 1962, 16, 501; e) Bergström, 
S.; Ryhase, R.; Samuelsson, B.; Sjövall, J. Biol. Chem. 1963, 238, 3555. 
29
 a) Bindra, J. S.; Bindra, R. Prostaglandin Synthesis, Academic Press, New York, 1977, 7 b) Mitra, A. 
The Synthesis of Prostaglandins; Wiley: New York, 1977 c) New Synthetic Routes to Prostaglandins and 
Tromboxanes; Roberts, S. M., Scheinmann, F., Eds.; Academic Press: New York, 1982 d) Newton, R. F.; 
Roberts, S. M. Prostaglandins and Tromboxanes; Butterworth: London, 1982 e) Corey, E. J.; Cheng, X.-
M. The Logic of Chemical Synthesis; John Wiley and Sons: New York, 1989 f) Nicolaou, K. C.; 
Sorensen, E. J. In Classics in Total Synthesis- Targets, Strategies, Methods; VCH: Weinheim, 1996, 65 g) 
Das, S.; Chandrasekhar, S.; Yadav, J. S.; Grée, R. Chem. Rev. 2007, 3286. 
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Arachidonic acid                 Prostanoids 
 
 
 
 
PGH2 synthase 
PGI2 OH
O
HO
COOH
  
 
 
 
 
TXA2
 
 
PGH2 
 
 
 
 
 
 
PGS 
Scheme 8 
Prostanoids are obtained by total synthesis30 following three main basic ideas: 1) the 
core structure cyclopentane is prepared with the right substituents in appropriate 
positions to add the chains later. In this elegant and versatile approach the Corey lactone 
7 31 can be considered a milestone in the prostaglandin synthesis (Figure 11); 2) a five-
membered cyclic compound containing the first chain is coupled with the second one; 
3) one pot procedure that exploits the three-component coupling. 
 
 
Corey lactone 
Figure 11 
Like described above, the Corey lactone derivates are highly versatile intermediates for 
the synthesis of prostaglandins.32 Bicyclo[3.2.0]heptanones and bicyclo[3.2.0]hept-3-
                                                 
30
 Nicolaou, K. C.; Vourlomis, D.; Wissinger, N.; Baran, P. S. Angew. Chem., Int. Ed. 2000, 39, 45. 
31
 Corey, E. J.; Weinshenker, N. M.; Schaaf, T. K.; Huber, W. J. Am. Chem. Soc. 1969, 91, 5675. 
32
 a) Corey, E. J.; Andersen, N. H.; Cadson, R. M. ; Paust, J.; Vedejs, E.; Vlattas, I.; Winter, R. E. K. J. 
Amer. Chem. Soc. 1968, 90, 3245; b) Corey, E. J.; Vlattas, I.; Andersen, N. H.; Harding K.; ibid., 1968, 
90, 3247; c) Corey, E. J.; Vlattas, I.; Harding K.; ibid., 1969, 91, 535. 
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en-6-ones33 could be attractive building blocks to generate these important molecules 
and other natural biologically active compounds. In particular we can consider the 1,2-
polysubstituted cyclobutanones34 like the monoterpenoids grandisol, filifolone, 
raikovenal, and lineatin 35 (Scheme 9). 
 
Bicyclo[3.2.0]hept-3-en-6-ones  
 
 
 … to prostacyclin 
 
 
 … to monoterpenoids 
Scheme 9 
These molecules are characterized by a rigid skeleton and the presence of two fused 
rings of different size that can be modified and functionalized in a straightforward 
manner. From a synthetic point of view, their attractive features appear to be: 1) the 
possession of two functional groups like the carbon-carbon double bond in the five-
membered ring and the carbonyl group in the four-one, 2) the wedge form, that make 
possible selective modifications at the less hindered top-side (exo-side), 3) the possible 
reactivity that involves both groups at once since they are joined by a bridge-head 
carbon atom (Figure 12).  
 
Figure 12 
                                                 
33
 Marotta, E.; Righi, P.; Rosini, G. Org. Proc. Res. & Devel. 1999, 3, 206 and references cited therein. 
34
 Lee-Ruff, E.; Mladenova, G.; Chem. Rev. 2003, 103, 1449. 
35
 Rosini, G.; Laffi, F.; Marotta, E.; Pagani, I.; Righi, P. J. Org. Chem. 1998, 63, 2389.  
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Due to the great importance of these cyclopentanic scaffolds, the last decades have seen 
many academic works devoted to find an efficient and versatile synthesis. For example, 
a general  convenient and racemic approach to bicyclo[3.2.0]hept-3-en-6-ones exploits 
heptenoic acids like starting material. In the Scheme 10 the reaction conditions and the 
mechanism are shown: the sequence of events demonstrates the impossibility to obtain 
an enantiopure product even if starting with a optical pure acid. The loss of chirality 
occurs during the 1,2 elimination of acetic acid to generate an α,β-unsaturated mixed 
anhydride. Olefinic α,β-unsaturated ketene can be generated in two isomers (E and Z), 
but only the 3,4-Z-unsaturated intermediate can cyclize intramolecularly.     
 
 
Scheme 10 
Enantiopure targets can be obtained by following a different synthetic route or simply 
resolving the racemic compounds. For example an efficient method for the resolution is 
the stereoselective reduction to the corresponding alcohols, followed by the conversion 
into diastereoisomers using (–)-(1S,4R)-camphanic acid chloride as resolving agent and 
then chromatography separation. After a mild alkaline hydrolysis, the conversion to the 
enantiopure target is performed by oxidation. The [α]D magnitudes of bicycles are 
consistent with the geometric structure of  these unsaturated ketone chromophores.36  
 
 
                                                 
36
 Erman, W. F.; Treptw, R. S.; Bakuzis, P.; Wenkert, E. J. Am. Chem. Soc. 1971, 93, 657. 
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3.1.2 Second part 
In the early years of the 20th century, Hermann Staudinger37 has discovered ketene38 and 
its reactions39 starting from the [2+2]-cycloaddition of cyclopentadiene with 
diphenylketene, prepared by the dehalogenation of chlorodiphenylacetyl chloride with 
granulated zinc (Scheme 11). This discovery has been made two decades before the 
development of the Diels-Alder cycloaddition, and is still a fundamental mainstay of the 
organic chemistry. 
 
diphenylketene [2+2] reaction with cyclopentadiene 
 
 
Scheme 11 
Ketenes are highly useful and versatile organic reactive intermediates that can undergo 
many possible transformations. They are characterized by an high electron density at the 
C2-substituted carbon and prefer to react with alkenes across the C=C rather than C=O 
bond. The traditional interpretation of the Staudinger reaction mechanism40 is shown in 
Figure 13. 
 
 
 
 
 
 
 
 
 
                                                 
37
 Staudinger, H. Chem. Ber. 1905, 38, 1735. 
38
 a) Staudinger, H. Die Ketene; Verlag Enke: Stuttgart, 1912; b) Staudinger, H. From Organic Chemistry 
to Macromolecules; Wiley: New York, 1970; c) Staudinger, H.; Klever, H. W. Chem. Ber. 1908, 41, 594; 
d) Staudinger, H.; Klever, H. W. Chem. Ber. 1908, 41, 1516. 
39
 a) Staudinger, H. Liebigs Ann. Chem. 1907, 356, 51; b) Staudinger, H. Chem. Ber. 1907, 40, 1145; c) 
Staudinger, H.; Suter, E. Chem. Ber. 1920, 53B, 1092; d) Staudinger, H.; Rheiner, A. Helv. Chim. Acta 
1924, 7, 8. 
40
 Machiguchi, T.; Hasegawa, T.; Ishiwata, A.; Terashima, S.; Yamabe, S.; Minato, T. J. Am. Chem. Soc. 
1999, 121, 4771 and references cited therein. 
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zwitterionic intermediate 
 
transition state 
Figure 13 
The bicycle can be formed through: 1) a two-step mechanism via a  zwitterionic 
intermediate or 2) a concerted pathway via transition state, where the cyclopentadiene 
HOMO orthogonally interact with the ketene LUMO. It is well known that in thermal 
reaction ketenes are regarded as good antarafacial components. A large number of 
experiments41 have followed the Staudinger pioneering studies, with important new 
discoveries from laboratories around the world. The most representative and remarkable 
development is found in a key initial stage of the total synthesis of  prostaglandins42 (see 
3.1.1). 
An alternative to ketenes cycloaddition involves the reaction of keteniminium salts with 
alkenes. The higher contribution to this field has been made by Ghosez43 and co-
workers. 
 
Electronic structure 
  
Ketene keteniminium ion 
Figure 14 
                                                 
41
 a) Tidwell, T. T. Ketenes; Wiley: New York, NY, 1995; b) Hyatt, J.; Raynolds, R. W. Org. React. 
1994, 45, 159; Tidwell, T. T. Eur. J. Org. Chem. 2006, 563. 
42
 a) Corey, E. J.; Schaaf, T. K.; Huber, W.; Koelliker, U.; Weinshenker, N. M. J. Am. Chem. Soc. 1970, 
92, 397; b) Corey, E. J.; Noyori, R.; Schaaf, T. K. J. Am. Chem. Soc. 1970, 92, 2586; c) Corey, E. J.; 
Shirahama, H.; Yamamoto, H.; Terashima, S.; Venkateswarlu, A.; Schaaf, T. K. J. Am. Chem. Soc. 1971, 
93, 1490. 
43
 Ghosez, L.; Marchand-Brynaert, J. "Iminium Salts in Organic Chemistry Part 1”; Bohme, J., Viehe, H. 
G., Eds., Wiley: New York, 1976, 421. 
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These ketene equivalents are readily available from amide, more electrophilic than 
ketenes and avoid the dimerization problem often encountered in ketene reactions 
(Figure 14). The presence of a tetravalent iminium cation permits to hook a chiral 
auxiliary group on nitrogen to yield pure cyclic and polycyclic derivates that are 
important building blocks for the stereocontrolled construction of more complex carbon 
frameworks. Keteniminium salts can be easily synthesized by treatment, in an inert 
solvent, of an amide with triflic anhydride and a non-nucleophilic base or from α-halo 
enamine.44 In a recent paper,45 Ghosez has provided an efficient [2+2]-cycloaddition 
between olefins and chiral keteniminium salt, generated in-situ from N-
tosylsarcosinamide 8 ( 
Scheme 12). This reaction involving ketenes bearing a chiral substituent led to 
asymmetric products. A model reaction with cyclohexene has been exploited to 
investigate the best auxiliary among various molecules with C2 symmetry. In the 
scheme has been report two auxiliary examples arising from an asymmetric Baker’s 
yeast reduction 8a46 and prolinol 8b.47 Ketenimium generated from these secondary 
amines has been tested in reaction of a wide variety of olefins with good yields and 
diastereoselection. 
 
CHNTsMe
N
R1 R2
O
NR1R2
MeTsN
a
O
NTsMe
8
b
 
a) Tf2O, 2,6-di-tert-butyl-4methylpyridine, cyclohexene; 
b) H2O/CCl4 N
8a 
N
OMe8b 
 81 % yield 70 % yield 
 93 % ee 92 % ee 
 
Scheme 12 
The cycloaddition of a ketene or keteniminium salt can be regarded as the most 
successful way for the four-membered carbocyclic compounds preparation48 and the 
                                                 
44
 a) Falmagne, J.-B.; Escudero, J.; Taleb-Sahraoui, S.; Ghosez, L. Angew. Chem., Int. Ed. Engl. 1981, 20, 
879; b) Saimoto, H.; Houge, C.; Hesbain-Frisque, A.-M.; Mockel, A.; Ghosez, L. Tetrahedron Letters 
1983, 24, 2251. 
45
 Ghosez, L.; Nahuteau-Betzer, F.; Genicot, C.; Vallribera, A.; Cordier, J. Chem. Eur. J. 2002, 8, 3411. 
46
 Masamune, S.; Kennedy, M.; Short, P. J. Org. Chem. 1989, 54, 1755. 
47
 Seebach, D.; Kalinowski, H.; Bastani, B.; Crass, G.; Daum, H.; Dörr, H.; DuPreez, N.; Ehrig, V.; 
Langer, W.; Nüssler, C.; Oei, H.; Schimdt, M. Helv. Chim. Acta 1977, 60, 301. 
48
 Snider, B. B.; Chem. Rev., 1988, 793 and references cited therein. 
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regio- and stereo-controlled polycyclic compounds can be obtained by the [2+2] 
intramolecular version49 (Figure 15).  
 
Intramolecular version 
 
Figure 15 
3.1.3 Third part 
The above described highly selective asymmetric reaction could provide an attractive 
route to a wide variety of enantiopure prostanoids scaffolds.50 To improve this 
methodology it could be interesting work with heptenoic acids 9 (to 
bicyclo[3.2.0]heptanones 10) and, more attractive, with heptadienoic acids 11 (to 
bicyclo[3.2.0]hept-3-en-6-ones 12). In this last hypothesis the base has to extract the γ-
proton to create a new double bond and the ketenimium salt. The geometry of this new 
β,γ-double bond is fundamental for the reaction outcome: the E-unsaturated 
intermediates cannot undergo bicyclization while the starting material double bond 
configuration is independent because of the α,β-double bond is destroyed in the reaction 
evolution (Scheme 13).  
 
 
 
 
 
                                                 
49
 a) Mark6, I.; Ronsmans, B.;  Hesbain-Frisque, A.; Dumas, S.; Ghosez, L. J. Am. Chem. Soc. 1985, 107, 
2192; b) Ghosez, L.; O'Donnell, M. J. Pericyclic Reactions; Marchand, A. P., Lehr, R. E., Eds.; 
Academic: New York, 1977; Vol. 11, 79; c) Frey, H. M.; Isaacs, N. S. J. Chem. SocB. 1970, 830; d) 
Brady, W. T. Tetrahedron 1981, 2949. Brady, W. T. Synthesis 1971, 415; e) Brady, W. T. The Chemistry 
of Ketenes, Allenes and Related Compounds; Patai, S., Ed.; Interscience: New York, 1980; 278. 
50
 Adam, J.; Ghosez, L.; Houk, K. N. Angew. Chem Int. Ed. 1999, 38, 2728. 
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Hypothesis 
 
 
 
 
heptadienoic acids  γ-proton extraction E-isomer  
  
 
 
  Z-isomer bicyclo 
Scheme 13 
This asymmetric [2+2] reaction has to be performed with a cheap, convenient and easily 
synthesized chiral auxiliary. We have decided to test the 5-benzyl-2,2,3-
trimethylimidazolidin-4-one 1351 as auxiliary. This compound is a secondary amine that 
can be obtained in large scale and in both enantiomeric forms starting from the amino 
acid phenylalanine 14 (Figure 16). The synthetic procedure reported in literature has 
been modified to optimize the synthetic process. For example, we replaced the 
crystallization step of crude 13 in hot isopropyl alcohol with a simple washing in 
acetone. 
 
auxiliary synthesis 
 
 (S) or (R) - 5-benzyl-2,2,3-trimethylimidazolidin-4-one 
Figure 16 
                                                 
51
 Ahrendt, K. A.; Borths, C. J.; MacMillan, D. W. C. J. Am. Chem. Soc. 2000, 122, 4243. 
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It is often employed as an organocatalyst, and is effective for various class of 
cycloaddition through the LUMO-lowering activation of α,β-unsaturated carbonyls via 
the reversible formation of iminium ions.52 In our case it could be able to enantioselect 
the cycloadduct inducing the closure of the cycle only from the favorite and less 
hindered side. The presence of a second amide group should not be a problem: if this 
group is attacked by the anhydride it can’t be transformed into keteniminium ion 
(Figure 17).  
 
N
N
O
O
R
Ph
 
Tf2O
N
N
O
R
O
Ph
Tf2O
 
N
N
OTf
R
TfO
Ph
Base
H
H H
 
N
N
C
TfO
Ph H
R H
 
Chiral amide Anhydride attack Proton extraction Keteniminium ion 
Figure 17 
Differently by the standard reaction condition we have decided to use two equivalents 
of anhydride to be sure of obtain one equivalent of keteniminium ion. 
 
3.2 Result and discussion 
3.2.1 Acids and Amides synthesis 
From these assumptions we have prepared a set of chiral amides with different 
substituents by reacting hepta-2,6-dienoic acids 11 or hepta-6-enoic acids 9 with the 
enantiopure MacMillan imidazolidinone 13 as auxiliary. Herein, we report the 
preparation of these classes of acids. Both synthetic strategies start from pent-4-enoic 
acids 15 (Scheme 14). 
 
 
                                                 
52
 a) Jen, W. S.; Wiener, J. J. M.; MacMillan, D. W. C. J. Am. Chem. Soc. 2000, 122, 9874, b) Paras, N. 
A.; MacMillan, D. W. C. J. Am. Chem. Soc. 2001, 123, 4370, c) Austin, J. A.; MacMillan, D. W. C. J. 
Am. Chem. Soc. 2002, 124, 1172; d) Brown, S. P.; Goodwin, N. C.; MacMillan, D. W. C. J. Am. Chem. 
Soc. 2003, 125, 1192; e) Ouellet, S. G.; Tuttle, J. B.; MacMillan, D. W. C. J. Am. Chem. Soc. 2005, 127, 
32. 
 
Chapter 3 
 35 
Route A  hepta-2,6-dienoic acids 
1) MeI, K2CO3 
2) DIBAL 
3) malonic acid, Pyridine or triethyl phosphonoacetate, 
NaH 
4) hydrolysis 
 
 
 
 
1) LAH 
2) p-toluenesulfonyl chloride  
3) diethyl malonate, NaH, NaI 
4) hydrolysis and reflux of HCl or Decalin® 
 
Route B  hepta-6-enoic acids 
Scheme 14 
In the route A to obtain the acids 11 (Scheme 15), the pent-4-enoic acids 15 were 
transformed into the corresponding methylesters 16 by treating with MeI and K2CO3 in 
DMF at room temperature for 1h to obtain good reducible substrates. The esters 16 were 
converted into aldehydes 17 with a cold solution of DIBAL in dry dichloromethane 
under inert atmosphere. The 4-pentenylaldehydes 17 were refluxed with dry pyridine 
and malonic acid until the condensation was complete (method A). The reaction times 
were too long and the yields are not high so a new synthetic strategy was followed. In 
the method B the aldehydic derivates 17 were treated with triethyl phosphonoacetate 
and NaH in dry THF, then hydrolyzed. In the Table 4 yields of all steps are 
summarized. 
 
Route A 
 
1) MeI, K2CO3 
2) DIBAL 
3) malonic acid, Pyridine or triethyl phosphonoacetate, NaH 
4) hydrolysis hepta-2,6-dienoic acids 
Scheme 15 
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Route A 
Reaction yields (%) 
Acid synthesis  
Entry 
 
Methylation Reduction to 
aldehyde Method 
A 
Method 
B 
Hepta-2,6-dienoic acids 
1 16a (100) 17a (100)  73 
 
2 
commercial ethyl 
4-methyl-4-
pentenoate 
17b (98)  74 
 
3 available 
compound a 17c (99)  80 
 
4 
commercial 
methyl 3,3-
dimethyl-4-
pentenoate 
17d (95)  52 
 
5  
commercial 5-
methylhex-5-en-
2-one 
 72 
 
6  commercial hex-5-en-2-one  77 
 
7 16b (95) 17e (87) 30  
 
8 16c (91) 17f (99) 45  
 
9  commercial cis-4-decenal 87  
 
a Marotta, E.; Righi, P.; Rosini, G. Org. Lett. 2000, 2, 4145. 
Table 4 
To obtain the hepta-6-enoic acids 9 we followed the second route B (Scheme 16): the 
pent-4-enoic acids 15 were reduced using a solution of LAH in dry THF under inert 
atmosphere to give the corresponding alcohols 18. These were converted in more 
reactive electrophiles 19 treating with p-toluenesulfonyl chloride and dry pyridine. 
Substituted 4-pentenylmalonates 20 were prepared in good yields by alkylation of 
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diethyl malonate with 4-pentyl tosylates using NaH as the base in presence of dry NaI. 
The desired acids 9 (Table 5) were obtained after a hydrolysis step conduced in 
decarboxylation conditions. The first approach was the removal of a molecule of carbon 
dioxide by treating with an excess of HCl at reflux. The moderate yields and the long 
reaction times (several days) suggested us to change decarboxylation agent. Decalin® 
was added to the diacids and heated until CO2 gas evolution ceased. The Decalin® 
removal afforded the crude mono-acids. 
Route B 
 
 
1) LAH 
2) p-toluenesulfonyl chloride 
3) diethyl malonate, NaH, 
NaI 
4) hydrolysis and reflux of 
HCl or Decalin® 
 
 
hepta-6-enoic acids 
 
 
Scheme 16 
Route B 
Reaction yields (%) 
Decarboxylation  
Entry 
 
Reduction 
to alcohol Tosylate Malonate HCl Decalin® 
Hepta-6-enoic acids 
1 18a (99) 19a (76) 20a (98) 58  
 
2 18b (95) 19b (66) 20b (98) 61  
 
3 18c (89) 19c (87) 20c (61)  87 
 
4  
Commerci
al 5-
bromopen
t-1-ene 
20d (100)  99 
 
5a      
 
a commercially available hept-6-enoic acid. 
Table 5 
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These resulting hepta-2,6-dienoic acids 11 and hepta-6-enoic acids 9 were successful 
converted into the corresponding acid chlorides by treatment with a cool solution of 
oxalyl chloride in anhydrous dichloromethane. Reaction of the chlorides with (R)- or 
(S)-imidazolidinone 13 in anhydrous dichloromethane, at room temperature and with 
pyridine presence gave in good yields the desired chiral amides 21 (Table 6). 
 
Synthetic amides 
 
 
Entry 
 
yield Amides from hepta-2,6-dienoic acids 
 
Entry 
 
yield Amides from hepta-2,6-dienoic acids 
1 37 
21a 
8a 89 
21h 
2 66 
21b 
9 86 
21i 
Entry yield Amides from hepta-6-enoic 
acids 
3 86 
21c 
10a 80 
21l 
4 26 
21d 
11 80 
21m 
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5 78 
21e 
12 50 
21n 
6a 63 
21f 
13 61 N
N
O
O
Ph
21o 
7a 82 
21g 
14 82 
21p 
a Synthesized with (R) –imidazolidinone too. 
Table 6 
3.2.2 The [2+2] reaction and bicycles 
As shown in Scheme 17, amides 21a-i from hepta-2,6-dienoic acids can be converted 
into the corresponding ketene iminium triflate by treatment with two equivalents of 
triflic anhydride (added dropwise over one hour) in the presence of 2,6-di-tert-butyl-4-
methylpyridine as base (1.2 eq.). The bicyclo[3.2.0]hept-3-en-6-ones 12 can be obtained 
after hydrolysis (H2O/CHCl3, reflux, 4h) of the crude iminium salts, while the auxiliary 
13 was recovered (c.a. 20 % yield) by the extraction of the aqueous layer at pH 14 with 
ether.  
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The [2+2] cycloaddition reaction 
N
N
O
Ph
O
N
N
TfO
Ph
C
TF2O/dichloroethane
N
N
OPh
2,6-di-tert-butyl-4-methylpyridine
H2O/CHCl3
O
*
*
N
H2
N
O
Ph
chiral auxiliary 13
enantioenriched bicyclo
*
*
21(a-i)
12
 
Scheme 17 
The bicycle relative structure was established by NOESY1D experiments and the 
absolute structure was assigned comparing the [α]D sign of these molecules with known 
compounds.53 As indicated in Table 7, at room temperature the cycloaddition affords 
cyclobutanones 12 with moderate to good yields, a good diastereoselection and high 
enantiomeric excess. Because of the high volatility of the product yields were calculated 
by GC analysis on the crude after the hydrolysis step.  
 
 
 
 
Bicyclo[3.2.0]hept-3-en-6-ones 
 
 
Entry 
 
Amide Product Dr a Yield
a
 
(%) Ee
b
 (%) 
1 21a 
12a 
 66 91 
2 21b 
12b 
- - - 
                                                 
53
 Pagani, I.; Righi, P.; Rosini, G.; Bertolasi, V.; Medici, A.; Tetrahedron: Asymmetry 1995, 6, 2319. 
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93 67 3 21c 
  
92/8 35 
Major  Minor 
 
 
12c Major 12c Minor     
4 21d 
12d 
 40 57 
5 21e 
O
12e 
- - - 
6c 21f 
O
12f 
 71 93 
7 c 21g 
12g 
 65 93 
  
87 84 8 c 21h 
  
51/49 66 
Major   Minor 
 
 
12h Major 12h Minor     
  
92 91 9 21i 
 
88/22 70 
Major   Minor 
  12i Major 12i Minor    
aCalculated to crude product by GC-analysis with an Agilent 19091Z-413E HP-1 Methyl siloxane column. bDetermined by GC-
analysis with a Restek 13104 Rt-betaDEXsm column. cSynthesized the opposite enantiomer with (R)- imidazolidinone. 
Table 7 
The reaction is sensitive of substituents at the C6 position, in fact entry 2 and 5 were 
unsuccessful. Testing reaction conditions we have found that acetic anhydride and 
trifluoroacetic anhydride are not active to fulfill ketene generation and that, 
interestingly, the diastereo- and enantiocontrol does not improve at lower temperatures.  
With optimized reaction conditions in hand, we set out to synthesize substituted 
bicyclo[3.2.0]heptanones trying intermolecular and intramolecular process (Table 8, 
Table 9) and oxa-bicyclo[3.2.0]heptanones (Table 10).  
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Bicyclo[3.2.0]heptan-6-ones 
 
INTRAMOLECULAR 
 
 
 
Entry 
 
Amide Product Dr a Yield
a
 
(%) Ee
b
 (%) 
  
85 90 1 21l 
  
55/45 32 
Major   Minor 
 
 
10a Major 10a Minor    
  
87 92 2 21m 
  
47/53 34 
Major   Minor 
 
 
10b Major 10b Minor    
  
79 93 3 21n 
  
67/33 28 
Major   Minor 
 
 
10c Major 10c Minor    
4 21o 
10d 
- - - 
5 21p 
10e 
 25 88 
  
92 91 6 21i c 
 
88/22 70 
Major   Minor 
  10f Major 10f Minor    
aCalculated to crude product by GC-analysis with an Agilent 19091Z-413E HP-1 Methyl siloxane column. bDetermined by 
GC-analysis with a Restek 13104 Rt-betaDEXsm column. cSynthesized by hydrogenation with H2 Pt/C of  12i bicycle. 
Table 8 
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The amides 22a, 22b for the intermolecular sequence were prepared as described 
previously starting from acetyl chloride 23 (yield 97%) and heptanoic acid 24 (yield 
81%) (Scheme 18). 
 
 
 
Scheme 18 
 
 
Bicyclo[3.2.0]heptan-6-ones 
 
INTERMOLECULAR 
 
 
 
Entry 
 
Amide Product Dr a Yield
a
 
(%) Ee
b
 (%) 
1 22a 
OH
H 10e 
 3 96 
  
63 80 2 22b 
 
65/35 5 
Major Minor 
  10f Major 10f Minor     
aCalculated to crude product by GC-analysis with an Agilent 19091Z-413E HP-1 Methyl siloxane column. bDetermined by 
GC-analysis with a Restek 13104 Rt-betaDEXsm column.  
Table 9 
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As shown in Table 8 the reaction proceed with moderate yields and high enantiomeric 
excess. The reaction with the amide 22a and 22b gave the corresponding bicycle in very 
low yields but with a high and opposite ee. So, starting from the same auxiliary [(S)-5-
benzyl-2,2,3-trimethylimidazolidin-4-one, (S)-13] the two mechanisms have an 
opposite enantioselectivity but the intermolecular process is disadvantage. The above 
results shown that the C2 is another denied position: the reaction critically depends on 
the no-replacement of the bridge head hydrogens. The resulting enantioselection is very 
good, instead diastereoselection is lower than bicyclo[3.2.0]hept-3-en-6-ones.  
Because of the great importance of these bicycles we have thought that the synthesis of 
molecules containing a hetero atom (like oxygen) could be interesting to expand the 
products set. The hepta-6-enoic acids 25 for the oxa-products were synthesized with two 
new synthetic routes starting from 3-buten-1-ol 26 and prop-2-en-1-ol 27 and then 
converted into the corresponding amides 28 (Scheme 19).  
 
 
 
Scheme 19 
These chiral intermediates 28 gave oxa-bicycles in moderate yields and enantiomeric 
excess (Table 10). 
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Oxa-Bicyclo[3.2.0]heptan-6-ones 
 
 
Entry 
 
Amide Product Yield
a
 
(%) 
Eeb 
(%) 
1 28a 
29a 
50 40 
2 28b O
OH
H 29b 
17 60 
aCalculated to crude product by GC-analysis with an Agilent 19091Z-413E HP-1 Methyl siloxane 
column. bDeterminated by GC-analysis with a Restek 13104 Rt-betaDEXsm column.  
Table 10 
To complete the study we have made a large number of experiments to obtain 
bicyclo[4.2.0]heptanones which, unexpectedly, have no success.  
 
3.3 Conclusion 
Several works followed the initial Corey route to the research of new syntheses of 
prostaglandins analogues and their intermediates. Because of the demonstrated 
importance of bicyclo[3.2.0]heptanones 10 and bicyclo[3.2.0]hept-3-en-6-ones 12 like 
versatile building blocks to generate these important molecules we decided to find an 
asymmetric synthesis. In this chapter, we have developed an efficient and simple 
method for preparing a large scale of bicycles with high regio- and stereoselectivity 
exploiting the [2+2]-cycloaddition of chiral keteniminium salts.  
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3.4 Experimental section 
Route A: synthesis of hepta-2,6-dienoic acids  
Route A 
 
1) MeI, K2CO3 
2) DIBAL 
3) malonic acid, Pyridine or triethyl phosphonoacetate, NaH 
4) hydrolysis hepta-2,6-dienoic acids 
 (Scheme 15) 
 
General Procedure54 for the synthesis of Methyl esters 16 : Solid potassium 
carbonate (1.1 eq.) was added to a solution of acid 15 (1 eq.) in DMF (1.0 mL/mmol) 
cooled with an ice-water bath. After 10 min, methyl iodide (2 eq.) was added and the 
mixture was stirred at 0 °C for 30 min. The reaction was warmed to room temperature 
and stirred for an additional hour. Water was added to the mixture and the aqueous layer 
was extracted three times with diethyl ether. The combined organic layers were dried 
with MgSO4 and the solvent was evaporated under reduce pressure. The methyl ester 
was directly used in the next step without further purification. 
 
 
 
Methyl pent-4-enoate (16a): 5.0 g (49.9 mmol) of commercial pent-4-enoic acid 
afforded 5.7 g of product (49.9 mmol, 100 % yield). 1H NMR (400MHz, CDCl3): δ 2.40 
(m, 4H), 3.68 (s, 3H), 5.00 (m, 1H), 5.06 (m, 1H), 5.82 (m, 1H); 13C NMR (100MHz, 
CDCl3): δ 28.7 (CH2), 33.2 (CH2), 51.4 (CH3), 115.4 (CH2), 136.5 (CH), 173.4 (C). 
 
 
 
Methyl 2-methylpent-4-enoate (16b): 10.4 g (98.6 mmol) of commercial 2-
methylpent-4-enoic acid afforded 10.9 g of product (85.0 mmol, 95 % yield). 1H NMR 
(300MHz, CDCl3): δ 1.16 (d, 3H, J = 6.8Hz), 2.18 (m, 1H), 2.41 (m, 1H), 2.53 (sext, 
                                                 
54
 In according to literature: Garner, P.; Park, J. M. Org. Syntheses Coll. Vol. 9, 1998, 300. 
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1H, J = 7.1Hz), 3.67 (s, 3H), 5.05 (m, 2H), 5.75 (m, 1H); 13C NMR (75MHz, CDCl3): δ 
16.5 (CH3), 37.7 (CH2), 39.1 (CH), 51.4 (CH3), 116.8 (CH2), 135.4 (CH), 176.5 (C). 
 
 
 
Methyl 3-methylpent-4-enoate (16c): 5.0 g (43.8 mmol) of commercial 3-methylpent-
4-enoic acid afforded 5.2 g of product (40.1 mmol, 91 % yield). 1H NMR (300MHz, 
CDCl3): δ 1.06 (d, 3H, J = 6.9Hz), 2.27 (dd, 1H, J = 7.4, 14.8Hz), 2.37 (dd, 1H, J = 7.1, 
14.8Hz), 2.68 (m, 1H), 3.67 (s, 3H), 4.96 (dt, 1H, J = 1.3, 10.2Hz), 5.02 (dt, 1H, J = 1.3, 
17.0Hz), 5.78 (ddd, 1H, J = 6.9, 10.2, 17.0Hz); 13C NMR (75MHz, CDCl3): δ 19.7 
(CH3), 34.4 (CH), 41.1 (CH2), 51.4 (CH3), 113.3 (CH2), 142.4 (CH), 162.3 (C). 
 
General Procedure54 for the reduction to aldehydes 17 : In a dry three-necked flask, 
equipped with magnetic stirring bar, rubber septa and low temperature thermometer, 
was added the methyl ester 16 (1 eq.) in dry dichloromethane (2.0 mL/mmol). The 
solution was cooled to -78 °C and a solution of DIBAL 1M in dichloromethane (1.7 eq.) 
was added dropwise. The rate of addition is adjusted to keep the internal temperature 
below -65° C. The reaction mixture was stirred at -78 °C until it was complete by GC 
analyses. The reaction was quenched by slowly addition of cold methanol 
(0.4 mL/mmol) again keeping the internal temperature below -65° C. The emulsion was 
slowly poured into an ice-cold solution of HCl 1M (6.7 mL/mmol) and stirred for 15 
min. The mixture was extracted three times with ether. The combined organic layers 
were washed with brine, dried with MgSO4 and the solvent was evaporated under 
reduce pressure. The crude aldehyde was directly used without further purification for 
the hepta-2,6-dienoic acid formation. 
 
General Procedure for the synthesis of hepta-2,6-dienoic acids 11 : 
Method A55 Malonic acid (1.2 eq.) and dry pyridine (1.6 eq.) were added to a stirred 
solution of the aldehyde 17 (1 eq.) in dry dichloromethane (2.0 mL/mmol). The mixture 
was heated to reflux until reaction was complete by GC analyses. The mixture was 
acidified to pH 1 with HCl 1M and washed three times with diethyl ether. The 
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combined organic layers were dried with MgSO4 and the solvent was evaporated. The 
crude products were purified by flash chromatography. 
 
 
 
2-Methylpent-4-enal (17e): 10.0 g (78.0 mmol) of methyl ester 16b afforded 6.7 g of 
product (67.8 mmol, 87 % yield).  
4-Methylhepta-2,6-dienoic acid (11g): 17e (7.0 g, 71.3 mmol) afforded the 
corresponding acid (3.0 g, 21.4 mmol, 30 % yield); chromatographic conditions : 
petroleum ether/EtOAc/CH2Cl2/AcOH = 87/8/5/0.1 gradient to 75/15/10/0.2; colorless 
oil; [Rf  (87/8/5/0.1) = 0.26]. 1H NMR (300MHz, CDCl3): δ 1.08 (d, 3H, J = 6.6Hz), 
2.16 (m, 1H), 2.44 (m, 1H), 5.04 (m, 2H), 5.73 (m, 1H), 5.80 (dd, 1H, J = 1.4, 15.6Hz), 
7.02 (dd, 1H, J = 7.4, 15.6Hz), 10.26 (s, OH); 13C NMR (75MHz, CDCl3): δ 18.5 
(CH3), 36.2 (CH), 39.9 (CH2), 116.8 (CH2), 119.2 (CH), 135.6 (CH), 156.4 (CH), 172.2 
(C). 
 
 
 
3-Methylpent-4-enal (17f): 5.1 g (40.0 mmol) of methyl ester 16c afforded 3.9 g of 
product (39.7 mmol, 99 % yield).  
5-Methylhepta-2,6-dienoic acid (11h): 17f  (3.9 g, 39.7 mmol) afforded the 
corresponding acid (2.5 g, 17.9 mmol, 45 % yield); chromatographic conditions : 
petroleum ether/EtOAc/CH2Cl2/AcOH = 87/8/5/0.1 gradient to 75/15/10/0.2; colorless 
oil; [Rf  (87/8/5/0.1) = 0.17]. 1H NMR (400MHz, CDCl3): δ 1.04 (d, 3H, J = 6.8Hz), 
2.25 (m, 1H), 2.34 (m, 1H), 4.98 (m, 1H), 5.01 (m, 1H), 5.73 (ddd, 1H, J = 6.9, 10.4, 
17.2Hz), 5.83 (dt, 1H, J = 1.5, 15.5Hz), 7.03 (ddd, 1H, J = 7.1, 7.7, 15.5Hz), 10.86 (s, 
OH); 13C NMR (100MHz, CDCl3): δ 19.6 (CH3), 36.7 (CH), 39.1 (CH2), 113.5 (CH2), 
121.9 (CH), 142.7 (CH), 150.3 (CH), 171.9 (C). 
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(6E)-Dodeca-2,6-dienoic acid (11i): commercial cis-4-decenal (850 mg, 4.4 mmol) 
afforded the corresponding acid (754 mg, 3.8 mmol, 87 % yield); chromatographic 
conditions : petroleum ether/EtOAc/CH2Cl2/AcOH = 75/15/10/0.2; colorless oil; [Rf  
(75/15/10/0.2) = 0.51]. IR (neat): ν 2957, 2927, 2857, 1696, 1651 cm-1. 1H NMR 
(300MHz, CDCl3): δ 0.89 (m, 3H), 1.30 (m, 6H), 2.01 (m, 2H), 2.25 (m, 4H), 5.38 (m, 
2H), 5.84 (m, 1H), 7.08 (m, 1H); 13C NMR (75MHz, CDCl3): δ 14.0 (CH3), 20.8 (CH2), 
22.5 (CH2), 25.5 (CH2), 27.2 (CH2), 29.2 (CH2), 31.4 (CH2), 32.3 (CH2), 120.8 (CH), 
127.4 (CH), 131.5 (CH), 151.7 (CH), 175.0 (C). 
 
General Procedure for the synthesis of hepta-2,6-dienoic acids 11 : 
Method B56 Triethyl phosphonoacetate (1 eq.) in THF (0.2 mL/mmol) was added to a 
suspension of NaH (60 % wt, 1 eq.) in THF (1.0 mL/mmol) at room temperature. The 
mixture was stirred for 1h, then ketone or aldehyde 17 (1 eq.) was added to the solution 
and the reaction was stirred overnight. The THF was removed via distillation, the 
residue was washed with water and the aqueous layer was extracted with diethyl ether. 
The combined organic layers were washed twice with brine and dried with MgSO4. The 
solvent was evaporated to obtain the crude ester. To a stirred solution of this esters 
(1 eq.) in THF (0.2 mL/mmol), a solution of NaOH 10% in water (2.5 eq.) was added. 
The mixture was heated to reflux until reaction was complete by TLC. The mixture was 
washed once with diethyl ether and acidified to pH 1 with HCl 1M. The aqueous layer 
was extracted three times with diethyl ether. The combined organic layers were dried 
with MgSO4 and the solvent was evaporated to afford the crude acid that was directly 
engaged in the next step without further purification. 
 
 
 
Pent-4-enal (17a): 5.7 g (49.9 mmol) of methyl ester 16a afforded 4.2g of product 
(49.9 mmol, 100 % yield). 
Hepta-2,6-dienoic acid (11a): 17a (4.2 g, 49.9 mmol) gave the corresponding acid 
(4.6 g, 36.8 mmol, 73 % yield) as a colorless oil. 1H NMR (400MHz, CDCl3): δ 2.24 
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(m, 2H), 2.34 (m, 2H), 5.02 (m, 1H), 5.06 (m, 1H), 5.80 (ddt, 1H, J = 6.4, 10.2, 23.5Hz), 
5.85 (dt, 1H, J = 1.5, 15.6Hz), 7.08 (dt, 1H, J = 6.7, 15.6Hz), 9.14 (s, OH); 13C NMR 
(100MHz, CDCl3): δ 31.5 (CH2), 31.8 (CH2), 115.6 (CH2), 121.0 (CH), 136.8 (CH), 
151.3 (CH), 171.9 (C). 
 
 
 
4-Methylpent-4-enal (17b): 1.5 g (10.5 mmol) of commercial ethyl 4-methylpent-4-
enoate afforded 1.0 g of product (10.2 mmol, 98 % yield). 
6-Methylhepta-2,6-dienoic acid (11b): aldehyde 17b (1.0 g, 10.2 mmol) afforded the 
corresponding acid (1.2 g, 7.6 mmol, 74 % yield) as a yellow oil. 1H NMR (400MHz, 
CDCl3): δ 1.73 (s, 3H), 2.18 (t, 2H, J = 7.7Hz), 2.38 (m, 2H), 4.73 (m, 1H), 5.85 (dt, 
1H, J = 1.5, 15.6Hz), 7.08 (dt, 1H, J = 6.7, 15.6Hz), 11.86 (s, OH); 13C NMR (100MHz, 
CDCl3): δ 22.2 (CH3), 30.2 (CH2), 35.7 (CH2), 110.8 (CH2), 120.8 (CH), 143.9 (C), 
151.4 (CH), 172.0 (C). 
 
 
 
3-(Benzyloxymethyl)pent-4-enal (17c): 6.0 g (24.1 mmol) of ethyl 3-
(benzyloxymethyl)pent-4-enoate afforded 4.9 g of product (24.0 mmol, 99 % yield). 
5-(Benzyloxymethyl)hepta-2,6-dienoic acid (11c): aldehyde 17c (4.9 g, 24.0 mmol) 
afforded the corresponding acid (4.7 g, 19.2 mmol, 80 % yield) as a colorless oil. IR 
(neat): υ 3030, 2858, 1695, 1651 cm-1. 1H NMR (400MHz, CDCl3): δ 2.28 (m, 1H), 
2.50 (m, 1H), 2.54 (m, 1H), 3.37 (dd, 1H, J = 6.6, 9.2Hz), 3.45 (dd, 1H, J = 5.3, 9.2Hz), 
4.50 (s, 2H), 5.08 (m, 1H), 5.11 (m, 1H), 5.69 (ddd, 1H, J = 7.7, 10.9, 16.8Hz), 5.83 (m, 
1H), 7.03 (dt, 1H, J = 7.3, 15.5Hz), 7.32 (m, 5H); 13C NMR (100MHz, CDCl3): δ 34.1 
(CH2), 42.8 (CH), 72.7 (CH2), 73.0 (CH2), 116.5 (CH2), 122.1 (CH), 127.5 (2CH), 
127.6 (2CH), 128.3 (CH), 138.0 (CH), 138.1 (C), 149.9 (CH), 171.8 (C). 
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3,3-Dimethylpent-4-enal (17d): 4.0 g (28.1 mmol) of commercial methyl 3,3-
dimethyl-4-pentenoate afforded 3.0 g of product (26.7 mmol, 95 % yield). 
5,5-Dimethylhepta-2,6-dienoic acid (11d): aldehyde 17d (3.0 g, 26.7 mmol) afforded 
the corresponding acid (2.1 g, 14.0 mmol, 52 % yield) as a colorless oil. IR (neat): 
υ 2954, 1697, 1651 cm-1. 1H NMR (400MHz, CDCl3): δ 1.04 (s, 6H), 2.22 (dd, 1H, J = 
1.5, 7.8Hz), 4.96 (dd, 1H, J = 1.1, 17.2Hz), 4.98 (dd, 1H, J = 1.1, 17.2Hz), 5.79 (dd, 1H, 
J = 10.9, 17.2Hz), 5.82 (dd, 1H, J = 1.5, 15.5Hz), 7.02 (dt, 1H, J = 7.7, 15.5Hz); 13C 
NMR (100MHz, CDCl3): δ 26.7 (2CH3), 36.9 (C), 45.2 (CH2), 111.4 (CH2), 122.7 
(CH), 146.8 (CH), 149.2 (CH), 171.8 (C). 
 
 
 
3,6-Dimethylhepta-2,6-dienoic acid (11e): commercial 5-methylhex-5-en-2-one 
(1.7 g, 15.4 mmol) afforded the corresponding acid (1.7 g, 11.0 mmol, 72 % yield) as a 
yellow oil. IR (neat): υ 2938, 1693, 1640 cm-1. 1H NMR (400MHz, CDCl3): δ 1.73 (s, 
3H), 2.18 (s, 3H), 2.25 (m, 4H), 4.72 (m, 2H), 5.70 (s, 1H), 11.60 (s, OH); 13C NMR 
(100MHz, CDCl3): δ 19.0 (CH3), 22.3 (CH3), 35.4 (CH2), 39.3 (CH2), 110.7 (CH2), 
115.3 (CH), 144.3 (C), 162.7 (C), 172.5 (C). 
 
 
3-Methylhepta-2,6-dienoic acid (11f): commercial hex-5-en-2-one (2.0 g, 20.4 mmol) 
afforded the corresponding acid (2.2 g, 15.6 mmol, 77 % yield) as a colorless oil. 1H 
NMR (600MHz, CDCl3): δ 2.17 (s, 3H), 2.26 (m, 4H), 5.02 (dd, 2H, J = 16.9, 32.8Hz), 
5.70 (m, 1H), 5.78 (m, 1H); 13C NMR (150MHz, CDCl3): δ 19.0 (CH3), 31.4 (CH2), 
40.3 (CH2), 115.4 (CH2), 115.5 (CH), 137.0 (CH), 162.3 (CH), 172.5 (C). 
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Route B: synthesis of hepta-6-enoic acids 
Route B 
 
 
1) LAH 
2) p-toluenesulfonyl chloride 
3) diethyl malonate, NaH, 
NaI 
4) hydrolysis and reflux of 
HCl or Decalin® 
 
 
hepta-6-enoic acids 
 
 
 (Scheme 16) 
 
General Procedure57 for the synthesis of alcohols 18: A solution of acid 15 (1.0 eq.) 
in dry THF (0.2 mL/mmol) was slowly added to a stirred solution of LiAlH4 (1 molar 
eq.) in dry THF (2.0 mL/mmol). The mixture was stirred overnight at room temperature. 
The reaction mixture was cooled to 0 °C and cautiously treated with water 
(0.038 mL/mmol), with a 15 % aqueous solution of NaOH (0.038 mL/mmol), and 
finally with water (0.11 mL/mmol). After 1 h at room temperature, the suspension was 
filtered through a pad of Celite. The solids were washed twice with diethyl ether. The 
filtrate was dried over MgSO4 and evaporated under reduced pressure. The crude 
product was used directly in the next step without further purification. 
 
 
 
2-Methylpent-4-en-1-ol (18a): commercial 2-methylpent-4-enoic acid (10.0 g, 
87.6 mmol) afforded the corresponding alcohol (8.7 g, 86.8 mmol, 99 % yield) as a 
colorless oil. 1H NMR (400MHz, CDCl3): δ 0.92 (d, 3H, J = 6.6Hz), 1.72 (m, 1H), 1.91 
(m, 1H), 2.18 (m, 1H), 2.36 (s, 1H), 3.46 (m, 1H), 5.00 (m, 1H), 5.72 (ddt, 1H, J = 7.1, 
10.1, 17.1Hz); 13C NMR (100MHz, CDCl3): δ 16.2 (CH3), 35.4 (CH), 37.7 (CH2), 67.6 
(CH2), 115.9 (CH2), 136.9 (CH). 
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3-Methylpent-4-en-1-ol (18b): commercial 3-methylpent-4-enoic acid (4.5 g, 
39.6 mmol) afforded the corresponding alcohol (3.8 g, 37.8 mmol, 95 % yield) as a 
colorless oil. 1H NMR (400MHz, CDCl3): δ 1.02 (d, 3H, J = 6.8Hz), 1.57 (q, 2H, J = 
6.8Hz), 2.30 (hept, 1H, J = 6.8Hz), 3.65 (t, 2H, J = 6.4Hz), 4.94 (m, 1H), 5.01 (m, 1H), 
5.72 (ddd, 1H, J = 8.0, 10.4, 17.2Hz); 13C NMR (100MHz, CDCl3): δ 20.3 (CH3), 34.7 
(CH), 39.2 (CH2), 61.0 (CH2), 112.9 (CH2), 144.0 (CH). 
 
 
 
hex-5-en-2-ol58 (18c): commercial hex-5-en-2-one (4.5 g, 45.8 mmol) afforded the 
corresponding alcohol (4.0 g, 40.6 mmol, 89 % yield) as a colorless oil. 1H NMR 
(300MHz, CDCl3): δ 1.19 (d, 3H, J = 6.0Hz), 1.54 (m, 2H), 2.14 (m, 2H), 3.81 (m, 
1H), 5.00 (m, 2H), 5.83 (ddt, 1H, J = 6.6, 10.1, 23.6Hz); 13C NMR (75MHz, CDCl3): 
δ 23.2 (CH3), 30.0 (CH2), 38.1 (CH2), 67.3 (CH), 114.5 (CH2), 138.4 (CH). 
 
General Procedure59 for the synthesis of tosylates 19: p-Toluenesulfonyl chloride 
(1.3 eq.) was added in small portions to a stirred solution of the alcohol 18 (1 eq.) in 
pyridine (6 eq.) at 0 °C. The suspension was stirred for 10 min, then it was warmed to 
room temperature and kept stirring for another 2 h. The mixture was poured in water 
and then it was extracted twice with Et2O. The organic layers were washed with HCl 1 
M, dried over MgSO4 and evaporated in vacuo. The crude product was purified by flash 
chromatography. 
 
 
 
2-Methylpent-4-enyl 4-methylbenzenesulfonate (19a): 9.0 g (89.9 mmol) of alcohol 
18a afforded 17.4 g of product (68.2 mmol, 76 % yield). Flash chromatographic 
conditions : petroleum ether/ Et2O = 4/1 gradient to 3/2; [Rf  (3/2) = 0.46]. 1H NMR 
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(400MHz, CDCl3): δ 0.90 (d, 3H, J = 6.8Hz), 1.90 (m, 2H), 2.10 (m, 1H), 2.45 (s, 3H), 
3.83 (dd, 1H, J = 6.0, 9.6Hz), 3.89 (dd, 1H, J = 6.0, 9.6Hz), 4.97 (m, 2H), 5.65 (m, 1H), 
7.35 (d, 2H, J = 8.4Hz), 7.79 (d, 2H, J = 8.4Hz); 13C NMR (100MHz, CDCl3): δ 16.0 
(CH3), 21.5 (CH3), 32.6 (CH), 36.9 (CH2), 74.3 (CH2), 117.0 (CH2), 127.8 (2CH), 129.7 
(2CH), 133.0 (C), 135.2 (CH), 144.6 (C). 
 
 
 
3-Methylpent-4-enyl 4-methylbenzenesulfonate (19b): 3.0 g (29.9 mmol) of alcohol 
18b afforded 5.0 g of product (19.7 mmol, 66 % yield). Flash chromatographic 
conditions : petroleum ether/ Et2O = 2/1; [Rf  (1/1) = 0.69]. 1H NMR (400MHz, CDCl3): 
δ 0.96 (d, 3H, J = 6.7Hz), 1.63 (m, 2H), 2.24 (m, 1H), 2.45 (s, 3H), 4.03 (m, 2H), 4.88 
(m, 2H), 5.54 (ddd, 1H, J = 7.9, 10.5, 16.9Hz), 7.34 (d, 2H, J = 8.8Hz), 7.79 (d, 2H, J = 
8.8Hz); 13C NMR (100MHz, CDCl3): δ 20.0 (CH3), 21.6 (CH3), 34.0 (CH), 35.1 (CH2), 
68.7 (CH2), 114.0 (CH2), 127.8 (2CH), 129.7 (2CH), 133.1 (C), 142.4 (CH), 144.6 (C). 
 
 
 
1-Methylpent-4-enyl 4-methylbenzenesulfonate (19c): 3.8 g (37.9 mmol) of alcohol 
18c afforded 8.4 g of product (33.1 mmol, 87 % yield). Flash chromatographic 
conditions : petroleum ether/ Et2O = 2/1; [Rf  (1/1) = 0.74]. 1H NMR (400MHz, CDCl3): 
δ 1.26 (d, 3H, J = 6.2Hz), 1.59 (dddd, 1H, J = 5.3, 6.2, 9.5, 14.4Hz), 1.72 (dddd, 1H, J 
= 6.0, 7.1, 9.0, 14.1Hz), 2.00 (m, 2H), 2.44 (s, 3H), 4.63 (m, 1H), 4.91 (m, 1H), 4.95 (m, 
1H), 7.33 (m, 2H), 7.79 (m, 2H); 13C NMR (100MHz, CDCl3): δ 20.6 (CH3), 21.4 
(CH3), 28.8 (CH2), 35.5 (CH2), 79.7 (CH), 115.2 (CH2), 127.5 (2CH), 129.6 (2CH), 
134.4 (C), 136.9 (CH), 144.4 (C).  
 
General Procedure60 for the synthesis of substituted 4-pentenylmalonates 20: 
Diethyl malonate (2 eq.) was added at 0 °C to a suspension of NaH (60% wt in mineral 
oil, 1.5 eq.) in a dry 10:1 mL THF/DMF mixture (2.5 mL THF/mmol) under N2. The 
reaction mixture was stirred for 30 min. Then the tosylate 19 (1 eq.) and anhydrous NaI 
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(0.4 eq.) were added at room temperature. The mixture was heated to reflux until 
reaction was complete by TLC. The mixture was quenched with a saturated NH4Cl 
solution. The aqueous layer was extracted three times with ether. The combined organic 
layers were dried with MgSO4 and the solvent was evaporated. The crude product was 
purified by flash chromatography. 
 
 
 
Diethyl 2-(2-methylpent-4-enyl)malonate (20a): 4.5 g (17.7 mmol) of tosylate 19a 
afforded 4.2 g of product (17.4 mmol, 98 % yield). Chromatographic conditions : 
petroleum ether/Et2O = 5/1; [Rf  (4/1) = 0.62]. IR (neat): υ 1751, 1733 cm-1. 1H NMR 
(300MHz, CDCl3): δ 0.91 (d, 3H, J = 6.6Hz), 1.27 (t, 6H, J = 7.2Hz), 1.53 (m, 1H), 1.69 
(m, 1H), 1.96 (m, 1H), 2.08 (m, 2H), 3.44 (dd, 1H, J = 6.6, 8.7Hz), 4.20 (2q overlapped, 
4H, J = 7.2, 7.5Hz), 4.99 (m, 1H), 5.04 (m, 1H), 5.75 (m, 1H); 13C NMR (75MHz, 
CDCl3): δ 14.0 (2CH3), 18.9 (CH3), 30.7 (CH), 35.2 (CH2), 40.9 (CH2), 50.0 (CH), 61.2 
(2CH2), 116.3 (CH2), 136.4 (CH), 169.5 (C), 169.7 (C).  
 
 
 
Diethyl 2-(3-methylpent-4-enyl)malonate (20b): 3.1 g (12.2 mmol) of tosylate 19b 
afforded 2.9 g of product (12.0 mmol, 98 % yield). Chromatographic conditions : 
petroleum ether/Et2O = 4.5/0.5; [Rf  (4/1) = 0.53]. IR (neat): υ 1749, 1732 cm-1. 1H 
NMR (400MHz, CDCl3): δ 1.00 (d, 3H, J = 6.8Hz), 1.27 (t, 6H, J = 7.2Hz), 1.32 (m, 
2H), 1.88 (m, 2H), 2.14 (hept, 1H, J = 7.2Hz), 3.29 (t, 1H, J = 7.6Hz), 4.19 (2q 
overlapped, 4H, J = 7.2, 7.2Hz), 4.96 (m, 2H), 5.66 (ddd, 1H, J = 7.6, 10.4, 17.2Hz); 
13C NMR (100MHz, CDCl3): δ 14.0 (2CH3), 20.1 (CH3), 26.5 (CH2), 34.0 (CH2), 37.5 
(CH), 52.0 (CH), 61.2 (2CH2), 113.2 (CH2), 143.7 (CH), 169.5 (2C). 
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Diethyl 2-(1-methylpent-4-enyl)malonate (20c): 8.0 g (31.4 mmol) of tosylate 19c 
afforded 4.7 g of product (19.2 mmol, 61 % yield). Chromatographic conditions : 
petroleum ether/Et2O = 4.5/0.5; [Rf (4.5/0.5) = 0.38]. IR (neat): υ 1752, 1733 cm-1. 1H 
NMR (400MHz, CDCl3): δ 1.00 (d, 3H, J = 6.8Hz), 1.27 (2t overlapped, 6H, J = 
7.1Hz), 1.32 (m, 1H), 1.54 (m, 1H), 2.04 (m, 1H), 2.15 (m, 1H), 2.28 (m, 1H), 3.24 (d, 
1H, J = 7.9Hz), 4.19 (q, 4H, J = 7.1Hz), 5.78 (ddt, 1H, J = 6.8, 10.2, 17.0Hz); 13C NMR 
(100MHz, CDCl3): δ 14.0 (CH3), 16.6 (2CH3), 30.9 (CH2), 32.6 (CH), 33.3 (CH2), 57.5 
(CH), 60.9 (CH2), 61.0 (CH2), 114.6 (CH2), 138.0 (CH), 168.6 (C), 168.7 (C). 
 
 
 
Diethyl 2-methyl-2-(pent-4-enyl)malonate (20d): Commercial 5-bromopent-1-ene 
(5.4 g; 34.4 mmol; 1.2 eq.) was used in place of the tosylate and reacted with 5.0 g 
(28.7 mmol, 1 eq.) of methyl diethyl malonate to afford 6.9 g of product (28.7 mmol, 
100 % yield). [Rf (4.5/0.5) = 0.45]. 1H NMR (400MHz, CDCl3): δ 1.25 (t, 6H, J = 
7.1Hz), 1.34 (m, 2H), 1.40 (s, 3H), 1.86 (m, 2H), 2.07 (m, 2H), 4.18 (q, 4H, J = 7.1Hz), 
4.95 (m, 1H), 5.01 (m, 1H), 5.78 (ddt, 1H, J = 6.6, 10.2, 16.8Hz); 13C NMR (100MHz, 
CDCl3): δ 13.9 (2CH3), 19.7 (CH3), 23.5 (CH2), 33.7 (CH2), 34.8 (CH2), 53.4 (2CH2), 
60.9 (C), 114.7 (CH2), 137.9 (CH), 172.2 (2C). 
 
General Procedure for the decarboxylation step to hepta-6-enoic acids 9 : 
Method A A solution of NaOH 10 % in water (2.5 eq.) was added to a stirred solution 
of the diester 20 (1 eq.) in THF (0.2 mL/mmol). The mixture was heated to reflux until 
the reaction was complete by TLC. The mixture was washed once with ether and 
acidified to pH=1 with HCl 1M. The aqueous layer was extracted three times with ether. 
The combined organic layers were dried with MgSO4 and the solvent was evaporated. 
THF (1.0 mL/mmol) and HCl 1M (2 eq.) were added to the crude product and the 
mixture was heated to reflux until decarboxylation was complete by TLC. The aqueous 
layer was extracted three times with ether. The combined organic layers were dried with 
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MgSO4 and the solvent was evaporated. The crude product was purified by flash 
chromatography. 
 
 
 
4-Methylhept-6-enoic acid (9a): 3.7 g (15.4 mmol) of diester 20a afforded 1.3 g of 
product (8.9 mmol, 58 % yield). Chromatographic conditions : petroleum 
ether/Et2O/AcOH = 3/2/0.1; [Rf  (3/2/0.1) = 0.36]. IR (neat): υ 2960, 2928, 1710 cm-1. 
1H NMR (300MHz, CDCl3): δ 0.90 (d, 3H, J = 6.5Hz), 1.46 (m, 1H), 1.56 (m, 1H), 1.71 
(m, 1H), 1.94 (m, 1H), 2.08 (m, 1H),  2.37 (m, 2H), 5.01 (m, 2H), 5.77 (m, 1H); 13C 
NMR (75MHz, CDCl3): δ 18.9 (CH3), 31.0 (CH), 31.8 (CH2), 32.2 (CH2), 41.0 (CH2), 
116.1 (CH2), 136.8 (CH), 180.5 (C).  
 
 
 
3-Methylhept-6-enoic acid (9b): 2.9 g (11.9 mmol) of diester 20b afforded 1.0 g of 
product  (7.3 mmol, 61 % yield). Chromatographic conditions : petroleum 
ether/Et2O/AcOH = 4/1/0.1; [Rf  (3/2/0.1) = 0.50]. 1H NMR (300MHz, CDCl3): δ 1.00 
(d, 3H, J = 6.6Hz), 1.34 (m, 2H), 1.63 (m, 2H), 2.12 (hept, 1H, J = 6.9Hz), 2.34 (t, 2H, J 
= 7.4Hz), 4.92 (m, 1H), 4.97 (m, 1H), 5.67 (ddd, 1H, J = 7.7, 10.2, 17.3Hz), 11.1 (s, 
OH); 13C NMR (75MHz, CDCl3): δ 20.0 (CH3), 22.3 (CH2), 34.0 (CH2), 35.8 (CH2), 
37.5 (CH), 112.8 (CH2), 144.0 (CH), 180.3 (C). 
 
Method B59 A solution of NaOH 10% in water (2.5 eq.) was added to a stirred solution 
of the diester 20 (1 eq.) in THF (0.2 mL/mmol),. The mixture was heated to reflux until 
reaction was complete by TLC. The mixture was washed once with ether and acidified 
to pH=1 with HCl 1M. The aqueous layer was extracted three times with ether. The 
combined organic layers were dried with MgSO4 and the solvent was evaporated. 
Decalin® (1:1 wt% ) was added to this crude product and the mixture heated to 185°C. 
CO2 evolution was monitored with a mineral oil bubbler. The reaction was stirred 
vigorously until gas evolution ceased. Upon cooling, Decalin®  was removed in vacuo 
affording acid. 
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3-Methylhept-6-enoic acid (9c): 3.0 g (16.1mmol) of diester 20c afforded 2.0 g of 
product (14.0 mmol, 87 % yield). 1H NMR (400MHz, CDCl3): δ 0.99 (d, 3H, J = 
6.8Hz), 1.39 (m, 2H), 2.01 (m, 1H), 2.08 (m, 2H), 2.28 (m, 2H), 4.98 (m, 2H), 5.79 (ddt, 
1H, J = 6.6, 10.1, 16.8Hz); 13C NMR (100MHz, CDCl3): δ 19.4 (CH3), 29.6 (CH), 31.1 
(CH2), 35.7 (CH2), 41.5 (CH2), 114.6 (CH2), 138.4 (CH), 179.8 (C). 
 
 
 
2-Methylhept-6-enoic acid (9d): 3.0 g (16.1 mmol) of diester 20d afforded 2.3 g of 
product (16.0 mmol, 99 % yield). 1H NMR (400MHz, CDCl3): δ 1.11 (d, 3H, J = 
6.9Hz), 1.37 (m, 3H), 1.63 (m, 1H), 1.99 (m, 2H), 2.39 (m, 1H), 4.88 (m, 1H), 4.94 (m, 
1H), 5.72 (ddt, 1H, J = 6.6, 10.2, 16.8Hz), 11.89 (s, OH); 13C NMR (100MHz, CDCl3): 
δ 16.7 (CH3), 26.3 (CH2), 32.9 (CH2), 33.5 (CH2), 39.3 (CH), 114.7 (CH2), 138.3 (CH), 
183.6 (C). 
 
Synthesis of (S)-5-Benzyl-2,2,3-trimethylimidazolidin-4-one hydrochloride51: 
auxiliary synthesis 
 
 (S) or (R) - 5-benzyl-2,2,3-trimethylimidazolidin-4-one 
Figure 16 
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(S)-5-Benzyl-2,2,3-trimethylimidazolidin-4-one hydrochloride (13) 
 
 
To a solution of ethanolic MeNH2 (8 M, 46 mL) was added (S)-phenylalanine methyl 
ester61 14(I) (22.1 g, 123 mmol) and the resulting mixture was stirred at room 
temperature for 15 h. The solvent and the excess of MeNH2 were removed in vacuo. 
The obtained (S)-phenylalanine N-methyl amide hydrochloride was treated with an 
aqueous solution NaHCO3 and the free amine was extracted three times with CHCl3, 
dried and concentrated. To this amide 14(II) (21.3 g, 119 mmol) was added MeOH (180 
mL), acetone (180 ml) and p-TsOH (220 mg, 1.2 mmol). The reaction mixture was 
heated to reflux for 24 h, cooled to room temperature and concentrated. The residue was 
taken up in Et2O and 119 mL of a HCl-Et2O (2 M) solution was added to precipitate 13. 
The yellow salt was washed with cool acetone and filtered to afford 30.3 g (yield 71%) 
as white solid. 
1H NMR (300MHz, d6DMSO): δ 1.61 (s, 3H), 1.76 (s, 3H), 2.92 (s, 3H), 3.13 (dd, 1H, J 
= 10.5, 15.1Hz), 3.53 (dd, 1H, J = 3.5, 15.2Hz), 4.66 (dd, 1H, J = 3.6, 10.6Hz), 4.86 (bs, 
2H), 7.23-7.51 (m, 5H); 13C NMR (75MHz, d6DMSO): δ 22.3 (CH3), 24.4 (CH3), 25.8 
(CH3), 35.0 (CH2), 59.8 (CH), 79.2 (C), 128.8 (2CH), 130.3 (2CH), 130.4 (CH), 136.7 
(C), 167.9 (C); HPLC (free amine) Chiralcel® OD-H, n-hexane/i-PrOH (96:4), flow 1 
mL/min, λ= 254 nm, tr(R) = 10.6 min, tr(S) = 12.1 min. 
 
General Procedure for the synthesis of chiral amides 21: A solution of oxalyl 
chloride (3 eq.) in dry dichloromethane (4.0 mL/mmol) was added dropwise to a stirred 
solution of acid 11 or 9 (1 eq.) in dry dichloromethane (4.5 mL/mmol) at 0 °C and under 
a positive pressure of nitrogen. After 5h at 0 °C, the solvent and the excess of oxalyl 
chloride was removed in vacuo. The crude chloride was dissolved in anhydrous 
dichloromethane (2.8 mL/mmol) and the (S)- or (R)-5-benzyl-2,2,3-
trimethylimidazolidin-4-one hydrochloride 13 (1.1 eq.) was added. The mixture was 
cooled to 0 °C and dry pyridine (2.2 eq.) was added. The mixture was allowed to warm 
to room temperature; after 24h TLC analysis revealed that the starting material was 
                                                 
61
 (S)-phenylalanine methyl ester hydrochloride: Effenberger, F ; Burkard, U. Liebigs Ann. Chem. 1986, 
334. (R)-phenylalanine methyl ester hydrochloride: commercially available. 
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consumed and water was added. The organic layer was washed twice with water, and 
then the aqueous layers were extracted three times with ether. The combined organic 
layers were dried with MgSO4 and the solvent was evaporated. The crude product was 
purified by flash chromatography. 
 
 
 
(S)-5-Benzyl-1-hepta-2,6-dienoyl-2,2,3-trimethylimidazolidin-4-one (21a): hept-2,6-
dienoic acid 11a (2.1 g, 16.6 mmol) gave the corresponding amide (2.0 g, 36.9 mmol, 
37 % yield); chromatographic conditions : petroleum ether/Et2O = 1/2; colorless oil; [Rf  
(1/1) = 0.28]. IR (neat): υ 1701, 1654 cm-1. 1H NMR (600MHz, CDCl3): δ 0.65 (s, 3H), 
1.55 (s, 3H), 2.28 (m, 2H), 2.40 (m, 2H), 2.67 (s, 3H), 3.16 (m, 1H), 3.35 (m, 1H), 4.57 
(m, 1H), 5.03 (m, 1H), 5.09 (m, 1H), 5.83 (m, 1H), 6.16 (m, 1H), 7.04 (m, 1H), 7.05 (m, 
2H), 7.21 (m, 3H); 13C NMR (100MHz, CDCl3): δ 22.4 (CH3), 23.8 (CH3), 24.2 (CH3), 
31.6 (CH2), 32.2 (CH2), 38.1 (CH2), 60.3 (CH), 79.0 (C), 115.7 (CH2), 122.7 (CH), 
127.3 (CH), 128.4 (2CH), 130.3 (2CH), 135.2 (C), 137.1 (CH), 146.6 (CH), 159.2 (C), 
169.4 (C). 
 
 
 
(S)-5-Benzyl-2,2,3-trimethyl-1-(6-methylhepta-2,6-dienoyl)imidazolidin-4-one 
(21b): hept-2,6-dienoic acid 11b (536 mg, 3.8 mmol) gave the corresponding amide 
(844 mg, 2.5 mmol, 66 % yield); chromatographic conditions : petroleum ether/Et2O = 
1/2; colorless oil; [Rf  (1/1) = 0.24]. IR (neat): υ 1704, 1660 cm-1. 1H NMR (400MHz, 
CDCl3): δ 0.64 (s, 3H), 1.10 (s, 3H), 1.11 (s, 3H), 1.57 (s, 3H), 2.31 (dd, 2H, J = 1.2, 
7.6Hz), 2.68 (m, 3H), 3.17 (dd, 1H, J = 5.6, 13.8Hz), 3.38 (dd, 1H, J = 2.0, 13.8Hz), 
4.60 (m, 1H), 4.99 (m, 1H), 5.01 (m, 1H), 5.86 (dd, 1H, J = 10.5, 17.3Hz), 6.17 (d, 1H, J 
= 15.0Hz), 7.04 (m, 1H), 7.06 (m, 2H), 7.22 (m, 3H); 13C NMR (100MHz, CDCl3): δ 
Chapter 3 
 61 
22.3 (2CH3), 23.7 (CH3), 24.1 (CH3), 30.2 (CH2), 36.0 (CH2), 38.0 (CH2), 60.2 (CH), 
79.5 (C), 110.9 (CH2), 122.5 (CH2), 127.2 (CH), 128.3 (2CH), 130.2 (2CH), 135.2 (C), 
144.1 (C), 146.7 (CH), 163.8 (C), 167.1 (C). 
 
 
 
(S)-5-Benzyl-1-(5-(benzyloxymethyl)hepta-2,6-dienoyl)-2,2,3-
trimethylimidazolidin-4-one (21c): hept-2,6-dienoic acid 11c (2.2 g, 9.1 mmol) gave 
the corresponding amide (3.5 g, 7.8 mmol, 86 % yield); chromatographic conditions : 
petroleum ether/EtOAc= 1/1; colorless oil; [Rf  (1/1) = 0.36]. IR (neat): υ 1704, 1661, 
1626 cm-1. 1H NMR (400MHz, CDCl3) (of the mixture of the two diastereoisomers): δ 
0.63 (s, 3Hminor), 0.64 (s, 3Hmajor), 1.56 (s, 3Hminor + 3Hmajor), 2.37 (m, 1Hminor 
+ 1Hmajor), 2.61 (m, 1Hminor + 1Hmajor), 2.68 (m, 1Hminor + 1Hmajor), 3.13 (m, 
1Hminor), 3.14 (m, 1Hmajor), 3.34 (m, 1Hminor + 1Hmajor), 3.48 (m, 2Hminor + 
2Hmajor), 4.53 (s, 2Hminor + 2Hmajor), 4.56 (m, 1Hminor + 1Hmajor), 5.15 (m, 
2Hminor + 2Hmajor), 5.76 (m, 1Hminor + 1Hmajor), 6.17 (m, 1Hminor + 1Hmajor), 
7.05 (m, 1Hminor + 1Hmajor), 7.28 (m, 10Hminor + 10Hmajor); 13C NMR (75MHz, 
CDCl3) (of the mixture of the two diastereoisomers): δ 21.9 (minorCH3), 22.0 
(majorCH3), 23.4 (majorCH3 + minorCH3), 23.8 (majorCH3 + minorCH3), 33.8 
(minorCH2), 34.1 (majorCH2), 42.8 (minorCH), 42.9 (majorCH), 59.8 (majorCH + 
minorCH), 72.5 (minorCH2), 72.7 (majorCH2 + minorCH2), 72.8 (majorCH2), 79.0 
(majorC + minorC), 116.2 (majorCH2), 116.4 (minorCH2), 123.5 (majorCH), 123.7 
(minorCH), 126.9 (minorCH), 127.1 (majorCH), 127.2 (minorCH), 127.3 (majorCH), 
128.0 (2majorCH + 2minorCH), 129.9 (majorCH), 130.0 (minorCH), 134.9 (minorC + 
majorC), 137.9 (majorCH), 138.2 (minorCH), 144.6 (majorCH), 144.7 (minorCH), 
163.3 (minorC + majorC), 166.7 (minorC + majorC). 
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(S)-5-benzyl-1-(5,5-dimethylhepta-2,6-dienoyl)-2,2,3-trimethylimidazolidin-4-one 
(21d): hept-2,6-dienoic acid 11d (2.0 g, 12.9 mmol) gave the corresponding amide 
(1.2 g, 3.4 mmol, 26 % yield); chromatographic conditions : petroleum ether/EtOAc = 
1/1; colorless oil; [Rf  (1/1) = 0.40]. IR (neat): υ 1704, 1661, 1626 cm-1. 1H NMR 
(600MHz, CDCl3): δ 0.64 (s, 3H), 1.10 (s, 3H), 1.11 (s, 3H), 1.57 (s, 3H), 2.31 (dd, 2H, 
J = 1.2, 7.6Hz), 2.68 (m, 3H), 3.17 (dd, 1H, J = 5.6, 13.8Hz), 3.38 (dd, 1H, J = 2.0, 
13.8Hz), 4.60 (m, 1H), 4.99 (m, 1H), 5.01 (m, 1H), 5.86 (dd, 1H, J = 10.5, 17.3Hz), 6.17 
(d, 1H, J = 15.0Hz), 7.04 (m, 1H), 7.06 (m, 2H), 7.22 (m, 3H); 13C NMR (150MHz, 
CDCl3): δ 22.2 (CH3), 23.7 (CH3), 24.0 (CH3), 26.5 (CH3), 26.9 (CH3), 37.1 (C), 37.9 
(CH2), 45.4 (CH2), 60.1 (CH), 79.4 (C), 111.3 (CH2), 124.5 (CH), 127.1 (CH), 128.3 
(2CH), 130.1 (2CH), 135.1 (C), 144.3 (CH), 146.9 (CH), 163.5 (C), 167.0 (C). 
 
 
 
(S)-5-benzyl-1-(3,6-dimethylhepta-2,6-dienoyl)-2,2,3-trimethylimidazolidin-4-one 
(21e): hept-2,6-dienoic acid 11e (1.0 g, 6.5 mmol) gave the corresponding amide (1.8 g 
, 5.1 mmol, 78 % yield); chromatographic conditions : petroleum ether/EtOAc = 3/2; 
colorless oil; [Rf  (3/2) = 0.32]. IR (neat): υ 1704, 1651 cm-1. 1H NMR (600MHz, 
CDCl3): δ 0.66 (s, 3H), 1.57 (s, 3H), 1.78 (s, 3H), 2.18 (s, 3H), 2.26 (m, 2H), 2.36 (m, 
2H), 2.68 (s, 3H), 3.19 (dd, 1H, J = 5.9, 14.1Hz), 3.31 (dd, 1H, J = 2.0, 14.1Hz), 4.50 
(dd, 1H, J = 1.7, 5.6Hz), 4.77 (d, 2H, J = 11.7Hz), 5.89 (s, 1H), 7.03 (m, 2H), 7.23 (m, 
3H); 13C NMR (150MHz, CDCl3): δ 18.6 (CH3), 22.3 (CH3), 22.5 (CH3), 23.7 (CH3), 
24.1 (CH3), 35.4 (CH2), 37.4 (CH2), 38.3 (CH2), 60.7 (CH), 79.3 (C), 110.9 (CH2), 
118.5 (CH), 127.1 (CH), 128.3 (2CH), 130.2 (2CH), 135.5 (C), 144.5 (C), 153.6 (C), 
165.2 (C), 167.4 (C). 
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(S)-5-benzyl-2,2,3-trimethyl-1-(3-methylhepta-2,6-dienoyl)imidazolidin-4-one 
(21f): hept-2,6-dienoic acid 11f (1.0 g, 7.1mmol) gave the corresponding amide (1.5 g , 
4.5 mmol, 63 % yield); chromatographic conditions : petroleum ether/EtOAc = 3/2; 
colorless oil; [Rf  (3/2) = 0.50]. 1H NMR (400MHz, CDCl3): δ 0.66 (s, 3H), 1.57 (s, 
3H), 2.32 (m, 3H), 2.68 (s, 3H), 3.20 (m, 1H), 3.31 (m, 1H), 4.51 (m, 1H), 5.05 (m, 1H), 
5.89 (s, 1H), 7.04 (m, 2H), 7.22 (m, 3H); 13C NMR (100MHz, CDCl3): δ 18.5 (CH3), 
22.4 (CH3), 23.6 (CH3), 24.0 (CH3), 31.4 (CH2), 37.3 (CH2), 39.5 (CH2), 60.6 (CH), 
79.2 (C), 115.5 (CH2), 118.7 (CH), 127.0 (CH), 128.2 (2CH), 130.1 (2CH), 135.4 (C), 
137.3 (CH), 153.3 (C), 165.0 (C), 167.3 (C). 
 
 
 
(S)-5-benzyl-2,2,3-trimethyl-1-(4-methylhepta-2,6-dienoyl)imidazolidin-4-one 
(21g): hept-2,6-dienoic acid 11g (1.5 g, 10.7 mmol) gave the corresponding amide 
(3.0 g, 8.8 mmol, 82 % yield); chromatographic conditions : petroleum ether/EtOAc = 
3/2; white solid, m.p. 114°C; [Rf  (3/2) = 0.25]. IR (KBr): υ 1715, 1660, 1633 cm-1. 1H 
NMR (400MHz, CDCl3) (of the mixture of the two diastereoisomers): δ 0.65 (s, 
3Hminor), 0.66 (s, 3Hmajor), 1.14 (d, 3Hminor, J = 5.5Hz), 1.16 (d, 3Hmajor, J = 
5.5Hz), 1.57 (2s overlapped, 3Hminor + 3Hmajor), 2.23 (m, 2Hminor + 2Hmajor), 2.53 
(hept, 2Hminor + 2Hmajor, J = 6.8Hz), 2.69 (2s overlapped, 3Hminor + 3Hmajor), 
3.17 (dd, 1Hminor, J = 4.5, 14.0Hz), 3.18 (dd, 1Hmajor, J = 5.5, 14.0Hz), 3.37 (2dd 
overlapped, 1Hminor + 1Hmajor, J = 2.2, 14.0Hz), 4.60 (m, 1Hminor + 1Hmajor), 5.07 
(m, 2Hminor + 2Hmajor), 5.79 (ddt, 1Hminor, J = 7.0, 10.3, 17.0Hz), 5.80 (ddt, 
1Hminor, J = 7.0, 10.3, 17.0Hz), 6.14 (d, 1Hminor + 1Hmajor, J = 15.0Hz), 6.96 (dd, 
1Hminor, J = 8.0, 15.0Hz), 7.03 (dd, 1Hmajor, J = 7.0, 15.0Hz), 7.05 (m, 2Hminor + 
2Hmajor), 7.22 (m, 3Hminor + 3Hmajor); 13C NMR (100MHz, CDCl3) (of the mixture 
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of the two diastereoisomers): δ 18.9 (minorCH3), 19.3 (majorCH3), 22.2 (majorCH3 + 
minorCH3), 23.6 (majorCH3 + minorCH3), 24.0 (majorCH3 + minorCH3), 36.0 
(minorCH), 36.6 (majorCH), 37.9 (minorCH2), 38.0 (majorCH2), 40.0 (minorCH2), 
40.4 (majorCH2), 60.1 (majorCH2 + minorCH2), 79.3 (majorC + minorC), 116.7 
(majorCH2 + minorCH2), 120.7 (minorCH), 121.0 (majorCH), 127.1 (majorCH + 
minorCH), 128.2 (2minorCH), 128.3 (2majorCH), 130.1 (2minorCH), 130.2 
(2majorCH), 135.1 (minorC + majorC), 135.7 (minorCH), 136.0 (majorCH), 151.6 
(minorCH), 151.7 (majorCH), 163.7 (minorC), 163.8 (majorC), 166.9 (minorC + 
majorC). 
 
 
 
(S)-5-benzyl-2,2,3-trimethyl-1-(5-methylhepta-2,6-dienoyl)imidazolidin-4-one 
(21h): hept-2,6-dienoic acid 11h (770 mg, 5.5 mmol) gave the corresponding amide 
(1.7 g , 4.9 mmol, 89 % yield); chromatographic conditions : petroleum ether/EtOAc = 
3/2; colorless oil; [Rf  (3/2) = 0.26]. IR (neat): υ 1704, 1651 cm-1. 1H NMR (400MHz, 
CDCl3) (of the mixture of the two diastereoisomers): δ 0.65 (2s overlapped, 3Hminor + 
3Hmajor), 1.10 (d, 3Hminor, J = 6.6Hz), 1.11 (d, 3Hmajor, J = 6.6Hz), 1.57 (2s 
overlapped, 3Hminor + 3Hmajor), 2.33 (m, Hminor + Hmajor), 2.38 (m, 2Hminor + 
2Hmajor), 2.69 (2s overlapped, 3Hminor + 3Hmajor), 3.17 (dd, 1Hminor + 1Hmajor, J 
= 5.6, 14.0Hz), 3.37 (dd, 1Hminor + 1Hmajor, J = 1.3, 14.0Hz), 4.60 (m, 1Hminor + 
1Hmajor), 5.00 (m, Hminor + Hmajor), 5.06 (m, Hminor + Hmajor), 5.80 (m, Hminor + 
Hmajor), 6.19 (m, Hminor + Hmajor), 7.02 (m, Hminor + Hmajor), 7.06 (m, 2Hminor + 
2Hmajor), 7.22 (m, 2Hminor + 2Hmajor); 13C NMR (100MHz, CDCl3) (of the mixture 
of the two diastereoisomers): δ 19.6 (minorCH3), 19.9 (majorCH3), 22.2 (majorCH3 + 
minorCH3), 23.6 (majorCH3 + minorCH3), 24.0 (majorCH3 + minorCH3), 36.8 
(minorCH), 37.0 (majorCH), 37.8 (minorCH2), 37.9 (majorCH2), 39.1 (minorCH2), 
39.4 (majorCH2), 60.0 (majorCH + minorCH), 79.3 (majorC + minorC), 113.4 
(majorCH2), 113.6 (minorCH2), 127.0 (majorCH + minorCH), 128.2 (2minorCH), 
128.3 (2majorCH), 130.1 (2minorCH), 130.2 (2majorCH), 135.1 (minorC + majorC), 
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142.9 (majorCH + minorCH), 145.4 (majorCH), 145.5 (minorCH), 163.5 (minorC + 
majorC), 166.9 (minorC + majorC). 
 
 
 
(S)-5-benzyl-1-((6Z)-dodeca-2,6-dienoyl)-2,2,3-trimethylimidazolidin-4-one (21i): 
hept-2,6-dienoic acid 11i (0.52 g, 2.7 mmol) gave the corresponding amide (0.71 g, 
1.8 mmol, 86 % yield); chromatographic conditions : petroleum ether/EtOAc = 3/2; 
colorless oil; [Rf  (3/2) =0.37]. 1H NMR (400MHz, CDCl3): δ 0.67 (s, 3H), 0.89 (m, 
3H), 1.30 (m, 6H), 1.57 (s, 3H), 2.05 (m, 2H), 2.32 (m, 4H), 2.69 (s, 3H), 3.17 (dd, 1H, 
J = 5.6, 14.1Hz), 3.37 (dd, 1H, J = 2.0, 14.1Hz), 4.59 (dd, 1H, J = 2.0, 5.5Hz), 5.42 (m, 
2H), 6.16 (d, 1H, J = 16.0Hz), 7.06 (m, 2H), 7.23 (m, 3H); 13C NMR (100MHz, CDCl3): 
δ 14.0 (CH3), 22.3 (CH3), 22.5 (CH2), 23.7 (CH3), 24.2 (CH3), 25.8 (CH2), 27.2 (CH2), 
29.2 (CH2), 31.4 (CH2), 32.5 (CH2), 38.1 (CH2), 60.2 (CH), 79.5 (C), 122.5 (CH), 127.2 
(CH), 127.8 (CH), 128.3 (2CH), 130.3 (2CH), 131.4 (CH), 135.2 (C), 146.9 (CH), 163.8 
(C), 167.2 (C). 
 
 
 
(S)-5-benzyl-2,2,3-trimethyl-1-(4-methylhept-6-enoyl)imidazolidin-4-one (21l): 
hept-6-enoic acid 9a (0.9 g, 6.3 mmol) gave the corresponding amide (1.7 g, 5.1 mmol, 
80 % yield); chromatographic conditions : petroleum ether/EtOAc = 3/2; colorless oil; 
[Rf  (3/2) = 0.30]. IR (neat): υ 1706, 1655 cm-1. 1H NMR (400MHz, CDCl3) (of the 
mixture of the two diastereoisomers): δ 0.69 (s, 6H), 0.94 (d, 6H, J = 6.3Hz), 1.54 (s, 
6H), 1.58 (m, 4H), 1.79 (m, 2H), 1.98 (m, 2H), 2.09 (m, 2H), 2.40 (m, 4H), 2.69 (s, 6H), 
3.16 (dd, 2H, J = 5.5, 14.0Hz), 3.36 (m, 2H), 4.51 (m, 2H), 5.03 (m, 4H), 5.80 (m, 2H), 
7.09 (m, 4H), 7.24 (m, 6H); 13C NMR (100MHz, CDCl3) (of the mixture of the two 
diastereoisomers): δ 19.2 (CH3), 19.4 (CH3), 22.3 (CH3), 22.4 (CH3), 23.9 (2CH3), 24.2 
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(2CH3), 31.6 (CH2), 31.7 (CH2), 32.3 (CH), 32.4 (CH), 33.1 (CH2), 33.2 (CH2), 38.0 
(2CH2), 41.0 (CH2), 41.2 (CH2), 61.6 (CH), 61.7 (CH), 79.5 (2C), 116.0 (CH2), 116.1 
(CH2), 127.3 (2CH), 128.4 (4CH), 130.2 (4CH), 135.2 (2C), 136.8 (2CH), 167.2 (2C), 
171.2 (C), 171.3 (C). 
 
 
 
(S)-5-benzyl-2,2,3-trimethyl-1-(5-methylhept-6-enoyl)imidazolidin-4-one (21m): 
hept-6-enoic acid 9b (0.51 g, 3.6 mmol) gave the corresponding amide (1.0 g, 
2.9 mmol, 80 % yield); chromatographic conditions : petroleum ether/EtOAc = 3/2; 
colorless oil; [Rf  (3/2) = 0.51]. IR (neat): υ 1707, 1656 cm-1. 1H NMR (400MHz, 
CDCl3) (of the mixture of the two diastereoisomers): δ 0.68 (s, 3H), 1.02 (dd, 3H, J = 
1.1, 6.7Hz), 1.37 (m, 2H), 1.54 (s, 3H), 1.73 (m, 2H), 2.16 (hept, 1H, J = 6.9Hz), 2.39 
(m, 2H), 2.68 (s, 3H), 3.16 (dd, 1H, J = 5.3, 14.1Hz), 3.36 (dd, 1H, J = 1.8, 14.1Hz), 
4.50 (dd, 1H, J = 2.2, 5.3Hz), 4.97 (m, 2H), 5.70 (ddd, 1H, J = 7.5, 10.2, 17.4Hz), 7.09 
(m, 2H), 7.24 (m, 3H); 13C NMR (100MHz, CDCl3) (of the mixture of the two 
diastereoisomers): δ 20.1 (CH3), 22.3 (CH3), 22.8 (CH2), 23.9 (CH3), 24.2 (CH3), 35.4 
(CH2), 36.0 (CH2), 37.7 (CH), 37.8 (CH2), 60.6 (CH), 79.5 (C), 112.9 (CH2), 127.3 
(CH), 128.4 (2CH), 130.2 (2CH), 135.1 (C), 144.1 (CH), 167.2 (C), 171.0 (C). 
 
 
 
(S)-5-benzyl-2,2,3-trimethyl-1-(3-methylhept-6-enoyl)imidazolidin-4-one (21n): 
hept-6-enoic acid 9c (1.1 g, 7.7 mmol) gave the corresponding amide (1.3 g, 3.7 mmol, 
50 % yield); chromatographic conditions : petroleum ether/EtOAc = 3/2; colorless oil; 
[Rf  (1/1) = 0.55]. IR (neat): υ 1704, 1658 cm-1. 1H NMR (600MHz, CDCl3) (of the 
mixture of the two diastereoisomers): δ 0.67 (2s overlapped, 6H), 0.93 (d, 3H, J = 
6.0Hz), 1.06 (d, 3H, J = 6.8Hz), 1.54 (s, 3H), 1.55 (s, 3H), 2.14 (m, 8H), 2.35 (m, 4H), 
2.67 (s, 3H), 2.68 (s, 3H), 3.26 (m, 2H), 4.52 (m, 1H), 4.54 (m, 1H), 4.99 (m, 4H), 5.81 
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(m, 2H), 7.09 (m, 4H), 7.14 (m, 6H); 13C NMR (150MHz, CDCl3) (of the mixture of the 
two diastereoisomers): δ 19.0 (CH3), 19.7 (CH3), 22.0 (CH3), 22.1 (CH3), 23.6 (2CH3), 
23.9 (2CH3), 29.7 (CH3), 30.2 (CH3), 30.9 (CH2), 31.0 (CH2), 35.3 (CH2), 36.0 (CH2), 
37.8 (2CH2), 42.5 (CH2), 42.7 (CH2), 60.4 (CH), 60.5 (CH), 79.3 (2C), 114.3 (CH2), 
114.4 (CH2), 127.0 (2CH), 128.2 (4CH), 130.0 (4CH), 134.9 (C), 135.0 (C), 138.2 
(2CH), 166.9 (C), 167.0 (C), 170.2 (C), 170.4 (C). 
 
N
N
O
O
Ph
 
 
(S)-5-benzyl-2,2,3-trimethyl-1-(2-methylhept-6-enoyl)imidazolidin-4-one (21o): 
hept-6-enoic acid 9d (1.3 g, 9.1 mmol) gave the corresponding amide (1.9 g, 5.6 mmol, 
61 % yield); chromatographic conditions : petroleum ether/EtOAc = 3/2; white solid; 
m.p. 76°C; [Rf  (3/2) = 0.20]. IR (KBr): υ 1699, 1649 cm-1. 1H NMR (400MHz, CDCl3) 
(of the mixture of the two diastereoisomers): δ 0.73 (s, 3H), 1.28 (d, 3H, J = 6.5Hz), 
1.42 (m, 3H), 1.54 (s, 3H), 1.63 (m, 1H), 2.03 (m, 2H), 2.67 (m, 1H), 2.68 (s, 3H), 3.08 
(dt, 1H, J = 5.3, 14.0Hz), 3.37 (dd, 1H, J = 2.6, 14.0Hz), 4.56 (dd, 1H, J = 2.5, 5.3Hz), 
4.97 (m, 1H), 4.99 (m, 1H), 5.75 (ddt, 1H, J = 6.7, 10.2, 23.8Hz), 7.11 (m, 2H), 7.24 (m, 
3H); 13C NMR (100MHz, CDCl3) (of the mixture of the two diastereoisomers): δ 17.0 
(CH3), 22.5 (CH3), 23.8 (CH3), 24.1 (CH3), 26.3 (CH2), 33.5 (CH2), 35.0 (CH2), 38.0 
(CH), 38.8 (CH2), 60.4 (CH), 79.5 (C), 114.9 (CH2), 127.2 (CH), 128.3 (2CH), 130.3 
(2CH), 135.0 (C), 137.9 (CH), 167.1 (C), 175.1 (C). 
 
 
 
(S)-5-benzyl-1-hept-6-enoyl-2,2,3-trimethylimidazolidin-4-one (21p): commercial 
hept-6-enoic acid (1.1 g, 8.6 mmol) gave the corresponding amide (2.3 g, 7 mmol, 82 % 
yield), [α]D20 +54.2 (c 1.000, CH2Cl2); chromatographic conditions : petroleum 
ether/EtOAc = 2/1; colorless oil; [Rf  (2/1) = 0.43, 0.31]. IR (neat): υ 1704, 1660, 1647 
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cm-1. 1H NMR (600MHz, CDCl3): δ 0.68 (s, 3H), 1.48 (m, 2H), 1.54 (s, 3H), 1.75 
(quintet, 2H, J = 7.4Hz), 2.11 (m, 2H), 2.39 (dt, 1H, J = 7.6, 15.2Hz), 2.44 (dt, 1H, J = 
7.3, 15.2Hz), 2.68 (s, 3H), 3.16 (dd, 1H, J = 5.6, 14.1Hz), 3.36 (dd, 1H, J = 2.3, 
14.1Hz), 4.51 (dd, 1H, J = 2.1, 5.3Hz), 4.97 (m, 1H), 5.03 (ddd, 1H, J = 1.4, 3.5, 
17.0Hz), 5.82 (ddt, 1H, J = 6.6, 10.0, 16.7Hz), 7.09 (m, 2H), 7.24 (m, 3H); 13C NMR 
(150MHz, CDCl3): δ 22.2 (CH3), 23.8 (CH3), 24.1 (CH3), 24.5 (CH2), 28.3 (CH2), 33.4 
(CH2), 35.1 (CH2), 37.8 (CH2), 60.5 (CH), 79.4 (C), 114.6 (CH2), 127.2 (CH), 128.3 
(2CH), 130.1 (2CH), 135.0 (C), 138.2 (CH), 167.1 (C), 170.9 (C). 
 
General Procedure45 for the [2+2] Intramolecular cycloaddition-hydrolysis 
sequence: Under N2, 2,6-di-tert-butyl-4-methylpyridine (1.2 eq.) was added to a stirring 
solution of amide 21 (1 eq.) in dry 1,2-dichloroethane (6.8 mL/mmol). A solution of 
triflic anhydride (2 eq.) in dry 1,2-dichloroethane (12.8 mL/mmol) was added dropwise 
in one hour to this mixture. Stirring was continued until reaction was complete by GC. 
The mixture was concentrated in vacuo and taken up in a biphasic system CHCl3/H2O = 
1/1 (9 mL/mmol). This mixture was refluxed for 5h, cooled, extracted with 
dichloromethane four times and dried over MgSO4. The solvent was removed by 
distillation to give a brownish oil. This oil was taken up in n-pentane (1 mL/mmol), 
caused the precipitation of the 2,6-di-tert-butyl-4-methylpyridine. The liquid was 
charged into a column for the flash chromatographic purification. Because of the high 
volatility of the product yields were calculate by GC analysis on the crude after the 
hydrolysis step. The amine was recovered (c.a. 20 % yield) by extracting the aqueous 
layer at pH 14 with diethyl ether. 
 
Bicyclo[3.2.0]hept-3-en-6-ones 
 
 
 
(1S,5S) Bicyclo[3.2.0]hept-3-en-6-one (12a): amide 21a (1.9 g, 6.0 mmol) gave the 
corresponding highly volatile bicycle (434 mg, 4.0 mmol, 66 % yield, 91 % ee); 
chromatographic conditions : n-pentane/ CH2Cl2 =  1/0 gradient to 2/1; colorless oil; [Rf  
(2/1) = 0.20]. 1H NMR (600MHz, CDCl3): δ 1.59 (m, 1H), 1.63 (m, 1H), 1.75 (m, 1H), 
1.84 (m, 2H), 2.04 (m, 1H), 2.68 (m, 3H), 2.49 (ddd, 1H, J = 3.2, 4.4, 18.2Hz), 2.89 (m, 
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1H), 3.19 (ddd, 1H, J = 4.4, 9.4, 18.5Hz), 3.55 (m, 1H); 13C NMR (150MHz, CDCl3): δ 
25.6 (CH2), 29.8 (CH), 40.2 (CH), 73.6 (CH), 125.1 (CH), 133.3 (CH), 207.6 (C); GC 
tr(1R,5R) = 7.72min, tr(1S,5S) = 8.46min. 
 
  
Major Minor 
 
(1R,2S,5S) and (1R,2R,5S) -2-(Benzyloxymethyl) bicyclo[3.2.0]hept-3-en-6-one 
(12c): amide 21c (2.3 g, 5.2 mmol) gave the corresponding bicycle (420 mg , 
1.8 mmol, 35 % yield) in a exo:endo mixture (dr 92/8; ee major 93 %; ee minor 67 %); 
chromatographic conditions : n-pentane/Et2O = 8/2; yellow oil; [Rf  (7/3) = 0.48]. 1H 
NMR (300MHz, CDCl3) (of the mixture of the two diastereoisomers): δ 2.66-3.72 (m, 
6H), 4.22 (m, 1H), 4.51 (m, 2H), 5.70 (m, 1H), 5.88 (m, 1H), 7.32 (m, 5H); 13C NMR 
(75MHz, CDCl3) (of the mixture of the two diastereoisomers): δ  28.8 (CH), 29.8 (CH), 
46.7 (CH2), 48.8 (CH), 52.8 (CH2), 54.6 (CH), 69.3 (CH2), 73.5 (CH), 73.6 (CH2), 73.7 
(CH2), 73.8 (CH2), 74.1 (CH), 127.3 (CH), 127.4 (4CH), 127.8 (CH), 128.9 (4CH), 
134.8 (CH), 134.9 (CH), 138.7 (2C), 206.51 (2C); GC (column: Agilent 19091Z-413E, 
HP-1 Methyl siloxane column; (initial column temperature 50°C (2min); heating rate, 
10°C/min (to 150°C), 25°C/min (to 275°C)): tr(major) = 16.4min, tr(minor) = 16.6min; 
GC (column: Restek 13104 Rt-βDEXsm; column temperature 180°C (30min)) major: 
tr(1S,2R,5R) = 14.7min, tr(1R,2S,5S) = 15.3min, minor: tr(1S,2S,5R) = 12.9min, 
tr(1R,2R,5S) = 13.4min. 
 
 
 
(1S,5S) 2,2-Dimethylbicyclo[3.2.0]hept-3-en-6-one (12d): amide 21d (1.1 g, 
1.2 mmol) gave the corresponding highly volatile bicycle (170 mg, 1.2 mmol, 40 % 
yield, 57 % ee); chromatographic conditions : n-pentane/ CH2Cl2 =  2/1; yellow oil; [Rf  
(2/1) = 0.28]. 1H NMR (300MHz, CDCl3): δ 1.10 (s, 3H), 1.18 (s, 3H), 2.54 (ddd, 1H, J 
= 6.1, 6.2, 8.6Hz), 2.88 (ddd, 1H, J = 4.4, 8.4, 17.9Hz), 3.13 (ddd, 1H, J = 3.1, 6.3, 
17.9Hz), 4.20 (m, 1H), 5.47 (dd, 1H, J = 2.6, 5.4Hz), 5.66 (dd, 1H, J = 2.2, 5.4Hz); 13C 
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NMR (75MHz, CDCl3): δ 21.2 (CH3), 30.6 (CH3), 37.5 (CH), 41.5 (C), 47.4 (CH2), 
73.2 (CH), 123.5 (CH), 144.7 (CH), 206.6(C); GC (column: Agilent 19091Z-413E, HP-
1 Methyl siloxane column; (initial column temperature 50°C (2min); heating rate, 
10°C/min (to 150°C), 25°C/min (to 275°C)): tr = 7.3min; GC (column: Restek 13104 
Rt-βDEXsm; column temperature 80°C (30min)): tr(1R,5R) = 29.7min, tr(1S,5S) = 
31.3min. 
O
 
 
(1S,5R) 4-Methylbicyclo[3.2.0]hept-3-en-6-one (12f): (S)-amide 21f (1.4 g, 
4.11 mmol) gave the corresponding bicycle (355 mg, 2.9 mmol, 71 % yield, 93 % ee); 
chromatographic conditions: n-pentane/CH2Cl2 =  4/1 gradient to 2/1; yellow oil; [Rf  
(2/1) = 0.28, permanganate]. 1H NMR (600MHz, CDCl3): δ 1.76 (m, 3H), 2.38 (m, 1H), 
2.80 (m, 3H), 3.23 (m, 1H), 4.02 (m, 1H), 5.46 (m, 1H); 13C NMR (150MHz, CDCl3): δ 
15.2 (CH3), 26.7 (CH), 40.2 (CH2), 53.3 (CH2), 76.1 (CH), 126.6 (CH), 134.9 (C), 207.5 
(C); GC (column: Agilent 19091Z-413E, HP-1 Methyl siloxane column; (initial column 
temperature 50°C (2min); heating rate, 10°C/min (to 150°C), 25°C/min (to 275°C)): tr = 
6.9min; GC (column: Restek 13104 Rt-βDEXsm; initial column temperature 120°C 
(20min); heating rate, 5°C/min (to 180°C)) : tr(1R,5S) = 5.4min, tr(1S,5R) = 5.5min. 
 
 
 
(1S,5R) 3-Methylbicyclo[3.2.0]hept-3-en-6-one (12g): (S)-amide 21g (1.8 g, 
5.3 mmol) gave the corresponding bicycle (422 mg, 3.5 mmol, 65 % yield, 93 % ee); 
[α]D20 + 783.5 (c 0.500, CHCl3); chromatographic conditions: n-pentane/CH2Cl2  = 
100/0 gradient to 2/1; yellow oil; [Rf  (2/1) = 0.15, permanganate]. 1H NMR (400MHz, 
CDCl3): δ 1.80 (m, 3H), 2.29 (m, 1H), 2.75 (m, 1H), 2.80 (m, 2H), 3.21 (m, 1H), 4.18 
(m, 1H), 5.21 (m, 1H); 13C NMR (100MHz, CDCl3): δ 16.5 (CH3), 26.5 (CH), 44.4 
(CH2), 53.1 (CH2), 73.5 (CH), 119.1 (CH), 134.9 (C), 208.6 (C); GC (column: Agilent 
19091Z-413E, HP-1 Methyl siloxane column; (initial column temperature 50°C (2min); 
heating rate, 10°C/min (to 150°C), 25°C/min (to 275°C)): tr = 7.3min; GC (column: 
Restek 13104 Rt-βDEXsm; initial column temperature 120°C (20min); heating rate, 
5°C/min (to 180°C)) : tr(1R,5S) = 6.5min, tr(1S,5R) = 7.6min. 
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Major Minor 
 
(1R,2R,5S) and (1R,2S,5S) 2-Methylbicyclo[3.2.0]hept-3-en-6-one (12h): (S)-amide 
21h (1.8 g, 5.3 mmol) gave the corresponding bicycle (422 mg, 3.5 mmol, 66 % yield) 
in a endo:exo mixture (dr 49/51; ee major 84 %; ee minor 87 %); chromatographic 
conditions: n-pentane/CH2Cl2  = 4/1 gradient to 2/1; yellow oil; [Rf  (2/1) = 0.31, 
permanganate]. 1H NMR (600MHz, CDCl3) (of the mixture of the two 
diastereoisomers): δ 1.05 (d, 3Hminor, J = 7.0Hz), 1.17 (d, 3Hmajor, J = 7.3Hz), 2.41 
(dt, 1Hminor,  J = 5.8, 9.0Hz), 2.75 (m, 1Hminor), 2.80 (m, 1Hmajor), 2.83 (m, 
1Hminor), 2.94 (m, 1Hmajor), 3.17 (dd, 1Hminor, J = 4.4, 9.0Hz), 3.20 (m, 1Hmajor), 
3.23 (m, 1Hmajor), 4.19 (m, 1Hmajor), 4.26 (m, 1Hminor), 5.56 (m, 1Hminor), 5.59 (m, 
1Hmajor), 5.69 (m, 1Hmajor), 5.89 (m, 1Hminor); 13C NMR (150MHz, CDCl3) (of the 
mixture of the two diastereoisomers): δ 13.4 (CH3major), 21.5 (CH3minor), 30.5 
(CH2major), 33.3 (CH2minor), 41.9 (CHminor), 45.8 (CH2major), 48.0 (CHminor), 
52.1 (CH2minor), 72.8 (CHmajor), 73.8 (CHminor), 124.3 (CHmajor), 124.9 
(CHminor), 139.4 (CHminor), 139.5 (CHmajor), 207.4 (Cmajor), 207.7 (Cminor); GC 
(column: Agilent 19091Z-413E, HP-1 Methyl siloxane column; (initial column 
temperature 50°C (2min); heating rate, 10°C/min (to 150°C), 25°C/min (to 275°C)): 
tr(major) = 6.9min, tr(minor) = 6.4min; GC (column: Restek 13104 Rt-βDEXsm; initial 
column temperature 120°C (20min); heating rate, 5°C/min (to 180°C)) major: 
tr(1S,2S,5R) = 5.1min, tr(1R,2R,5S) = 5.6min; minor: tr(1S,2R,5R) = 6.0min, tr(1R,2S,5S) 
= 6.5min. 
 
 
Major Minor 
  
(1S,5S,7S) and (1S,5S,7R) 7-Pentylbicyclo[3.2.0]hept-3-en-6-one (12i): amide 21i 
(460 mg, 1.2 mmol) gave the corresponding bicycle (178 mg , 0.8 mmol, 70 % yield) in 
mixture (dr 88/22; ee major 92 %; ee minor 91 %); chromatographic conditions : n-
pentane/CH2Cl2  = 3/1 gradient to 2/1; yellow oil; [Rf  (2/1) = 0.31]. IR (neat): υ 2956, 
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2926, 2855, 1774 cm-1. 1H NMR (600MHz, CDCl3) (of the mixture of the two 
diastereoisomers): δ 0.89 (t, 3Hmajor, J = 7.0Hz), 0.89 (m, 3Hminor), 1.29 (m, 
4Hmajor + 4Hminor), 1.38 (m, 2Hmajor + 2Hminor), 1.48 (m, 1Hminor), 1.50 (m, 
1Hmajor), 1.60 (m, 1Hminor), 1.70 (m, 1Hmajor), 2.47 (m, 1Hmajor), 2.50 (m, 
1Hmajor), 2.52 (m, 1Hminor), 2.57 (m, 1Hminor), 2.84 (ddq, 1Hmajor, J = 2.3, 7.9, 
15.6Hz), 2.95 (ddt, 1Hmajor, J = 3.2, 5.98, 9.0Hz), 3.09 (m, 1Hminor), 3.28 (m, 
1Hminor), 4.14 (m, 1Hmajor), 4.25 (m, 1Hminor), 5.60 (m, 1Hminor), 5.65 (dq, 
1Hmajor, J = 2.6, 5.3Hz), 5.88 (dq, 1Hmajor, J = 2.3, 4.7Hz), 5.91 (m, 1Hminor); 13C 
NMR (150MHz, CDCl3) (of the mixture of the two diastereoisomers): δ 13.9 
(CH3major), 22.4 (CH2major), 26.5 (CH2minor), 26.8 (CH2major), 28.0 (CH2minor), 
28.9 (CH2major), 29.6 (CH2minor), 30.1 (CH3minor), 30.4 (CHminor), 31.6 
(CH2minor), 31.7 (CH2major), 32.7 (CH2minor), 33.3 (CHmajor), 40.5 (CH2major), 
61.7 (CHminor), 66.0 (CHmajor), 70.7 (CHmajor), 71.5 (CHminor), 116.1 (CHminor), 
125.3 (CHminor), 126.2 (CHmajor), 133.3 (CHmajor), 211.2 (Cminor + Cmajor); GC 
(column: Agilent 19091Z-413E, HP-1 Methyl siloxane column; (initial column 
temperature 50°C (2min); heating rate, 10°C/min (to 150°C), 25°C/min (to 275°C)): 
tr(major) = 11.2min, tr(minor) = 11.5min; GC (column: Restek 13104 Rt-βDEXsm; 
initial column temperature 120°C (20min); heating rate, 5°C/min (to 180°C)) major:  
tr(1R,5R,7R) = 22.8min, tr(1S,5S,7S) = 23.2min, minor: tr(1R,5R,7S) = 25.6min, 
tr(1S,5S,7R) = 26.3min. 
 
Bicyclo[3.2.0]heptan-6-ones 
 
  
Major Minor 
  
(1S,3R,5S) and (1S,3S,5S) 3-Methylbicyclo[3.2.0]heptan-6-one (10a): (S)-amide 21l 
(1.17 g, 3.4 mmol) gave the corresponding bicycle (136 mg, 1.1 mmol, 32 % yield) in a 
exo:endo mixture (dr 55/45; ee major 85 %; ee minor 90 %); chromatographic 
conditions : n-pentane/ CH2Cl2 = 4/1 gradient to 3/2; colorless oil; [Rf  (2/1) = 0.27, 
permanganate]. IR (neat): υ 2952, 2920, 2847, 1734 cm-1. 1H NMR (600MHz, CDCl3) 
(of the mixture of the two diastereoisomers): δ 1.04 (d, 3Hmajor, J = 6.7Hz), 1.05 (d, 
3Hminor, J = 6.0Hz), 1.18 (ddd, 1Hminor, J = 6.0, 8.9, 13.0Hz), 1.26 (m, 1Hmajor), 
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1.42 (ddd, 1Hmajor, J = 7.2, 11.7, 12.7Hz), 1.54 (ddd, 1Hminor, J = 5.6, 8.5, 13.0Hz), 
1.89 (dd, 1Hmajor, J = 5.9, 13.0Hz), 1.95 (dddd, 1Hminor, J = 1.0, 6.9, 9.9, 13.0Hz), 
2.09 (m, 1Hmajor), 2.12 (m, 1Hmajor), 2.18 (m, 1Hminor), 2.26 (m, 1Hminor), 2.56 
(ddd, 1Hmajor, J = 3.6, 4.3, 18.4Hz), 2.69 (dt, 1Hminor, J = 3.5, 17.9Hz), 2.82 (m, 
1Hminor), 2.88 (m, 1Hmajor), 3.19 (m, 1Hmajor + 1Hminor), 3.56 (m, 1Hmajor), 3.63 
(m, 1Hminor); 13C NMR (100MHz, CDCl3) (of the mixture of the two 
diastereoisomers): δ 18.8 (majorCH3), 20.0 (minorCH3), 29.4 (majorCH), 30.1 
(minorCH), 32.8 (majorCH), 36.7 (minorCH2), 38.0 (majorCH2), 39.9 (minorCH), 41.2 
(majorCH2), 42.2 (minorCH2), 51.9 (majorCH2), 52.6 (minorCH2), 65.2 (majorCH), 
65.8 (minorCH), 214.1 (majorC), 215.0 (minorC); GC (column: Agilent 19091Z-413E, 
HP-1 Methyl siloxane column; (initial column temperature 50°C (2min); heating rate, 
10°C/min (to 150°C), 25°C/min (to 275°C)): tr(major) = 6.86min, tr(minor) = 7.1min; 
GC (column: Restek 13104 Rt-βDEXsm; column temperature 80°C (30min)) : major: 
tr(1R,3S,5R) = 21.6min, tr(1S,3R,5S) = 28.9min; minor: tr(1R,3R,5R) = 23.7min, 
tr(1S,3S,5S) = 28.1min. 
 
  
Major Minor 
 
(1R,2R,5S) and (1R,2S,5S) 2-Methylbicyclo[3.2.0]heptan-6-one (10b): (S)-amide 
21m (0.95 g, 2.7 mmol) gave the corresponding bicycle (118 mg, 0.9 mmol, 34 % yield) 
in a endo:exo mixture (dr 53/47; ee major 87 %, ee minor 92 %); chromatographic 
conditions: n-pentane/CH2Cl2  = 2.5/1; colorless oil; [Rf  (2/1) = 0.19, permanganate]. 
1H NMR (600MHz, CDCl3) (of the mixture of the two diastereoisomers): δ 0.95 (d, 
3Hminor, J = 7.0Hz), 1.06 (d, 3Hmajor, J = 6.7Hz), 1.56 (m, 2Hmajor), 1.66 (m, 
2Hminor), 1.83 (m, 2Hmajor + 2Hminor), 2.17 (m, 1Hminor + 1Hminor), 2.52 (m, 
1Hmajor + 1Hminor), 2.71 (m, 1Hmajor), 2.77 (m, 1Hmajor), 2.89 (ddd, 1Hmajor, J = 
4.7, 9.1, 18.2Hz), 3.17 (ddd, 1Hminor, J = 4.7, 9.9, 19.0Hz), 3.52 (m, 1Hmajor), 3.57 
(m, 1Hminor); 13C NMR (100MHz, CDCl3) (of the mixture of the two 
diastereoisomers): δ 14.7 (majorCH3), 20.0 (minorCH3), 26.9 (minorCH2), 28.6 
(majorCH2), 31.6 (minorCH2), 31.8 (majorCH2), 33.3 (majorCH), 36.3 (minorCH), 
37.2 (majorCH), 39.6 (minorCH), 45.1 (majorCH2), 51.2 (minorCH2), 64.2 (minorCH), 
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64.7 (majorCH), 214.0 (minorC), 214.1 (majorC); GC (column: Agilent 19091Z-413E, 
HP-1 Methyl siloxane column; (initial column temperature 50°C (2min); heating rate, 
10°C/min (to 150°C), 25°C/min (to 275°C)): tr(major) = 7.2min, tr(minor) = 7.0min; 
GC (column: Restek 13104 Rt-βDEXsm; column temperature 80°C (30min)) :  major: 
tr(1S,2S,5R) = 25.9min, tr(1R,2R,5S) = 28.6min; minor: tr(1S,2R,5R) = 24.9min, 
tr(1R,2S,5S) = 27.5min. 
 
  
Major Minor 
 
(1S,4S,5S) and (1S,4R,5S) 4-Methylbicyclo[3.2.0]heptan-6-one (19c): amide 21n 
(1.28 g, 3.7 mmol) gave the corresponding bicycle (130 mg, 1.05 mmol, 28 % yield) in 
a endo:exo mixture (dr 67/33; ee major 79 %; ee minor 93 %); chromatographic 
conditions : n-pentane/CH2Cl2  = 4/1 gradient to 3/2; colorless oil; [Rf  (2/1) = 0.22, 
permanganate]. 1H NMR (600MHz, CDCl3) (of the mixture of the two 
diastereoisomers): δ 0.89 (d, 3Hminor, J = 7.3Hz), 1.13 (d, 3Hmajor, J = 7.0Hz), 1.38 
(m, 1Hmajor), 1.55 (dd, 1Hminor, J = 6.7, 12.9Hz), 1.82 (m, 2Hminor + 2Hmajor), 1.84 
(m, 1Hmajor), 2.00 (m, 1Hminor), 2.11 (m, 1Hmajor), 2.43 (quintet, 1Hminor, J = 
6.7Hz), 2.49 (ddd, 1Hmajor, J = 3.5, 4.4, 18.4Hz), 2.51 (m, 1Hminor), 2.83 (m, 
1Hminor), 2.91 (m, 1Hmajor), 3.12 (ddd, 1Hmajor, J = 4.7, 9.0, 18.4Hz), 3.17 (ddd, 
1Hminor, J = 4.4, 9.4, 18.4Hz), 3.23 (m, 1Hminor), 3.41 (m, 1Hmajor); 13C NMR 
(150MHz, CDCl3) (of the mixture of the two diastereoisomers): δ 15.3 (majorCH3), 
19.7 (minorCH3), 28.7 (minorCH), 29.3 (majorCH), 30.2 (majorCH2), 31.8 
(minorCH2), 32.9 (majorCH2 + minorCH2), 37.0 (minorCH), 39.2 (majorCH), 51.1 
(minorCH2), 51.5 (majorCH2), 69.0 (majorCH), 72.0 (minorCH), 213.1 (majorC), 213.9 
(minorC); GC (column: Agilent 19091Z-413E, HP-1 Methyl siloxane column; (initial 
column temperature 50°C (2min); heating rate, 10°C/min (to 150°C), 25°C/min (to 
275°C)): tr(major) = 13.5min, tr(minor) = 13.7min; GC (column: Restek 13104 Rt-
βDEXsm; column temperature 80°C (30min)): major: tr(1S,4S,5S) = 26.2min, 
tr(1R,4R,5R) = 29.0min; minor: tr(1R,4S,5R) = 24.3min, tr(1S,4R,5S) = 25.9min. 
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(1S,5S) Bicyclo[3.2.0]heptan-6-one (10e): amide 21p (750 mg, 2.28 mmol) gave the 
corresponding highly volatile bicycle (63  mg, 0.57 mmol, 25 % yield, 88 % ee); 
[α]D20 +182.6 (c 0.390, CHCl3); chromatographic conditions : n-pentane/CH2Cl2  = 3/1 
gradient to 2/1; colorless oil; [Rf  (2/1) = 0.20, permanganate]. 1H NMR (600MHz, 
CDCl3): δ 1.59 (m, 1H), 1.63 (m, 1H), 1.75 (m, 1H), 1.84 (m, 2H), 2.04 (m, 1H), 2.49 
(ddd, 1H, J = 3.2, 4.4, 18.2Hz), 2.89 (m, 1H), 3.19 (ddd, 1H, J = 4.4, 9.4, 18.5Hz), 3.55 
(m, 1H); 13C NMR (150MHz, CDCl3): δ 24.7 (CH2), 28.8 (CH), 29.8 (CH2), 32.7 (CH2), 
51.5 (CH2), 64.8 (CH), 214.8 (C); GC (column: Agilent 19091Z-413E, HP-1 Methyl 
siloxane column; (initial column temperature 50°C (2min); heating rate, 10°C/min (to 
150°C), 25°C/min (to 275°C)): tr = 4.3min; GC (column: Restek 13104 Rt-βDEXsm; 
column temperature 80°C (30min)) : tr(1R,5R) = 16.7min, tr(1S,5S) = 18.9min. 
 
 
Major Minor 
 
(1R,5S,7S) and (1R,5S,7R) 7-Pentylbicyclo[3.2.0]heptan-6-one (10f): 2-
Methylbicyclo [3.2.0]hept-3-en-6-one 12i (60 mg, 0.33 mmol, 1 eq.) was dissolved in 
methanol (2 mL/mmol) and the flask was saturated with nitrogen. To this solution Pd/C 
5 % (13 mg, 0.04 g/ mmol) was added and the flask was saturated with hydrogen. At the 
flask was connected a gas-burette of hydrogen and the reaction was stirred until the H2 
adsorption end. After 3h the mixture was filtered through a pad of celite and the filtrate 
was concentrated under reduce pressure to afford 43 mg (0.24 mmol, 71 % yield) of 
product as colorless oil. IR (neat): υ 2953, 2929, 2857, 1771 cm-1. 1H NMR (600MHz, 
CDCl3) (of the mixture of the two diastereoisomers): δ 0.90 (t, 3H, J = 7.0Hz), 1.33 (m, 
4H), 1.53 (m, 1H), 1.64 (m, 2H), 1.77 (m, 1H), 1.86 (m, 2H), 2.00 (m, 1H), 2.55 (m, 
1H), 2.60 (m, 1H); 13C NMR (150MHz, CDCl3) (of the mixture of the two 
diastereoisomers): δ 13.4 (CH3major + CH3minor), 22.0 (CH2major), 22.9 (CH2minor), 
24.8 (CH2major), 26.2 (CH2minor), 26.3 (CH2minor), 26.3 (CH2major), 26.9 
(CH2minor), 28.5 (CHminor), 28.9 (CH2major), 29.1 (CHmajor), 29.6 (CH2minor), 
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31.2 (CH2major), 31.3 (CH2minor), 32.4 (CH2major), 33.2 (CH2minor), 36.1 
(CH2major), 60.3 (CHminor), 61.1 (CHmajor), 63.6 (CHmajor), 62.3 (CHminor), 119.4 
(Cminor + Cmajor); GC (column: Agilent 19091Z-413E, HP-1 Methyl siloxane 
column; (initial column temperature 50°C (2min); heating rate, 10°C/min (to 150°C), 
25°C/min (to 275°C)): tr(major) = 11.8min, tr(minor) = 11.5min; GC (column: Restek 
13104 Rt-βDEXsm; initial column temperature 120°C (20min); heating rate, 5°C/min 
(to 180°C)) major:  tr(1S,5R,7R) = 23.8min, tr(1R,5S,7S) = 24.1min, minor: tr(1S,5R,7S) 
= 25.5min, tr(1R,5S,7R) = 25.8min. 
 
General Procedure45 for the [2+2] Intermolecular cycloaddition-hydrolysis 
sequence: 2,6-Di-tert-butyl-4-methylpyridine (1.1 eq.) was added to a solution of amide 
22a or 22b (1 eq.) in dry 1,2-dichloroethane (10 mL/mmol). This mixture was cooled at 
0 °C and then a solution of triflic anhydride (2 eq.) in dry 1,2-dichloroethane 
(2 mL/mmol) was added dropwise in one hour. The mixture was stirred until reaction 
was complete by GC. It was concentrated in vacuo and taken up in a biphasic system 
CHCl3/H2O = 1/1 (9 mL /mmol). This mixture was refluxed for 5h, cooled, extracted 
four times with dichloromethane and dried over MgSO4. The solvent was removed by 
distillation to give a brownish oil. This oil was taken in n-pentane (1 mL/mmol), which 
caused the precipitation of the 2,6-di-tert-butyl-4-methylpyridine. The liquid was 
charged into column for the flash chromatographic purification. Because of the high 
volatility of the products the yields were calculate by GC analysis on the crude after the 
hydrolysis step. The chiral amine was recovered by extracting the aqueous layer at pH 
14 with ether.  
 
OH
H
 
 
(1R,5R) Bicyclo[3.2.0]heptan-6-one (10e): amide 22a (600 mg, 2.30 mmol) gave the 
corresponding bicycle (8 mg, 0.07 mmol, 3 % yield, 96 % ee); chromatographic 
conditions : n-pentane/CH2Cl2  = 3/1 gradient to 2/1; colorless oil; [Rf  (2/1) = 0.20, 
permanganate].  
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Major Minor 
 
(1S,5R,7R) and (1S,5R,7S) 7-Pentylbicyclo[3.2.0]heptan-6-one (10f): amide 22b 
(400 mg, 1.2 mmol) gave the corresponding bicycle (12 mg, 0.065 mmol, 5 % yield) in 
mixture (dr 65/35; ee major 63 %; ee minor 80 %); chromatographic conditions : n-
pentane/CH2Cl2  = 1/0 gradient to 3/1; yellow oil; [Rf  (3/1) = 0.23, permanganate].  
 
 
 
2-(But-3-enyloxy)acetic acid 25a 62: Sodium hydride (50% dispersion in mineral oil, 
3.1 g, 65 mmol) was washed with hexanes and suspended in 50 mL of dry THF, and the 
mixture was cooled to 0 °C. 3-Buten-1-ol 26 (5.1g, 71 mmol) was added dropwise over 
15 min. The resulting mixture was stirred at 0 °C for 15 min, warmed to 25 °C for 15 
min, and then recooled to 0°C. In a second flask, sodium hydride (50% dispersion in 
mineral oil, 3.1 g, 65 mmol) was washed with hexanes and suspended in 25 mL of THF, 
and the mixture was cooled to 0 °C. Bromoacetic acid (9 g, 65 mmol) dissolved in 25 
mL of THF was added into the second flask, and the mixture was stirred at 0 °C for 5 
min. The sodium alkoxide of the alcohol was then added into the flask containing the 
sodium carboxylate of bromoacetic acid. The resultant mixture was warmed to room 
temperature and stirred for 3 h. The reaction was quenched with water, and the THF 
was removed in vacuo. The aqueous layer was washed with diethyl ether, acidified and 
then extracted three times with diethyl ether. The extracts were washed with water, 
dried over Na2SO4, filtered, and concentrated in vacuo. The alkoxyacetic acid was 
obtained in 94% yield and was used without further purification.  
1H NMR (400MHz, CDCl3) : δ 2.39 (tt, 1H, J = 1.4, 6.7Hz), 2.41 (tt, 1H, J = 1.4, 
6.7Hz), 3.63 (t, 2H, J = 6.7Hz), 4.15 (s, 2H), 5.08 (m, 1H), 5.13 (m, 1H), 5.82 (ddt, 1H, 
J = 6.7, 10.0, 17.0Hz), 10.9 (s, 1H); 13C NMR (100MHz, CDCl3): δ 33.8 (CH2), 67.6 
(CH2), 71.1 (CH2), 116.9 (CH2), 134.3 (CH), 175.7 (C). 
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 Crimmins, M. T.; Choy, A. L. J. Am. Chem. Soc. 1999, 121, 5653. 
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(S)-5-benzyl-1-(2-(but-3-enyloxy)acetyl)-2,2,3-trimethylimidazolidin-4-one 28a: A 
solution of oxalyl chloride (5.8 g, 46 mmol) in 12 mL of dry toluene was added 
dropwise to a stirred solution of acid 25a (2 g, 15 mmol) in 60 mL of dry toluene at 
0 °C and under a positive pressure of nitrogen. After 5min at 0 °C, few drops of dry 
DMF were added and the mixture was stirred at room temperature for 2h. The solvent 
and the excess of oxalyl chloride were removed in vacuo. The crude chloride was 
dissolved in 35 mL of anhydrous dichloromethane and the (S)-5-benzyl-2,2,3-
trimethylimidazolidin-4-one hydrochloride 13 (4.1 g, 16 mmol) was added. The mixture 
was cooled to 0 °C and dry pyridine (2.6 g, 32 mmol) was added. The mixture was 
allowed to warm to room temperature; after 24h TLC analysis revealed that the starting 
material was consumed and water was added. The organic layer was washed twice with 
water, and then the aqueous layers were extracted three times with ether. The combined 
organic layers were dried with MgSO4 and the solvent was evaporated. The crude was 
purified by flash column chromatography (CH2Cl2/MeOH 97:3) to afford the 
corresponding amide (3.1 g, yield 64 %). 
Colorless oil, Rf 0.38 (CH2Cl2/MeOH 97:3), 1H NMR (400MHz, CDCl3): δ 0.70 (s, 
3H), 1.57 (s, 3H), 2.42 (m, 2H), 2.69 (s, 3H), 3.12 (dd, 1H, J = 5.6, 14.2Hz), 3.35 (dd, 
1H, J = 2.5, 14.2Hz), 3.62 (m, 2H), 4.21 (dd, 1H, J = 13.8, 55.5Hz), 4.77 (m, 1H), 5.08 
(m, 1H), 5.13 (m, 1H),  5.84 (ddt, 1H, J = 6.7, 10.2, 17.1Hz), 7.11 (m, 2H), 7.24 (m, 
3H); 13C NMR (100MHz, CDCl3): δ 22.5 (CH3), 24.0 (CH3), 24.4 (CH3), 34.2 (CH2), 
37.6 (CH2), 59.9 (CH), 71.4 (CH2), 71.9 (CH2), 80.1 (C), 117.2 (CH2), 127.6 (CH), 
128.7 (2CH), 130.4 (2CH), 134.8 (CH), 135.5 (C), 167.6 (C), 170.9 (C). 
 
 
 
(1S,5S)-2-oxabicyclo[3.2.0]heptan-7-one 29a: Under N2, 2,6-di-tert-butyl-4-
methylpyridine (2.2 g, 11 mmol) was added to a stirring solution of amide 28a (3.0 g, 
9.1 mmol) in 53 mL of dry 1,2-dichloroethane. A solution of triflic anhydride (5.1 g, 18 
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mmol) in 18 mL of dry 1,2-dichloroethane was added dropwise in one hour to this 
mixture. Stirring was continued until reaction was complete by GC. The mixture was 
concentrated in vacuo and taken up in a biphasic system CHCl3/H2O = 60/60. This 
mixture was refluxed for 5h, cooled, extracted with dichloromethane four times and 
dried over MgSO4. The solvent was removed by distillation to give a brownish oil. This 
oil was taken up in n-pentane and the liquid was charged into a column for the flash 
chromatographic purification (CH2Cl2/n-pentane 4:1 gradient to 0:1) to afford 100 mg 
(yield 50%, ee 40%) of oxabicyclo.  
1H NMR (400MHz, CDCl3): δ 1.93 (m, 1H), 2.09 (m, 1H), 2.54 (ddd, 1H, J = 3.4, 4.0, 
18.0Hz), 3.11 (m, 1H), 3.18 (m, 1H), 3.77 (ddd, 1H, J = 5.6, 9.2, 11.3Hz), 4.23 (m, 1H), 
5.08 (m, 1H); 13C NMR (100MHz, CDCl3): δ 30.5 (CH), 31.7 (CH2), 49.5 (CH2), 68.8 
(CH2), 93.8 (CH), 210.9 (C); GC (column: Agilent 19091Z-413E, HP-1 Methyl 
siloxane column; (initial column temperature 50°C (2min); heating rate, 10°C/min (to 
150°C), 25°C/min (to 275°C)): tr = 6.5min; GC (column: Restek 13104 Rt-βDEXsm; 
initial column temperature 100°C (2min); heating rate, 1.5°C/min (to 180°C)) : 
tr(1R,5R) = 9.6min, tr(1S,5S) = 10.2min. 
 
 
 
3-(Allyloxy)propanoic acid 25b 63: Dry Cs2CO3 (3.2 g, 10 mmol) was suspended in 6 
mL of dry DMF. The mixture was cooled to 0°C and tert-butyl acrylate (1.3 g, 10 
mmol) was added dropwise. After 15min a solution of Prop-2-en-1-ol 27 (0.6 g, 10 
mmol) in 4 mL of DMF was slowly added. The reaction was stirred overnight at 40°C. 
Then, brine was added and the product was extracted three times with diethyl ether. The 
organic phase was washed three times with brine, then the organic layer was dried with 
anhydrous Na2SO4. The solvent was removed under reduced pressure to afford the tert-
butyl ester as colorless oil (1.1 g, 58 % yield). This ester was dissolved in 20 mL of dry 
CH2Cl2, treated with 1.9 g (17.4 mmol) of trifluoroacetic acid and stirred overnight at 
40°C. The solvent and the acid excess were removed under reduced pressure to afford 
672 mg (89% yield) of acid. 
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 In according to literature: Perrone, M. G.; Santandrea, E.; Dell’Uomo, N.; Giannessi, F.; Milazzo, F. 
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1H NMR (400MHz, CDCl3) : δ 2.62 (m, 2H), 3.70 (m, 2H), 3.99 (m, 2H), 5.17 (m, 1H), 
5.25 (m, 1H), 5.87 (m, 1H), 10.3 (s, 1H); 13C NMR (100MHz, CDCl3): δ 35.0 (CH2), 
65.3 (CH2), 72.2 (CH2), 117.6 (CH2), 134.5 (CH), 177.5 (C). 
 
 
 
((R)-1-(3-(allyloxy)propanoyl)-5-benzyl-2,2,3-trimethylimidazolidin-4-one 28b: A 
solution of oxalyl chloride (3.8 g, 30 mmol) in 8 mL of dry dichloromethane was added 
dropwise to a stirred solution of acid 25b (1.3 g, 10 mmol) in 40 mL of dry 
dichloromethane at 0 °C and under a positive pressure of nitrogen. After 5min at 0 °C, 
few drops of dry DMF were added and the mixture was stirred at room temperature for 
2h. The solvent and the excess of oxalyl chloride were removed in vacuo. The crude 
chloride was dissolved in 30 mL of anhydrous dichloromethane and the (R)-5-benzyl-
2,2,3-trimethylimidazolidin-4-one hydrochloride 13 (2.7 g, 10.3 mmol) was added. The 
mixture was cooled to 0 °C and dry pyridine (1.6 g, 20.7 mmol) was added. The mixture 
was allowed to warm to room temperature; after 24h TLC analysis revealed that the 
starting material was consumed and water was added. The organic layer was washed 
twice with water, and then the aqueous layers were extracted three times with ether. The 
combined organic layers were dried with MgSO4 and the solvent was evaporated. The 
crude was purified by flash column chromatography (CH2Cl2/MeOH 97:3) to afford the 
corresponding amide (1.8 g, yield 60 %). 
Colorless oil, Rf 0.36 (CH2Cl2/MeOH 97:3), 1H NMR (400MHz, CDCl3): δ 0.66 (s, 
3H), 1.54 (s, 3H), 2.67 (s, 3H), 2.70 (m, 2H), 3.21 (dd, 1H, J = 5.6, 14.0Hz), 3.38 (dd, 
1H, J = 2.2, 14.0Hz), 3.85 (m, 2H), 4.03 (m, 2H), 4.59 (m, 1H), 5.18 (m, 1H), 5.28 (m, 
1H),  5.91 (ddt, 1H, J = 5.5, 10.3, 17.1Hz), 7.14 (m, 2H), 7.22 (m, 3H); 13C NMR 
(100MHz, CDCl3): δ 22.2 (CH3), 23.7 (CH3), 24.1 (CH3), 35.9 (CH2), 37.7 (CH2), 60.5 
(CH), 66.2 (CH2), 72.1 (CH2), 79.4 (C), 116.9 (CH2), 127.1 (CH), 128.2 (2CH), 130.3 
(2CH), 134.4 (CH), 135.1 (C), 167.0 (C), 169.2 (C). 
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(1R,5S)-3-oxabicyclo[3.2.0]heptan-6-one 29b: Under N2, 2,6-di-tert-butyl-4-
methylpyridine (1.3 g, 6.2 mmol) was added to a stirring solution of amide 28b (1.7 g, 
5.1 mmol) in 31 mL of dry 1,2-dichloroethane. A solution of triflic anhydride (2.9 g, 10 
mmol) in 27 mL of dry 1,2-dichloroethane was added dropwise in one hour to this 
mixture. Stirring was continued until reaction was complete by GC. The mixture was 
concentrated in vacuo and taken up in a biphasic system CHCl3/H2O = 34/34. This 
mixture was refluxed for 5h, cooled, extracted with dichloromethane four times and 
dried over MgSO4. The solvent was removed by distillation to give a brownish oil. This 
oil was taken up in n-pentane and the liquid was charged into a column for the flash 
chromatographic purification (CH2Cl2/n-pentane 5:1 gradient to 0:1) to afford 100 mg 
(yield 17%, ee 60%) of oxabicyclo.  
1H NMR (400MHz, CDCl3): δ 2.75 (ddd, 1H, J = 3.2, 4.6, 18.0Hz), 3.11 (m, 1H), 3.23 
(m, 1H), 3.54 (dd, 1H, J = 6.9, 9.5Hz), 3.72 (m, 1H), 3.75 (m, 1H), 4.10 (d, 1H, J = 
4.1Hz), 4.31 (m, 1H); 13C NMR (100MHz, CDCl3): δ 30.2 (CH), 51.9 (CH2), 65.4 (CH), 
70.7 (CH2), 74.2 (CH2), 210.1 (C); GC (column: Agilent 19091Z-413E, HP-1 Methyl 
siloxane column; (initial column temperature 50°C (2min); heating rate, 10°C/min (to 
150°C), 25°C/min (to 275°C)): tr = 6.3min; GC (column: Restek 13104 Rt-βDEXsm; 
initial column temperature 100°C (2min); heating rate, 1.5°C/min (to 180°C)) : tr(1S,5R) 
= 8.2min, tr(1R,5S) = 8.7min. 
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Chapter 4 
 
A different process to Iloprost 
 
4.1 The drug 
In 1976 Prostacyclin (PGI2) 30 was discovered by Vane et al.,64 it is a metabolite of 
arachidonic acid (see chapter 3, paragraph 3.1.1), and has been shown to be a potent 
inhibitor of human platelet aggregation and a relaxer of vascular tissue. These important 
biological properties have attracted the attention of chemistry, medicine and biology65 
and make Prostacyclin per se an interesting drug for treatment of cardiovascular 
diseases. However, because of the labile enol ether linkage, PGI2 30 is a very unstable 
compound: under physiological conditions its chemical and metabolic instability is 
demonstrated by a half-life of only 3 seconds. The chemical instability is provoked by a 
fast hydration of the ring O-atom. The metabolic instability is caused by the enzymatic 
degradation of both α and ω-chain via a rapid oxidation in the α-position to the carboxy 
group (Figure 18). 
OH
O
HO
COOH
-side chain
-side chain
enol ether moiety
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Figure 18 
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 a) Moncada, S.; Gryglewski, R.; Bunting, S.; Vane, J. R. Nature 1976, 263, 663; b) Gryglewski, R. J.; 
Stock, G. Prostacyclin and its Stable Analogue Iloprost; Springer: Heidelberg, 1987; c) Wise, H.; Jones, 
R. L.; Prostacyclin and its Receptors; Kluwer Academic Publishers: New York, 2000. 
65
 a) Prostacyclin; Vane, J. R., Bergström, S., Eds.; Raven Press: New York 1979; b) Collins, P. W.; 
Djuric, S. W. Chem. Rev. 1993, 93, 1533; c) Schinzer, D. In Organic Synthesis Highlights II; Waldmann, 
H., Ed.; VCH: New York, 1995; p 301; d) Platelets and Their Factors; von Bruchhausen, F., Walter, U., 
Eds.; Springer-Verlag: Berlin, 1997. 
Chapter 4 
 84 
This disadvantageous feature severely hampers the medicinal application. Intensive 
efforts were devoted to synthesize a wide number of analogs in the search for stable and 
therapeutically useful mimics as possible new antithrombotic drugs. The carba-
prostacyclin analogues carbacyclin66 and isocarbacyclin67 show chemically and 
biologically stability but a reduced activity as compared to PGI2 30. The Schering group 
headed by Vorbrüggen and Skuballa, successfully designed and developed carbocyclic 
prostacyclin analogue like Iloprost 31, 64,68  3-oxa-iloprost 32,69 and cicaprost 3370 
(Scheme 20).  
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 a) Kojima, K.; Sakai, K. Tetrahedron Letters 1978, 3743; b) Nicolaou, K. C.; Sipio, W. J.; Magolda, R. 
L. Seitz, S.; Barnette, W. E. J. Chem. Soc., Chem. Commun. 1978, 1067. 
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 Shibasaki, M.; Torisawa, Y.; Ikegami, S. Tetrahedron Letters 1983, 24, 3493. 
68
 a) Skuballa, W.; Vorbrüggen, H. Angew. Chem. 1981, 93, 1080; b) Schenker, K. V.; von Philipsborn, 
W.; Evans, C. A.; Skuballa, W.; Hoyer, G. A. Helv. Chim. Acta 1986, 69, 1718; c) Kramp, G. J.; Kim, 
M.; Gais, H. J.; Vermeeren, C. J. Am. Chem. Soc. 2005, 127, 17910. 
69
 a) Skuballa, W.; Raduechel, B.; Vorbrüggen, H.; Mannesmann, G.; Nieuweboer, B.; Town, M. H.; DE 
3221193, 1983; [Chem. Abstr. 1984, 101, 6931]; b) Tsai, A.-l.; Vijjeswarapu, H.; Wu, K. K. Biochim. 
Biophys. Acta 1988, 942, 220; c) Ashby, B. Prostaglandins 1992, 43, 255. 
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 a) Skuballa, W.; Schillinger, E.; Stuerzebecher, C. S.; Vorbrüggen, H. J. Med. Chem. 1986, 29, 313; b) 
Schneider, M. R.; Schirner, M.; Lichtner, R. B.; Graf, H. Breast Cancer Res. Treat. 1996, 38, 133; c) 
Harre, M.; Trabandt, J.; Westermann, J. Liebigs Ann. Chem. 1989, 108; d) Lerm, M.; Gais, H. J.; Cheng, 
K.; Vermeeren, C. J. Am. Chem. Soc. 2003, 125, 9653. 
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Modification on the ω-chain proved to be the solution for the attainment of highly 
active and stable prostacyclin mimics. In Iloprost 31 a methylene group replaces the O 
atom at the c position, another one methylene group is introduced at Cg and a triple 
bond at Ch. This biologically highly potent and chemically stable analogue has already 
been commercialized for the treatment of peripheral arterial occlusive and Raynaud’s 
disease as Ilomedin. The previous active compound has been also marketed as Ventavis 
with indications for the treatment of pulmonary arterial hypertension. The two drugs are 
introduced in commerce like a mixture of isomers. The mixture contains Cg-(S)-Iloprost 
31 and its less active Cg-(R)-isomer approximately in ratio 1:1. Iloprost 31 is orally 
active, but it has a short duration, so Ilomedin is administered by intravenous infusion 
and Ventavis by inhalation (Scheme 21).  
 
ILOPROST  
Ilomedin 
• 1 ml of Ilomedin contains 0.1mg of  Iloprost. 
• It promotes the healing of ulcerations secondary to 
ischemia (a blood vessel obstruction) and alleviates 
the pain in severe, long lasting disturbances of 
arterial circulation 
• It widens narrow blood vessels in the lung, which 
in turn allows the heart to function more effectively 
Ventavis 
a
OHHO
COOH
bc
d
e
f
g
h
 
 
31 
• 2 mL nebulizer solution contains 20 µg of  Iloprost 
• It is used to treat cases of pulmonary hypertension 
that may have been caused by some defect of the 
vessel walls, by connective tissue disease, or by 
blood clots in the lungs. It widens blood vessels, 
allowing more blood to reach the lungs and receive 
oxygen 
Scheme 21 
4.2 Literature  
4.2.1 Papers 
Prostacyclin 30 is the most potent endogenous blood platelet antiaggregantig and 
because of its considerable medicinal importance the last decades have witnessed a 
broad production of academic papers, that seek a fully stereocontrolled synthesis. 
Below, we report a panoramic summary of some synthetic strategies. In the 1985, 
Kojima and co-workers71 reported a short synthesis of 9(O)-methanoprostacyclin in an 
                                                 
71
 Kojima, K.; Anemiya, S.; Koyama, K.; Sakai, K. Chem. Pharm. Bull. 1985, 33, 2688. 
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optically active form (Scheme 22). The target enantiopure molecule was obtained by the 
optical resolution of racemic acid with (S)-phenylethanamine as chiral resolving agent 
accomplished by recrystallization of its salt with the amine in CH3Cl.  
 
 
OH
CO2H
OO
resolving agent
CH3Cl
OH
CO2
OO
Ph
H3N
OH
CO2
OO
Ph
H3N
 
Racemic acid  In solution Precipitate 
Scheme 22 
Mori72 synthesized a stable mimic of PGI2 exploiting the kinetic resolution of a racemic 
β-keto-ester by yeast reduction (Scheme 23). The enantioselective reduction was carried 
out with wet yeast in a phosphate buffer containing glucose. This procedure gave the 
recovered (+)-β-keto-ester and the reduced (+)-β-hydroxy-ester simply separable under 
chromatographic conditions.  
 
 
 
racemic β-keto-ester  (+)-β-keto-ester (+)-β-hydroxy-ester 
Scheme 23 
In the 1987, Brooks and co-workers73 developed a useful application of reduction by 
baker’s yeast for the preparation of chiral target compounds for asymmetric synthesis of 
carbaprostaglandine (Scheme 24). They reported an enzymatic reaction of an 
enantiomeric pair involving a simultaneous dual kinetic resolution by two different 
enzymes in baker’s yeast. This process involves ester hydrolysis by an esterase and a 
                                                 
72
 Mori, K.; Tsuji, M. Tetrahedron 1986, 42, 435. 
73
 Brooks, D. W.; Wilson, M.; Webb, M. J. Org. Chem. 1987, 52, 2244. 
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subsequent decarboxylation of the β-keto-acid intermediate to produce the achiral 
starting ketone. The reaction of the enantiopure β-hydroxy-ester with NaBH4 at -20°C 
proceed stereo-selective to provide the active configuration trans.  
 
Racemic ester Achiral ketone Cis-isomer Trans-isomer 
 
 
 
Scheme 24 
Another fascinating procedure is the kinetic deprotonation of prochiral cyclohexanones 
studied by Koga.74 Chiral lithium amides in the presence of excess trimethylsilyl 
chloride afforded the corresponding enantiopure silyl enol ethers, that are important 
carbacyclin synthons (Scheme 25). 
 
Racemic ester Enantiopure silyl enol ether 
 
 
Scheme 25 
 
                                                 
74
 Izaka, H.; Shirai, R.; Kawasaki, H.; Kim, H.; Koga, K. Tetrahedron Letters 1989, 7221. 
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4.2.2 Patent 
Herein, we report the synthesis of Iloprost 31 described in the DE 3816801 German 
patent (Scheme 26). This approach provides access to the drug in sufficient quantities 
and starts with the commercial dimethyl-1,3-acetonedicarboxylate 34. In this synthetic 
route the racemic β-acyl-ester 35 is selected as the key intermediate for a highly stereo- 
and regio-controlled synthesis of the target molecule. This compound is asymmetric 
transformed into the corresponding chiral alcohol by a microbial resolution (Alcaligenes 
Marshallii). The unreduced enantiomer of β-acyl-ester 35 is separated from the desired 
enantiopure β-hydroxy-ester by chromatography on silica gel. In the following steps the 
ω and α-chains are introduced to the enantiopure bicyclic framework.  
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Scheme 26 
Enzyme or microbial-catalyzed processes have various advantages like the selectivity 
(region, stereo and enantio) and the mild reaction conditions (aqueous solvent, room 
temperature). They present several negative factors that can limit the commercial utility 
too. Most organisms are active in mild conditions, but moving outside these temperature 
and pH ranges often they are destroyed. Frequently they need high dilutions and 
expensive recover at the end of a reaction. They are easily poisoned and they can have a 
high prize. All these factors plus the high initial price can dramatically increase the cost 
of using biocatalysts. 
 
4.3 Process intensification  
Green chemistry is often confused with ‘environmental’ chemistry; a science that study 
the effects of chemicals on the earth, like the contamination of land and water. In 
contrast, green chemistry is focused on the optimization of production processes, 
maximizing efficiency in the use of resources, avoiding the generation and use of 
hazardous composts, dramatically reducing the waste formation and environmental 
impact, redesigning a safer, cheaper and cleaner plant. Following all these guidelines, 
this new chemistry has to produce materials and products needed by the society in 
acceptable cost without causing damage to the environment. To obtain a greener and 
sustainable chemical process, process intensification is necessary. This concept is 
concerned with cost reduction, safety and product quality improvements, greater 
throughput, better process control and simplified reactors and ancillary equipment.  
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4.4 Result and Discussion  
4.4.1 The racemic β-hydroxy-ester 
The racemic β-hydroxy-ester 36 (Figure 19) appears to be an interesting starting 
building block to the development of an efficient and possible industrial synthetic 
process.  
 
OH
OO
CO2Me
H2H1
 
OH
O O
MeO2C
H2 H1
 
The β-hydroxy-ester 36 enantiomers 
Figure 19 
To provide the active Iloprost 31 isomer, this compound has to be a fixed relative 
structure, where the hydroxyl group has a trans correlation with both the ester and the 
bridge-head hydrogens. This attractive molecule contains four asymmetric centers, 
where the hydrogens H1 and H2 are closed in a cis structure. It possesses a cis-
bicyclo[3.3.0]octane skeleton and carries functional groups in appropriate positions for 
the step-by-step insertion of the ω and α-side chains.  
Our synthetic approach to this fundamental key substrate 36 began with the Weiss-Cook 
condensation75 of glyoxal 37 and dimethyl-1,3-acetonedicarboxylate 34. In the Weiss 
reaction the dicarboxylate was added to a cooled solution of NaOH and then the glyoxal 
37 was slowly introduced at reflux condition. The obtained disodium-salt 38 was 
directly subjected to a hydrolysis step, following by a decarboxylation reaction. The 
reaction work up can be improved if the reaction co-product methanol is distilled off 
during the decarboxylation process. Crystallization of the tetracarboxylate diketone 39 
in n-hexane was the only needed operation of purification. This methodology allowed 
the preparation of the corresponding diketone 40 on a large scale and in very good yield 
(Scheme 27).  
                                                 
75
 a) Bertz, S.; Cook, J. M.; Gawish, A.; Weiss, U. Org. Synth. 1985,64, 27; b) Weiss, U.; Edwards, J. 
M.Tetrahedron Letters 1968, 4885. 
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a) NaOH, MeOH; b) H2O, CHCl3, HCl; c) acetic acid, HCl 
Diketone synthesis 
Scheme 27 
Following the work of Piers,76 the mono-acetal 41 was obtained by the treatment with 
the protecting group in presence of a catalytic amount of TsOH. Monoacetalisation of 
diketone 40 gave a statistical 1:2:1 product mixture comprising bis-acetal 42, mono-
acetal 41 and recovered starting material 40. After chromatographic separation on silica 
gel the bis-acetal 42 was transformed into mono-acetal 41 and the recovered diketone 
40 was recycled. In contrast to the literature this reaction was conduced in toluene, not 
in benzene, and only in two hours (the described time is four hours). The bis-acetal 42 
was hydrolyzed in two hours with a mixture of THF/H2O/Acetic acid to gave a product 
mixture with a ratio of 5:1 in favor of the mono-acetal 41 (Scheme 28). 
 
                                                 
76
 Piers, E.; Karunaratne, V. Can. J. Chem. 1989, 67, 160. 
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Monoacetal synthesis 
Scheme 28 
The mono-protected ketone 41 has a concave-convex structure that allows a stereo-
selective functionalization: the acylation was conduced in dimethylcarbonate as solvent 
in presence of NaH and a catalytic amount of MeOH like reaction starter. A simple 
filtration on silica gel afforded the purified β-keto-ester 43 as a mixture of racemic endo 
and exo isomers at the methoxycarbonyl group. Trying to improve the acylation process 
we found that it is possible halve the quantity of solvent and increase the yield 
conducing the reaction at 50°C. The reduction of the β-keto-ester 43 with molecular 
hydrogen using like catalyst PtO2 proceeded stereoselectively to the racemic synthetic 
key β-hydroxy-ester 36 in quantitative yield with the appropriate relative structure trans 
(Scheme 29). To maximize this reaction we performed a set of reduction experiments. 
We have found that the catalyst quantity can be decrease allowing a minor reaction cost 
(1g of Pt2O costs about 100€). The better compromise between time and cost is to work 
with 3.5 bar of pressure of H2 for one night with 5% (w/w) of PtO2.  
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Trans-racemic compound 
β-hydroxy-ester synthesis 
Scheme 29 
The trans-structure of the β-hydroxy-ester 36 was confirmed by NMR analysis 
comparing the H signals with literature.73 Moreover, the cis and trans isomers can be 
obtained by the reduction of the ketone with NaBH4 at room temperature. The cis-one 
can be converted into trans skeleton by the extraction of the acid hydrogen in α position 
at the carbonyl group. The treatment of the cis isomer with Na and MeOH gave the 
more stable trans. Our product does not change conformation under the above described 
reaction conditions (Scheme 30). 
 
 
Scheme 30 
The total synthesis described above is simple, efficient and scalable with a 14% overall 
yield in six steps. It is an example of improved eco-efficient product process that 
optimizes the use of resources, minimize waste simplifying the work up. Hence it is an 
example of process intensification. 
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4.4.2 Acids and optical resolution  
We have described the preparation in racemic form of the β-hydroxy-ester 36, that is a 
potential precursor for the synthesis of a broad range of natural and biologically active 
compounds. In our case, the right absolute structure is obtained by an optical resolution 
of diastereomeric salts (see chapter 2, paragraph 2.2), and their separation by 
crystallization. The three molecules 44, 45 and 46 shown in Figure 20 were assumed 
like potential substrates for a good resolution.  
 
 
Figure 20 
Acid 44 could be easily obtained in gram quantities with a minimum of synthetic 
transformations (Scheme 31). Starting from the β-hydroxy-ester 36, after treatment with 
tert-butyldimethylsilyl chloride (to afford protected alcohol 47) and reduction with 
DIBAL, primary alcohol 48 was obtained.77 This alcohol was derivatized to carboxylic 
acid 49 by the reaction with phthalic anhydride in pyridine.   
 
                                                 
77
 Sheddan, N. A.; Mulzer, J. Org. Letters 2005, 7, 5115. 
Chapter 4 
 96 
O
OO
Si
O
O
O
HO
O
OO
Si
OH
OH
OO
OMe
O O
OO
Si
OMe
O
TBDMSCl, Hym.
DIBAL , Py.
O
O
O
36 47
48 49
 
Scheme 31 
The corresponding diastereomeric salts 50 were obtained by a simple precipitation with 
one equivalent of (S)-phenylethanamine 51 (Scheme 32). Various solvents were tested 
but all the attempts to obtain the precipitation of only one enantiomer had no success.  
 
Salt formation 
 
Scheme 32 
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The acid 45 was synthesized by saponification of the β-silyl-ester 47 in a KOH 
methanol solution (Scheme 33). The absence of a simple and efficient analytic method 
to analyze the acid enantiomeric excess like HPLC or GC with chiral columns 
convinced us to change molecule. 
 
 
Scheme 33 
The introduction of the required carboxylic function directly into the β-hydroxy-ester 36 
can be the best idea for a good optical resolution. The acid 46 was obtained by the 
treatment of the alcohol with phthalic anhydride and pyridine as solvent (Scheme 34). 
  
 
Scheme 34 
This acid 46 was dissolved in diisopropyl ether and (S)-phenylethanamine 51 was 
slowly added to the solution. The white precipitate 52 was filtered and submitted to a 
slow enantio-selective crystallization (Scheme 35). The HPLC analysis of the salt 52 
showed the presence of the cis isomer in small quantity. 
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Salt formation 
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Scheme 35 
Several tests were performed to find the best resolution conditions. Finally we found 
that the acid 46 can be resolved refluxing the salt in a solvent mixture i-Pr2O:MeOH 
with a ratio 4:1 and allowing a slowly precipitation under mechanical agitation. We 
started with a racemic mixture of 46 with a diastereomeric ratio 94:6 in trans:cis 
isomers. In the first crystallization we obtained a salt 52 composition with a 
diastereomeric excess of 88% and an enantiomeric of 86% in the trans isomer. With the 
second crystallization we obtained only the trans acid 46 with an enantiomeric excess of 
96% (Figure 21).  
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Optical Resolution 
 
 
Dr (trans/cis) = 94/6 
Er (trans) = 50/50 
trans cis i-Pr2O/MeOH  
 
 
Dr (trans/cis) = 97/3 
Er (trans) = 7/93 
Ee (trans) = 86% 
trans cis i-Pr2O/MeOH 
 
 
Dr (trans/cis) = 100/0 
Er (trans) = 2/98 
Ee (trans) = 96% 
trans cis 
 
Figure 21 
4.5 Conclusion 
Taking into account the medicinal and biological importance of prostacyclin, new 
synthetic process and various types of significant intermediates have been discovered in 
the chemistry of these natural products and their mimic analogues. In this chapter we 
have described a methodology to intensify the synthetic process of the racemic β-
hydroxy-ester 36. This improved process obtains the required key intermediate with 
simple work up, cheap reactions and good yields. Moreover, we have described an 
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efficient asymmetric optical resolution of the corresponding carboxylic acid 46 
highlighting a full stereo- and enantio-control of all stereogenic carbons. This practical 
synthesis and resolution is proven feasible on a large scale and can be considerate a 
good strategy to obtain, in according with the principles of green chemistry, only one 
enantiomer of a Iloprost precursor. 
 
4.6 Experimental section 
Tetramethyl 3,7-dihydroxybicyclo[3.3.0]octa-2,6-diene-2,4,6,8-tetracarboxylate 
(39)75 
 
 
A 1-L, three-necked flask was equipped with a thermometer, mechanical stirrer and 
reflux condenser. To a stirred solution of  15.9 g (398 mmol) of NaOH in  280 mL of 
methanol, cooled in an ice bath, 68.1 g (191 mmol) of  dimethyl 1,3-
acetonedicarboxylate 34 was added dropwise. The resulting slurry was heated to reflux, 
at which point the white salt dissolved. Aqueous 40% glyoxal 37 (32.0 g, 221 mmol) 
was added at a rate sufficient to maintain the internal temperature at 65°C. The mixture 
was allowed to cool to room temperature and stirred overnight. The precipitate was 
filtrated, washed three times with 60 mL of methanol, and dried under reduced pressure. 
The yield of the white to light yellow disodium salt 38 was 72.8 g (76%). A 2-L 
Erlenmeyer flask equipped with a large magnetic stirring bar was charged with 500 mL 
of chloroform and a solution of 100 g of the disodium salt (231 mmol) in 400 mL of 
water. To the vigorously stirred mixture 463 mL of cold 1 M hydrochloric acid was 
added. After 20 minutes, the layers wee separated and the aqueous phase was extracted 
with three times with 100 mL of chloroform. The combined organic layers were washed 
once with saturated  sodium chloride, dried over anhydrous magnesium sulfate, and 
concentrated under reduced pressure by rotary evaporation. Crystallization from 270 
mL of a solution 2 : 1 hexane–ethyl acetate afford 55.8 g (65% based on dimethyl 1,3-
acetonedicarboxylate) of the tetraester 39. 
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White solid, mp 92-95°C, IR (KBr) υ 3010, 1743, 1674, 1636, 1444, 1332, 1274, 1198, 
1163, 1051 cm-1; 1H NMR (300MHz, CDCl3): δ 3.65 (m, 2H), 3.79 (s, 6H), 3.81 (s, 
6H), 3.87 (m, 2H), 10.32 (broad s, 2H); 13C NMR (75MHz, CDCl3): δ 43.8 (2CH3), 
51.7 (2CH), 52.6 (2CH), 55.2 (2CH3), 103.7 (2C), 169.1 (2C), 170.6 (2C), 170.8 (2C). 
 
Cis-Bicyclo[3.3.0]octane-3,7-dione (40)75 
 
 
A 1-L, three-necked flask equipped with two reflux condensers and mechanical stirrer 
was charged with 27 g (73 mmol) of the tetraester 39, 15 mL of glacial acetic acid, and 
150 mL of 1 M hydrochloric acid. The mixture was stirred vigorously and heated at 
reflux for 1.5 hours, then other 27 g (73 mmol) of the tetraester was added. The 
evolution of CO2 was monitored with a mineral oil bubbler. The co-product methanol 
was distilled off at the end of the decarboxylation process. After 5.5 hours the solution 
was cooled in an ice bath and the product was extracted with five 100 mL portions of 
chloroform. The organic layers were combined, and the solution was concentrated by 
rotary evaporation. The residue was dissolved in 120 mL of fresh chloroform. The 
solution was washed with 40-mL of saturated sodium bicarbonate until the aqueous 
layer remains basic to litmus paper and dried with anhydrous sodium sulfate. The 
evaporation under reduced pressure afforded 19.0 g (137 mmol) of the bicycle with 
94% yield.. 
White solid, mp 85-86°C, IR (KBr) υ cm-1 2958, 1746, 1445, 1051; 1H NMR (400MHz, 
CDCl3): δ 2.16 (dd, 4H, J = 5.3, 19.6Hz), 2.58 (dd, 4H, J = 8.6, 19.6Hz), 3.06 (m, 2H); 
13C NMR (100MHz, CDCl3): δ 36.3 (2CH), 43.5 (4CH2), 217.8 (2C). 
 
Cis-Bicyclo[3.3.0]octan-3,7-dione-(2’,2’-dimethylpropylidene) acetal (41)  
 
 
From dione 40 monoacetalisation76: To a 500-mL flask fitted with a Dean-Stark 
apparatus, condenser 16 g of dione 40 (116 mmol), 12 g (116 mmol) of 2,2-dimethyl-
1,3-propanediol, 80 mg (0.4 mmol) of p-toluenesulphonic acid monohydrate were added 
to 180 mL of toluene. The reaction mixture was heated at the reflux until evolution of 
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water ceased (2 hours). The solution was cooled to room temperature and K2CO3 was 
added. The suspension was filtered and the solvent removed in vacuo. The crude was 
purified by flash chromatography (2:1 petroleum ether/EtOAc to 1:2, crude mixture was 
loaded with 36 mL of 3:2:1 petroleum ether/EtOAc/CH2Cl2 solution). The first eluted 
compound was the bis-acetal 42 (5.8 g, 16% yield), obtained as a white crystalline solid. 
The second compound was the required mono-acetal 41 (11.5 g, 44% yield), obtained as 
a colorless solid.  The last collected compound was the recovered starting material 
dione 40 (4.2 g, 26% yield). 
From bis-acetal 42 hydrolysis: A 150-mL flask equipped with a reflux condenser and 
magnetic stirrer was charged with 8 g (25.8 mmol) of bis-acetal 42 and 50 mL of a 3:1:1 
THF/H2O/AcOH solution. The mixture was heated at the reflux for 2.5 hours, then 
cooled at room temperature. The solution was neutralized with NaOH 1M and the 
aqueous layer was extracted with three 50 mL portions of Et2O. The combined organic 
layers were washed with 50-mL of brine, dried with anhydrous sodium sulfate and 
concentrated by rotary evaporation. The crude was purified by flash chromatography 
(2:1 petroleum ether/EtOAc to 1:2) to afford 3.4 g (60% yield) of the mono-acetal 41. 
 
Cis-Bicyclo[3.3.0]octan-3,7-dione-(2’,2’-dimethylpropylidene) acetal (41) 
White solid, mp 49-51°C, Rf 0.24 (petroleum ether/Et2O 1:1), IR (KBr) υ 2953, 2864, 
1751, 1471, 1394, 1359, 1328, 1213, 1117, 1042, 1008, 906, 769 cm-1; 1H NMR 
(400MHz, CDCl3): δ 0.96 (s, 6H), 1.83 (dd, 2H, J = 5.1, 13.7Hz), 2.17 (dd, 2H, J = 4.6, 
19.4Hz), 2.30 (dd, 2H, J = 8.7, 13.7Hz), 2.48 (dd, 2H, J = 9.8, 19.4Hz), 2.83 (m, 2H), 
3.45 (s, 2H), 3.48 (s, 2H); 13C NMR (100MHz, CDCl3): δ 22.3 (2CH3), 29.9 (C), 36.6 
(2CH), 41.0 (2CH2), 44.4 (2CH2), 71.0 (2CH2), 72.0 (2CH2), 109.4 (C), 219.9 (C). 
 
Cis-Bicyclo[3.3.0]octan-3,7-dione-bis-(2’,2’-dimethylpropylidene) acetal (42) 
 
 
White crystalline solid, mp 137-138°C, Rf 0.51 (petroleum ether/Et2O 1:1), IR (KBr) υ 
2953, 1472, 1393, 1359, 1306, 1222, 1116, 1018, 872, 789 cm-1; 1H NMR (400MHz, 
CDCl3): δ 0.96 (s, 12H), 1.72 (dd, 4H, J = 6.2, 13.2Hz), 2.20 (dd, 4H, J = 8.9, 13.2Hz), 
2.54 (m, 2H), 3.46 (s, 4H), 3.47 (s, 4H); 13C NMR (100MHz, CDCl3): δ 22.5 (4CH3), 
30.0 (2C), 36.9 (2CH), 39.7 (4CH2), 71.6 (2CH2), 72.3 (2CH2), 109.8 (2C). 
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Methyl-3-one-7,7-(2’,2’-dimethylpropylidenedioxy)  
bicyclo[3.3.0]octane-2-carboxylate (43)78 
O
O
O
O O
 
 
In a three-necked 500-mL flask equipped with a mechanical stirrer and a thermometer , 
92mL of freshly distilled dimethyl carbonate were added to 9.6 g of NaH (60% wt in 
mineral oil, 400 mmol) under N2. The solution was heated to 50°C. A solution with 15 g 
of mono-acetal 41 (66.9 mmol) in 55 mL of freshly distilled dimethyl carbonate was 
prepared, and 7.5 mL of this solution were added to the reaction mixture. Then 0.3 mL 
of methanol was added and the remaining mono-acetal 41 solution was added over 6.5 
hours. The reaction was stirred at 50°C overnight. The mixture was cooled with an ice 
bath and 40mL of toluene were added. Methanol (30mL) was slowly added, followed 
by 8.3mL of acetic acid. Water (45mL) was added and the slurry was filtered by gooch. 
The organic layer was separated. The solid residue was washed twice with 50mL of 
toluene. The combined organic layers were washed twice with 20mL of water and 
concentrated by rotary evaporation. Toluene (20mL) was added and the solution was 
evaporated. The crude was purified by flash chromatography (3:1 petroleum ether/Et2O) 
to afford 14 g (74% yield) of the required product as a diastereoisomers mixture. 
White solid, mp 74-75°C, Rf 0.62 (petroleum ether/Et2O 3:1), IR (KBr) υ 3008, 1669, 
1618, 1440, 1337, 1276, 1145, 1114, 790 cm-1; 1H NMR (400MHz, CDCl3) (of the 
mixture of two diastereoisomers): δ 0.94 (s, 3H), 0.95 (s, 3H), 0.96 (s, 3H), 0.99 (s, 3H), 
1.63 (m, 1H), 1.71 (ddd, 1H, J = 0.9, 6.1, 13.6Hz), 1.83 (m, 1H), 2.04 (m, 1H), 2.22-
2.43 (m, 7H), 2.61-2.80 (m, 3H), 2.94 (m, 1H), 3.17 (m, 1H), 3.28 (m, 2H), 3.44-3.54 
(m, 8H), 3.74 (s, 3H), 3.76 (s, 3H); 13C NMR (100MHz, CDCl3) (of the mixture of two 
diastereoisomers): δ 22.3 (2CH3), 22.4 (CH3), 22.5 (CH3), 30.0 (C), 30.1 (C), 33.2 
(CH), 34.9 (CH), 38.7 (CH2), 38.9 (CH2), 40.2 (CH2), 40.9 (CH2), 41.0 (CH), 41.4 
(CH), 42.0 (CH), 44.7 (CH2), 51.0 (CH), 52.5 (CH), 60.6 (2CH), 71.6 (CH3), 71.7 
(CH3), 72.3 (CH2), 72.5 (CH2), 108.6 (C), 109.1 (C), 169.7 (C), 174.8 (C), 211.8 (2C). 
                                                 
78
 German Patent DE 3816801. 
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Methyl-3-hydroxy-7,7-(2’,2’-dimethylpropylidenedioxy) bicyclo[3.3.0]octane-2-
carboxylate (36)78 
OH
O
O
O O
 
 
 
In a 300-mL batch reactor, 12.4 g (44 mmol) of β-keto-ester 43 were dissolved in 120 
mL of ethyl acetate and the reaction system was saturated with argon. To this solution 
Platinum (IV) oxide (0.62 g, 5 % w/w) was added and the reactor was saturated with 
hydrogen. The reaction was mechanical stirred overnight with 3.5 bar of H2 pressure. 
The mixture was filtered through a thin pad of celite and the filtrate was concentrated 
under reduce pressure to afford 12.5 g (100 % yield) of trans-alcohol. 
Colorless oil, Rf 0.20 (petroleum ether/EtOAc 7:3), IR (neat) υ 2952, 2867, 1731 cm-1; 
1H NMR (400MHz, CDCl3): δ 0.96 (s, 3H), 0.97 (s, 3H), 1.54 (ddd, 1H, J = 9.3, 10.2, 
12.2Hz), 1.89 (ddd, 1H, J = 1.3, 4.7, 13.3Hz), 2.00-2.16 (m, 3H), 2.25 (ddd, 1H, J = 6.4, 
8.2, 12.2Hz), 2.52 (m, 1H), 2.62 (m, 2H), 2.82 (m, 1H), 3.46 (s, 2H), 3.50 (s, 2H), 3.72 
(s, 3H), 4.22 (m, 1H); 13C NMR (100MHz, CDCl3): δ 22.3 (CH3), 22.4 (CH3), 29.8 (C), 
35.5 (CH), 38.7 (CH2), 38.9 (CH2), 40.4 (CH2), 41.4 (CH), 51.6 (CH3), 57.8 (CH), 71.6 
(CH2), 72.0 (CH2), 75.6 (CH), 109.7 (C), 175.2 (C). 
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Methyl-3-(tert-butyldimethylsilyloxy)-7,7-(2’,2’-dimethylpropylidenedioxy) 
bicyclo[3.3.0]octane-2-carboxylate (47)77 
O
O
O
O O
Si
 
 
To a solution of β-hydroxy-ester 36 (16.0 g, 56 mmol) and imizadole (9.6 g, 141 mmol) 
in anhydrous DMF (41 mL), TBSCl (10 g, 68 mmol) in anhydrous DMF (30 mL) was 
dropwise added and the reaction mixture was stirred overnight. To the mixture 60 mL of 
water and 60 mL of Et2O were added, and the solution was extracted with Et2O (5 x 70 
mL). Combined organic layers were washed with 50 mL of water and 35 mL of brine, 
dried over MgSO4, filtered and concentrated. The crude was purified by flash column 
chromatography (petroleum ether/EtOAc 5:1) to afford the corresponding protected 
alcohol (18.2 g, 81%). 
Colorless oil, Rf 0.59 (petroleum ether/EtOAc 5:1), IR (neat) υ cm-1 1735, 1636, 1256, 
116; 1H NMR (600MHz, CDCl3): δ 0.00 (s, 3H), 0.01 (s, 3H), 0.84 (s, 9H), 0.92 (s, 3H), 
0.98 (s, 3H), 1.50 (dt, 1H, J = 9.1, 12.3Hz), 1.80 (dd, 1H, J = 5.3, 12.6Hz), 1.91 (m, 
1H), 2.08-2.16 (m, 3H), 2.50 (m, 1H), 2.60 (m, 2H), 3.45 (dd, 2H, J = 11.4, 18.8Hz), 
3.49 (dd, 2H, J = 11.7, 19.0Hz), 3.67 (s, 3H), 4.26 (m, 1H); 13C NMR (100MHz, 
CDCl3): δ -5.1 (CH3), -4.8 (CH3), 17.8 (C), 22.4 (CH3), 22.5 (CH3), 25.6 (3CH3), 30.1 
(C), 36.1 (CH), 38.3 (CH2), 40.5 (CH2), 41.7 (CH2), 42.1 (CH), 51.5 (CH3), 58.8 (CH), 
71.9 (CH2), 72.0 (CH2), 77.5 (CH), 109.8 (C), 175.5 (C). 
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3-(tert-butyldimethylsilyloxy)-7,7-(2’,2’-dimethylpropylidenedioxy) 
bicyclo[3.3.0]octane-2-carboxylic acid (45) 
O
OH
O
O O
Si
 
 
To a stirred solution of 1.0 g (2.5 mmol) of β-tert-butyldimethylsilyloxy ester 47 a 
solution of 10% KOH  in methanol was added. The mixture was stirred overnight at 
room temperature. The mixture was concentrated and washed once with Et2O. The 
aqueous layer was acidified to pH=5 with HCl 1M and extracted three times with Et2O. 
The combined organic layers were dried with MgSO4 and the solvent was evaporated to 
afford 0.9 g (2.3 mmol, 91%) of the crude acid that was directly engaged in the next 
step without further purification. 
White solid, mp 87-90°C, Rf 0.33 (petroleum ether/EtOAc 5:1), IR (neat) υ cm-1 2954, 
1702, 1115; 1H NMR (400MHz, CDCl3): δ 0.01 (s, 3H), 0.02 (s, 3H), 0.84 (s, 9H), 0.91 
(s, 3H), 0.98 (s, 3H), 1.51 (dt, 1H, J = 9.1, 12.2Hz), 1.81 (dd, 1H, J = 5.5, 13.7Hz), 1.98 
(m, 1H), 2.06-2.19 (m, 3H), 2.51 (m, 1H), 2.62 (m, 2H), 3.45 (m, 2H), 3.49 (m, 2H), 
4.26 (m, 1H); 13C NMR (100MHz, CDCl3): δ -5.0 (CH3), -4.8 (CH3), 17.9 (C), 22.4 
(CH3), 22.5 (CH3), 25.7 (3CH3), 30.0 (C), 36.0 (CH), 38.0 (CH2), 40.7 (CH2), 41.6 
(CH2), 42.0 (CH), 58.6 (CH), 71.9 (CH2), 72.0 (CH2), 77.3 (CH), 109.8 (C), 180.8 (C). 
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3-(tert-butyldimethylsilyloxy)-7,7-(2’,2’-dimethylpropylidenedioxy) 
bicyclo[3.3.0]octane-2-methanol (48)77 
O
OH
O O
Si
 
 
Under nitrogen, to a stirred solution of 5.0 g (12.5 mmol) of β-tert-
butyldimethylsilyloxy-ester 47 in 20 mL of dry CH2Cl2 a solution 1M of DIBAL (19 
mL) was added dropwise at -78°C within 1.5 h. The reaction mixture was stirred at 0°C 
for 2 h, then 4 mL of MeOH and 45 mL of an aqueous potassium tartrate solution were 
added. The mixture was filtered through Celite which was washed with CH2Cl2. The 
combined organic phases were dried and concentrated in vacuo. Purification by flash 
column chromatography (petroleum ether/EtOAc 3:1) gives 4.5 g (11.6 mmol, 92%) of 
alcohol. 
Colorless solid, mp 79-82 °C, Rf 0.34 (petroleum ether/EtOAc 3:1), IR (neat) υ 3150, 
1644, 1010 cm-1; 1H NMR (400MHz, CDCl3): δ 0.04 (s, 3H), 0.06 (s, 3H), 0.86 (s, 9H), 
0.92 (s, 3H), 0.97 (s, 3H), 1.44 (m, 1H), 1.71-1.92 (m, 3H), 1.99-2.20 (m, 4H), 2.25 (s, 
1H), 2.36 (m, 1H), 3.46 (m, 4H), 3.64 (m, 2H), 3.85 (m, 1H); 13C NMR (100MHz, 
CDCl3): δ -4.9 (CH3), -4.1 (CH3), 17.8 (C), 22.4 (CH3), 22.5 (CH3), 25.7 (3CH3), 30.0 
(C), 35.6 (CH), 38.5 (CH2), 39.1 (CH), 40.6 (CH2), 41.5 (CH2), 55.1 (CH), 65.4 (CH2), 
71.9 (CH2), 72.2 (CH2), 78.3 (CH), 110.2 (C). 
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3-(tert-butyldimethylsilyloxy)-7,7-(2’,2’-dimethylpropylidenedioxy) 
bicyclo[3.3.0]octane-2-methoxy- carbonyl benzoic acid (49) 
O
O
O O
Si
O
HO
O
 
 
In a 50-mL flask equipped with a magnetic stirrer and a reflux condenser 4.0 g (10.8 
mmol) of alcohol 48 were dissolved in 4.3 mL of freshly distilled pyridine. Phthalic 
anhydride (1.6 g, 10.8 mmol) was added and the solution was heated to 70°C. After 24h 
the solution was cooled to room temperature and 25 mL of water were added. The 
mixture was washed once with Et2O. The aqueous layer was acidified with HCl 1M and 
extracted three times with Et2O. The combined organic layers were dried with MgSO4 
and the solvent was evaporated to afford 3.9 g (7.6 mmol, 70%) of the required acid. 
Colorless oil, IR (neat) υ 1727, 1633, 1258, 1118 cm-1; 1H NMR (400MHz, CDCl3): δ 
0.00 (s, 6H), 0.84 (s, 9H), 0.92 (s, 3H), 0.93 (s, 3H), 1.46 (m, 1H), 1.75 (dd, 1H, J = 6.6, 
13.1Hz), 1.85 (dd, 1H, J = 5.6, 12.8Hz), 2.14-1.99 (m, 2H), 2.34-2.16 (m, 3H), 2.40 (m, 
1H), 3.45 (s, 2H), 3.46 (s, 2H), 3.88 (m, 1H), 4.22 (dd, 1H, J = 6.6, 10.9Hz), 4.41 (dd, 
1H, J = 4.0, 10.9Hz) 7.55 (m, 2H), 7.69 (m, 1H), 7.88 (m, 1H); 13C NMR (100MHz, 
CDCl3): δ -4.9 (CH3), -4.5 (CH3), 17.9 (C), 22.4 (2CH3), 25.7 (3CH3), 30.0 (C), 35.7 
(CH), 39.3 (CH2), 40.1 (CH2), 40.2 (CH), 41.4 (CH2), 52.9 (CH), 66.3 (CH2), 71.7 
(CH2), 72.2 (CH2), 75.6 (CH), 110.3 (C), 128.7 (CH), 129.7 (CH), 130.8 (C), 130.9 
(CH), 131.7 (CH), 132.9 (C), 168.2 (C), 170.7 (C). 
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2-(methoxycarbonyl)-7,7-(2’,2’-dimethylpropylidenedioxy) bicyclo[3.3.0]octane-3-
oxy- carbonyl benzoic acid (46) 
O
O
O
O O
O
O OH
 
 
In a 50-mL flask equipped with a magnetic stirrer and a reflux condenser 6.8 g (24.1 
mmol) of β-hydroxy-ester 36 were dissolved in 10 mL of freshly distilled pyridine. 
Phthalic anhydride (3.6 g, 24.1 mmol) was added and the solution was heated to 70°C. 
After 24h the solution was cooled to room temperature and 50 mL of water were added 
to the reaction mixture. The reaction solution was acidified with 120 mL of HCl 1M and 
extracted twice with Et2O. To completely remove the pyridine presence the combined 
organic layers were washed with 25 mL of saturated CuSO4. The organic layer was 
dried with MgSO4 and the solvent was evaporated to afford 8.3 g (19.1 mmol, 80%) of 
acid 46 with a diastereomeric ratio 94:6 in trans:cis isomers. 
Colorless oil, Rf 0.48 (petroleum ether/EtOAc/AcOH 1:1:0.01), IR (neat) υ 1733, 1288, 
1121 cm-1; 1H NMR (400MHz, CDCl3): δ 0.92 (s, 3H), 0.93 (s, 3H), 1.75 (dt, 1H, J = 
7.8, 13.0Hz), 1.93 (dd, 1H, J = 5.1, 13.7Hz), 2.07 (dd, 1H, J = 4.6, 13.5Hz), 2.18 (m, 
2H), 2.54 (m, 1H), 2.68 (m, 1H), 2.74 (m, 1H), 2.97 (t, 1H, J = 8.0Hz), 3.46 (s, 2H), 
3.49 (s, 2H), 3.71 (s, 3H), 5.48 (m, 1H), 5.90 (s, 1H), 7.56 (m, 2H), 7.68 (m, 1H), 7.86 
(m, 1H); 13C NMR (100MHz, CDCl3): δ 22.6 (CH3), 22.7 (CH3), 30.2 (C), 37.4 (CH), 
37.7 (CH2), 39.0 (CH2), 40.3 (CH2), 43.0 (CH), 52.3 (CH3), 55.5 (CH), 72.2 (CH2), 72.3 
(CH2), 79.5 (CH), 110.2 (C), 129.2 (CH), 129.6 (CH), 131.2 (CH), 131.8 (CH), 132.7 
(2C), 167.6 (2C), 170.5 (C),174.5 (C).     
The optical resolution: (S)-Phenylethanamine 51 (1.4 g, 11.6 mmol) is slowly added to 
a refluxed solution of acid 46 (5.0 g, 11.6 mmol) in 191 mL of a mixture i-Pr2O:MeOH 
(4:1). The mixture is mechanical stirred at room temperature over night. The precipitate 
crystalline (2.0 g, ee 88%) is collected by filtration and re-crystallized from i-
Pr2O:MeOH (4:1) affording 1.4 g of enantiopure trans-acid 46 (ee 96%). HPLC (acid) 
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Chiralpak® AD-H, n-hexane/i-PrOH/i-PrOH(AcOH 4%) (80:10:10), flow 1 mL/min, λ= 
254 nm, tr(trans) = 9.3 min, tr(trans) = 10.5 min, tr(cis) = 11.9 min, tr(cis) = 14.7 min. 
Salt characterization (52): White solid, mp 154-156°C ,IR (KBr) υ 2096, 1640 cm-1; 
1H NMR (400MHz, CDCl3): δ 0.93 (s, 3H), 0.94 (s, 3H), 1.49 (d, 3H, J = 6.7Hz), 1.61 
(m, 1H), 1.78 (dd, 1H, J = 5.5, 13.3Hz), 1.96-2.18 (m, 3H), 2.34 (m, 1H), 2.49 (m, 1H), 
2.67 (m, 1H), 2.90 (t, 1H, J = 8.2Hz), 3.43 (s, 4H), 3.64 (s, 3H), 4.26 (q, 1H, J = 6.7Hz), 
5.28 (m, 1H), 7.17 (m, 3H), 7.26-7.37 (m, 5H), 7.54 (m, 1H), 8.30 (s, 3H); 13C NMR 
(100MHz, CDCl3): δ 21.3 (CH3), 22.4 (2CH3), 29.9 (C), 36.6 (CH), 37.6 (CH2), 38.8 
(CH2), 40.0 (CH2), 42.3 (CH), 51.0 (CH), 51.8 (CH3), 55.3 (CH), 71.8 (CH2), 72.0 
(CH2), 78.0 (CH), 109.6 (C), 126.6 (2CH), 127.8 (2CH), 127.9 (2CH), 128.1 (2CH), 
128.6 (CH), 130.1 (C), 130.7 (C), 139.9 (C) 167.8 (C), 173.8 (C), 174.2 (C). 
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Chapter 5 
 
General considerations on Experimental sections 
All moisture-sensitive reactions were performed in an inert, dry atmosphere of argon or 
nitrogen in oven-dried glassware. Reagent grade solvents were used for either 
chromatography or extraction. THF was distilled from Na/benzophenone under argon; 
CH2Cl2, acetonitrile, toluene, Et3N, dimethyl carbonate, 1,2-dichloroethane were 
distilled from CaH2 under argon; pyridine was distilled from KOH under argon and 
DMF was distilled over 4Å molecular sieves. Analytical thin-layer chromatography 
(TLC) was performed using Merck precoated tlc plates (Silica gel 60 GF254 0.25 mm). 
Flash chromatography was performed using Merck Silica gel 60 (230-400 mesh). The 
solvent compositions reported for all separations are on a volume/volume basis. Gas 
chromatography (GC) was performed using a Hewlett Packard HP6890 or an Agilent 
6850 instruments. GC yield analyses were performed with an Agilent 19091Z-413E, 
HP-1 Methyl siloxane column, GC enantiomeric excess determinations were performed 
with a Restek 13104 Rt-βDEXsm column. 
High performance liquid chromatography (HPLC) was performed using a Hewlett 
Packard 1100 or Agilent 1100 instruments equipped with a Chiralpak® AD-H (250 mm 
x 4.6 mm ID) or with a Chiralcel® OD-H (250 mm x 4.6 mm ID) 
1H NMR spectra were recorded at 300,400 or 600 MHz at 20 °C with either 
tetramethylsilane (δ 0.00), chloroform (δ 7.26) as the internal standard. 13C NMR 
spectra were recorded at 75,100 or 150 MHz at 20 °C with either chloroform (δ 77.0) as 
the internal standard. Carbon assignments were based on DEPT, HMQC experiments. 
Melting points were determined through a Büchi instrument and are uncorrected. 
Specific optical rotations were determined at the D line through a Perkin Elmer 341 
polarimeter. 
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Abbreviations and acronyms 
[α]D20 Optical rotation at 589 nm  HOMO highest occupied molecular 
orbital 
Ac Acetyl HMPA 4-Hydroxymethyl-3-
methoxyphenoxyacetic acid 
B base HPLC High performance liquid 
chromatography 
Bn Benzyl IR Infrared spectroscopy 
c concentration LAH LiAlH4 
cat catalyst LUMO lowest unoccupied 
molecular orbital 
ChA Chrysanthemic acid Me methyl 
CH2Cl2 Dichloromethane MeOH methanol 
CH3Cl Chloroform ML Mother liquor 
CCl4 Methane tetrachloride mp Melting pot 
CO(OMe)2 Dimethyl carbonate PGI2 prostacyclin 
DIBAL Diisobutylaluminium 
hydride 
n.d. No date 
DMAD threo-2-dimethylamino-1-
(4-nitrophenyl)-1,3-
propanediol 
NOESY Nuclear Overhauser Effect 
Spectroscopy 
DMF N,N-dimethylformamide Ph Phenyl 
DMPP threo-2-dimethylamino-1-
phenyl-1,3-propanediol 
i-Pr isopropyl 
dr Diastereoisomeric ratio Py pyridine 
DSC Differential scanning 
calorimetry 
TFA Trifluoroacetic acid 
ee Enantiomeric excess TBDMS Tert-butyldimethylsilyl 
er Enantiomeric ratio t-Bu Tert-Butyl 
Et Ethyl Tf triflic 
Et3N Triethylamine THF tetrahydrofuran 
Et2O Diethyl ether THP tetrahydropyran 
EtOAc Ethyl acetate TLC Thin layer chromatography 
GC Gas chromatography tr Retention time 
ImH Imidazole Ts Tosyl (p-toluenesulfonyl) 
 
